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Thesis summary  
 
Caveolae are small cup-shaped plasma membrane invaginations. These 
multifunctional organelles play a key role in cell mechanoprotection and cell 
signaling. Indeed our laboratory reported that caveolae have the ability to flatten out 
upon membrane tension increase, protecting cells from mechanical strains (Sinha et 
al., 2011). Since caveolae play a key role in cell signaling we hypothesized that the 
mechano-dependent cycle of caveolae disassembly/reassembly may constitute a 
mechanical switch for signaling pathways (Nassoy and Lamaze, 2012). In this 
project, we elucidated the molecular mechanism underlying the control of JAK-STAT 
signaling by caveolae mechanics. The fate of caveolar components upon caveolae 
disassembly remains elusive. We showed that caveolin-1 (Cav1), the essential 
structural component of caveolae, is released and become highly mobile at the 
plasma membrane under mechanical stress. Considering that caveolae are important 
signaling hubs at the plasma membrane, we addressed the effects of the mechanical 
release of Cav1 on cell signaling. Using high throughput screening, we identified the 
JAK-STAT signaling pathway as a candidate. To further dissect the molecular 
mechanism underlying the control of JAK-STAT signaling by caveolae mechanics, 
we addressed the role of Cav1 in the control of JAK-STAT signaling stimulated by 
IFN-α. We found that Cav1 was a specific negative regulator of the JAK1 dependent 
STAT3 phosphorylation. Furthermore, the level of Cav1 interaction with JAK1 
depended on mechanical stress. We could show that Cav1-JAK1 interaction was 
mediated by the Caveolin Scaffolding domain (CSD), abolishing JAK1 kinase activity, 
hence, interfering with STAT3 activation upon IFN-α stimulation. Interestingly, STAT1 
activation by IFN-α was not affected by caveolae mechanics. Altogether our results 
show that caveolae are mechano-signaling organelles that disassemble under 
mechanical stress, releasing non-caveolar Cav1, which binds to the JAK1 tyrosine 
kinase and inhibits its catalytic activity, preventing thereby JAK-STAT signal 
transduction.  
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Résumé de la thèse 
 
Les cavéoles sont des invaginations en forme de coupelle à la membrane 
plasmique. Ces organelles multifonctionnelles jouent entre autres, un rôle clé dans la 
mécanoprotection et la signalisation cellulaire. En effet, notre laboratoire a démontré 
que les cavéoles ont la faculté de s’aplanir en réponse à l’augmentation de la tension 
membranaire, afin de protéger la cellule des contraintes mécaniques (Sinha et al., 
2011). Les cavéoles jouant un rôle clé dans la signalisation cellulaire, nous avions 
émis l’hypothèse que le cycle mécano-dépendent de désassemblage/réassemblage 
des cavéoles constitue un interrupteur mécanique de certaines voies de 
signalisation. Ce projet consiste à élucider le mécanisme moléculaire responsable du 
contrôle de la voie de signalisation JAK-STAT par la mécanique des cavéoles. Le 
devenir des constituants cavéolaires lors du désassemblage des cavéoles, reste à ce 
jour inconnu. Dans ces travaux, nous avons pu démontré que la cavéoline-1 (Cav1), 
un constituant essentiel des cavéoles, est libérée et devient hautement mobile au 
niveau de la membrane plasmique. Considérant les propriétés de signalisation de 
Cav1, nous avons testé l’effet du désassemblage des cavéoles sur la signalisation 
cellulaire. En effectuant un criblage à haut débit, nous avons identifié la voie de 
signalisation JAK-STAT stimulée par l’IFN-α comme voie modèle pour cette étude. 
En effet, la transduction du signal JAK-STAT induit par l’IFN-α est modulée par la 
mécanique des cavéoles. Afin de disséquer le mécanisme moléculaire responsable 
du control de la signalisation JAK-STAT par la mécanique des cavéoles, nous avons 
déterminé le rôle de Cav1 dans le contrôle de la signalisation JAK-STAT stimulée par 
l’IFN-α. Nous avons observé que Cav1 est un régulateur négatif de la 
phosphorylation de STAT3 dépendante de la kinase JAK1. De plus, nous avons 
démontré que Cav1 interagit avec JAK1 en fonction de la tension membranaire. 
Nous avons également démontré que cette interaction Cav1-JAK1 fait intervenir le 
« scaffolding domain » de Cav1 (CSD), et que celui-ci est responsable de l’abolition 
de l’activité kinase de JAK1. Par conséquent, l’interaction de Cav1 avec JAK1 
empêche l’activation de STAT3 par la kinase JAK1. De manière surprenante, STAT1 
échappe à cette régulation. En effet, l’activation de STAT1 par l’IFN-α n’est pas 
affectée par la mécanique des cavéoles. Ces résultats démontrent que les cavéoles 
sont des organelles de mécanosignalisation, qui, lors d’un stress mécanique,  
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libèrent de la Cav1 non cavéolaire capable d’inactiver la kinase JAK1, empêchant 
ainsi, la transduction du signal JAK-STAT induite par une stimulation à l’IFN-α.  
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Figure 1. Mechanical forces and mechanoreciprocity  
(a) Tension stress is applied perpendicular to the cell and leads to expansion. Compression stress is 
applied perpendicular to the cell and leads to compaction. Shear stress is applied parallel to the 
surface of the cell (adapted from Butcher et al., 2009). (b) The cell senses soft matrix and deforms the 
ECM by contracting. The cell has only few focal adhesions (purple sticks) and actin fibers (black 
arrows). It can also loosen the matrix by secreting metalloproteinases that digest the ECM (red dots) 
(left). The same cell on stiff matrix that cannot be deformed, the number of focal adhesions increases. 
The secretion of crosslinking factors (green dots) can mediate ECM stiffening. Substrate stiffening 
results in more and thicker actin stress fibers (black arrows) leadind to cell spreading and stiffening 
(right). (c) The basic machinery that senses and responds to ECM-generated mechanical signal. The 
cell surveys its mechanical environment with periodic contractions of stress fibers, which are attached 
to integrins that pull against matrix. Immature focal adhesions cannot sense matrix stiffness or exert 
strong mechanical forces on the ECM (left). While mature focal adhesions recruits myosin that allows 
force generation in response to matrix stiffening and recruits vinculin and actinin that increase F-actin 
number and crosslink the filaments to enlarge and strengthen focal adhesions and generates more 
contraction force (right) (based on Janmey et al., 2011). 
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Introduction  
1 Cell mechanics and mechanotransduction 
1.1 Cell and tissue mechanics 
 Of course, as every element of our universe, cells are subjected to the laws of 
physics and the renewal of the study of mechanics applied to the cell with the 
emergence of a mechanobiology field has already changed our understanding of 
most of fundamental biological processes.  
1.1.1 Force generation (may the force be with you) 
Cells are continuously subjected to mechanical forces including tensile force, 
compression, shear stress or hydrostatic pressure. Cells accommodate them by 
modifying their behavior and remodeling their microenvironment (Fig. 1). The 
interplay between cells and their microenvironment contribute through the resulting 
mechanical strains to fundamental biological processes but also to the development 
of pathologies (Egeblad et al., 2010; Kai et al., 2016). Tissues are composed of 
multiple constituents, among those; one can find different cell types and the extra 
cellular matrix (ECM). Each of these components can be characterized by several 
mechanical properties such as elasticity, viscosity, plasticity and stiffness (Janmey 
and Miller, 2011). All these physical properties govern how a tissue senses, transmits 
and responds to mechanical cues. For example, ECM stiffness can modulate 
essential biological processes at the level of individual cell such as differentiation, 
motility and morphology (Weaver et al., 1997; Engler et al., 2006; Vogel and Sheetz, 
2009). Pelman and Wang, who used collagen-coated beads embedded in substrate 
with different stiffness, demonstrated that increasing substrate stiffness leads to the 
modulation of the size and dynamics of focal adhesion and therefore cell locomotion 
(Pelham and Wang, 1998). On the other hand, cells can generate mechanical strains 
      
 
Figure 2. Biochemical versus mechanical signal 
Biochemical signal diffuses and form a gradient from a point of source and can be re released into the 
circulation (upper left). The strength of the signal decreases with the distance from its origin at a rate 
of 1/r2 (bottom left). Mechanical signals are transmitted through forces directionally applied to a target 
cell, directly or indirectly (through cell-cell contacts or matrix deformation) (upper right). Mechanical 
signals do not significantly decrease with the distance (bottom right, black). How ever signal intensity 
might be altered by the physical properties of the transmitting substance (cell or ECM) such as 
elasticity. Therefore the full force of the initial deformation might not be transmitted (red) (adapted from 
Janmey et al., 2011).  
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on the ECM and surrounding cells (Fig. 1b, c). Indeed, cells could wrinkle a soft 
rubber sheet on which they were cultured (Harris et al., 2008). This phenomenon 
occurs through active processes including actin assembly and ROCK dependent 
actomyosin contraction. The cytoskeleton appears to play a central role in the 
mechanobiology of the cell. It allows the cells to exert forces in the nanoNewton 
range on their surrounding environment and sense the mechanics of cells or 
substrate around them (du Roure et al., 2005). The overall cytoskeletal organization 
of cells, including actin filaments, intermediate filaments and microtubules, in 
interplay with the ECM components dictate the viscoelastic property of a tissue and 
the resulting forces. ECM is highly dynamic since cells constantly remodel their 
microenvironment with the secretion of either metalloproteinases leading to ECM 
degradation (Mrkonjic et al., 2017), or in contrast, of ECM components (Lu et al., 
2011) and crosslinking enzymes such as lysyl oxidases and transglutaminases that 
stiffen the ECM (Lee et al., 2015). By using inner active processes such as 
cytoskeletal reorganization together with the secretion of ECM degrading/crosslinking 
enzymes, cells are able to adapt to their physical microenvironment to reach the 
mechanical equilibrium. Thus, all cells respond to mechanical forces by a mechanism 
called “mechanoreciprocity” (Fig. 1) (Ding et al., 2013).  
1.1.2 Biochemical versus mechanical signal  
The major difference between these two types of signal is their way of 
spreading. Indeed, chemical messengers passively diffuse from the source of 
production to the target receptor (Fig. 2). This implies that the signal is not directed 
and equally irradiates to all directions from the production site. However, in the 
context of chemotaxis, the interpretation of the signal by the target is directed but 
limited in terms of distances. The diffusion of first messengers upon paracrine and 
autocrine signaling occurs through the microenvironment, therefore, it is subjected to 
environmental forces such as flow. Thus, it rapidly decays over time (at the rate of 
1/radius2) and depends on the rate of production over the rate of neutralization (Fig. 
2). Moreover, chemical molecules can only signal across few tens of micrometers. 
On the contrary, mechanical forces can be directed in a specific direction through 
fibers within the cells or the ECM (Janmey and Miller, 2011). A meshwork of 
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filaments such as those composing the ECM or the cytoskeleton can align in the 
direction of the stress to convert filament bending into filament stretching (Onck et al., 
2005). Unlike chemical signals, mechanical signals decay linearly and therefore can 
rapidly propagate up to hundreds of micrometers away from its point of generation 
(Winer et al., 2009). Transduction of mechanical signals is a rapid process generated 
from the perturbation of the mechanical equilibrium between cells and their 
microenvironment. While biochemical signaling is generally a slower process with 
timescales of seconds or minutes, (except for processes such as synaptic 
transduction), mechanotransduction is believed to be a fast process. For example, 
Sarcoma kinase (Src) activation by mechanical cues occurs in less than 0.3s while 
chemokine mediated activation of Src requires more than 12s (Na et al., 2008). 
1.1.3 The dark side of the force 
As discussed above, the cell microenvironment and its mechanical properties 
govern a wide range of biological processes. For example, substrate stiffness can 
control cell fate (Fig. 3a). Mesenchymal stem cells (MsCs) can differentiate into three 
cell types depending on their substrate stiffness. MsCs cultured on substrates 
mimicking brain (0.15-0.30 kPa), muscle (8-14 kPa) or bone stiffness (25-45 kPa) 
respectively differentiate into neuronal, muscle-like or bone cells (Engler et al., 2006). 
Therefore, any abnormality in the ECM that could modify its mechanical properties 
such as stiffness can perturb essential biological events by generating abnormal 
mechanical signal. These processes may trigger non-physiological conditions where 
tissue mechanics alter programmed cell functions leading to pathologies. Indeed, 
mechanical stress is involved in a myriad of diseases such as liver, renal, muscular 
diseases and cancer. The relationship between mechanical deregulation and 
pathological behavior in the context of cardiovascular, muscular pathologies and 
cancer are described below. 
1.1.3.1 Cardiovascular/and/muscular/pathologies/
Myocytes, by their function of contraction – relaxation are constantly subjected 
to mechanical stress. Any mechanical dysfunction of the cell itself or its 
      
 
 
Figure 3. Tissue rheology and pathological development  
(a) All cells are exposed to mechanical forces that are generated by cell-cell or cell-ECM interactions. 
These mechanical forces influence cell function. Each cell type is specifically tuned to the specific 
tissue in which it resides. Following transformation, breast tissue becomes progressively stiffer and 
tumor cells become significantly more contractile and hyper-responsive to mechanical cues. (b) 
Transformation (blue cells) resulting from accumulation of genetic and epigenetic alterations in the 
epithelium along with an altered stromal matrix leads to unchecked proliferation and enhanced survival 
of luminal epithelial cells, which compromises normal ductal structure. The abnormal pre-neoplastic 
luminal mammary epithelial cells eventually expand to fill the breast ducts exerting outwards projecting 
compression forces on the basement membrane and adjacent myoepithelium. The damaged pre-
neoplastic tissue produces soluble factors that stimulate cell infiltration and activation of fibroblast to 
induce a dramatic reorganization and stiffening of the ECM over time. The rigid parenchyma exerts a 
progressively greater inward projecting resistance force on the expanding pre-neoplastic duct. Over 
time, the number of myoepithelial cells surrounding the pre-neoplastic mass decreases and the 
basement membrane thins, probably owing to increased matrix metalloproteinases (from Butcher et 
al., 2009). 
a
b
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microenvironment preventing the myocyte normal functions is highly deleterious. For 
example, myocardial infarct leads to fibrotic stiffening that impairs cardiac output 
(Cecelja and Chowienczyk, 2009). Indeed, embryogenic myocytes grown on a heart-
like substrate stiffness of approximately 11 kPa normally beat, while those grown on 
a myocardial scar-like substrate stiffness (35-70 kPa) exhibit a drastic decrease of 
beat frequency (Engler et al., 2008).  
 
 An increased stiffness of muscle fibers most likely due to ECM stiffening by 
collagen crosslinking, is responsible for diastole in the context of congenital heart 
disease (Chaturvedi et al., 2010).  Similarly, aortic stiffness increases the risk of heart 
failure and strokes (DeLoach and Townsend, 2008). 
 
 More recently our lab discovered that caveolin-3 mutations involved in 
muscular dystrophies prevent caveolae formation at the plasma membrane. Hence 
myotubes carrying these mutations are more prone to plasma membrane disruption 
under mechanical stress due to a defect of caveolae mechanoprotection (developed 
in 2.3.3). It also exhibits a defect of IL6/STAT3 mechanosignaling (Dewulf et al., 2018 
under revision, see annex 3). 
1.1.3.2 Cancer/
1.1.3.2.1 Mechanical-forces-in-the-context-of-tumor-progression-
Some cancer clinical diagnoses rely on the detection of abnormal mechanical 
properties of the tissue. Indeed, detection of stiffen tissues is proceeded by palpation, 
X-ray, and ultrasound techniques. Most of the solid tumors are stiffer than 
surrounding healthy tissues. For example, normal breast tissue stiffness is around 
0.2 kPa while breast tumors stiffness is increased by approximately 20 folds 
(Levental et al., 2007; Baker et al., 2009). Similar stiffness increase is found for 
pancreatic and colorectal cancer (Butcher et al., 2009; Kai et al., 2016). Abnormal 
tissue stiffness most likely originates from the imbalance between ECM deposition 
and its degradation increasing the total ECM quantity. Tissue stiffening is not only the 
result of pathological processes; it also promotes their establishment (Fig. 3b). 
Collagen crosslinking and stiffening induce the invasiveness of oncogene activated 
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epithelial cells by generating larger focal adhesion sites (Levental et al., 2009). 
Secretion of several metalloproteinases at the level of the invadosome such as MT1-
MMP loosen and reduce matrix stiffness to counteract this crosslinking process 
(Willis et al., 2013) in response to mechanical cues (Mrkonjic et al., 2017). Stromal 
cells also exert considerable forces on the ECM. Cancer associated fibroblasts 
(CAFs) deform the extracellular matrix via strong actomyosin contractions, 
contributing to ECM stiffening (Laklai et al., 2016). The increase of cell density also 
promotes tissue stiffening. Cancer cells are usually stiffer than healthy cells (Fabry et 
al., 2001). Moreover “jamming” of cancer cells prevents their spatial reorganization to 
adapt to mechanical strains therefore contributing to tissue stiffening. Ultimately, in 
the context of metastasis, tumor cells have to squeeze through matrix fibers, travel 
through the organism and establish in a new tissue with different mechanical 
properties, which are as many processes that subject the cells to different 
mechanical stresses with a variety of biological consequences on tumor cells.  
 
1.1.3.2.2 Tumor-physical-microenvironment-influences-cancer-progression-
Tissue stiffening is not only symptomatic of cancer development; it also 
actively drives tumor progression. As discussed above mechanical forces influence a 
wide range of biological processes. Hence, throughout evolution, devices named 
mechanotransducers have been conserved to convert mechanical cues into 
interpretable biochemical information (detailed in 1.2). Most of pathological situations 
emerge from altered signal transduction such as irrelevant pathway activation or 
inactivation. Similarly to aberrant biochemical signaling such as growth hormone 
signaling, aberrant mechanical signaling also promotes tumor progression. For 
example abnormally stiff ECM drives epithelial to mesenchymal transition (EMT) and 
metastasis through the TWIST1-G3BP2 mechanotransduction pathway (Wei et al., 
2015a). The most well-known mechanosignaling hubs are focal adhesions. The 
direct anchorage to the ECM and their link with the cytoskeleton, place these 
structures at the perfect place to integrate mechanical cues provided by ECM 
deformation. Several focal adhesion components such as integrins, talin, paxillin and 
Cas are sensitive to mechanical strains. Focal adhesions regulate a myriad of 
signaling molecules of major cancer pathways such as Src, FAK, Rho, ERK, PTEN 
(Kandoth et al., 2013; Mouw et al., 2014). Together with filamentous actin, integrins 
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also control the mechanical activation of the YAP/TAZ oncogenes (Dupont et al., 
2011; Lamar et al., 2012). In three dimensional situation, studies have emphasized 
the role of integrins clustering in the transduction of mechanical cues (Harunaga and 
Yamada, 2011). Tumor cells are subjected to mechanical stretch at the periphery of 
the tumor but cells in the deep interior of the tumor are subjected to compressive 
forces (Fig. 3b). Mechanical forces are known to control cell cycle and apoptosis 
therefore promoting growth heterogeneity within the tumor (Chang et al., 2008; Lien 
et al., 2013). Cells sense and adapt to the microenvironment physical strains through 
the reorganization of their cytoskeleton, however such a process also implies plasma 
membrane topological reorganization to achieve mechanoadaptation and 
mechanosensation. Indeed, some mechanoreceptors engaged in cancer evolution 
reside inside the lipid bilayer. For example, stretch sensitive channel Piezo 1 and 2 
that triggers calcium signaling and other TRP ion channels are involved in tumor 
pogression (Li et al., 2015; Wu et al., 2017; Pardo-Pastor et al., 2018).  
1.2 Signal mechanotransduction 
Cells can generate precise three-dimensional structure through morphogenic 
movements and ensure the cell/organism structural stability. As gravity and muscle 
contraction shape bones, shear stress from flowing blood influences the heart 
vasculature and many other examples show that the ability of cells to convert 
mechanical cues into biochemical signal is essential. Failure of these mechanisms 
contributes to a wide breadth of pathologies (Janmey and Miller, 2011) as discussed 
in 1.1.3. Therefore, considerable efforts are currently directed toward determining 
how a variety of mechanical stimuli lead to the regulation of gene expression. 
 
Mechanotransduction is achieved through a rich set of mechanisms. In this 
introduction, only a few of them will be presented as examples. One of the best-
studied mechanisms of signal mechanotransduction is the conversion of physical 
forces into biochemical signal through protein structural refolding. In general, proteins 
adopt the conformation that favors the lowest free energy. Therefore, changes in the 
energy landscape induced by physical strains lead to the reshaping of the protein 
(Orr et al., 2006). This process is comparable to other post-translational modifications 
      
 
Figure 4. Mechanosensitive channels  
(a) Mechanism of activation of mechanosensitive channels (MSCs). The channel occupies a restricted 
area in resting, while proceeding to rearrangement into open conformation to decrease energy cost 
due to membrane tension and exposition of its hydrophobic part induced by membrane thinning. (b) 
Schematic structure of Piezo1 viewed from above, showing the three “propeller blades” surrounding a 
centrale pore (left). Side view of the structure of Piezo1 (center). When the cell is not submitted to to 
pressure, Piezo1 bends to make a dome-like structure pointing inside the cell, and the channel is 
closed. When the membrane is stretched the complex flattens, openning the channel (Chesler et al., 
2018).
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such as phosphorylation. Phosphorylation introduces a negatively charged 
phosphate group, inducing protein refolding due to charge repulsion in the inner 
structure of the protein. These modifications will then induce structural changes that 
will modulate the catalytic activity or the interaction ability to transduce a signal. 
1.2.1 Mechanosignaling at the plasma membrane 
The best example of plasma membrane mechanotransducers are 
mechanosensitive channels (MSCs) such as voltage gating mechanochannels 
(Martinac, 2004). These channels can sense membrane stretch and curvature. 
Pressure sensitive channels such as Piezo 1 and 2 are also an emerging important 
category of MSCs (Coste et al., 2011). Increasing the membrane tension, increases 
the probability to open the channel (Martinac and Hamill, 2002). In this context, 
MSCs opened conformation occupies a greater space in the stretched lipid bilayer, 
favoring lower free energy. Hence the opening of this gate induces membrane 
permeability to ions (Fig. 4). The inner leaflet of the plasma membrane is negatively 
charged therefore the arrival of positively charged ions into the cytoplasm leads to 
membrane depolarization and generates an electrical signal. Moreover Ca2+ entry 
through MSCs also leads to the activation of Ca2+ sensitive molecules such as 
calmodulin domain-containing proteins. Piezo and the other MSCs are involved in 
many biological processes such as hearing, touch, nociception and proprioception.
1.2.2 Mechanosignaling in the cytosol 
On the other hand, direct application of a stalling force against a molecular 
motor or an enzyme inhibits its catalytic activity, most likely by unfolding its catalytic 
domain (Finer et al., 1994; Yin et al., 1995; Ingber, 2006).  Similarly, some proteins 
unfold in a stepwise manner when they are mechanically extended. This unfolding 
may lead to the exposure of cryptic binding or phosphorylation sites for potential 
signaling downstream effectors (Ingber, 2006) (Fig. 5a). In addition, mechanical 
strains can also influence signal transduction by strengthening or weakening protein-
protein interaction (Evans and Calderwood, 2007). 
 
      
 
 
Figure 5. Mechanotransduction at the level of the protein and protein complex 
(a) Stress on mechanosensors can induce conformational changes generating a biochemical signal 
(based on Ding et al., 2013). (b) Cas molecule with unextended configuration of substrate domain and 
with moderate extension of substrate domain at the cell-matrix contact site of spread cells, 
respectively (left). Extension-dependent phosphorylation of Cas substrate domain by SFK and 
enhancement of its downstream signaling. SH3 and SB represent the SH3 and Src-binding domain of 
Cas, respectively (right) (Sawada et al., 2006). 
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Focal adhesion sites (FA) are probably the most studied mechanosignaling 
platforms. Its direct link with the cell cytoskeleton and the ECM put this structure in 
perfect position to transduce mechanical signals. Mechanical forces directly control 
the shape, size and dynamics of FA (Galbraith et al., 2002). Indeed, clusters of 
integrins (focal adhesion) can generate forces on the overall cell through the 
cytoskeleton. Nevertheless, focal adhesion can sense mechanical forces (Grashoff et 
al., 2011). For example shear stress-induced cytoskeletal reorganization is controlled 
by integrins activation balance (Macek Jilkova et al., 2014). Integrins are connected 
to the cytoskeleton through several adaptor proteins such as talin, vinculin, zyxin, 
Cas etc., which are as many components susceptible to transduce mechanical cues. 
 
For example, talin directly links integrins to the actin filaments. Upon ECM 
deformation or actomyosin contractions, talin rods are stretched and deformed by the 
mechanical strain. The unfolding of talin unveils cryptic binding sites for vinculin 
interaction (Fig 5a). Hence, talin unfolding leads to the recruitment of vinculin that 
strengthen the link with filamentous actin and cluster the integrins into focal adhesion 
sites (del Rio et al., 2009). 
 
Similarly, p130Cas (Crk associated substrate) binds to the focal adhesion 
kinase (FAK) and the Src family of protein kinase (SFK). Upon cell stretch, Cas 
substrate domain unfolds exposing phosphorylation sites (Fig. 5b). Their 
phosphorylation by the SFK kinase triggers the recruitment of signaling partners and 
the activation of the p38/MAPK pathway through Ras associated protein 1 (Rap1) 
activation (Sawada et al., 2006). 
 
Another example of cytosolic mechanotransduction is the yes associated 
protein/taffazin (YAP/TAZ) pathway that controls processes such as proliferation and 
differenciation (Dupont et al., 2011; Mosqueira et al., 2014). YAP/TAZ is an emerging 
mechanotransduction pathway. It transduces mechanical signals from the 
cytoskeleton to the nucleus. YAP/TAZ are transcriptional co-factors that are well 
studied in the context of the Hippo signaling, where upstream large tumor suppressor 
kinases (LATS) phosphorylate YAP and TAZ leading to their cytosolic retention (Low 
et al., 2014). There are clear evidences linking YAP/TAZ regulation to cell 
mechanics. Indeed, the subcellular distribution of YAP/TAZ is highly dependent on 
      
 
Figure 6. Schematic representations of mechanical stimuli influencing YAP and 
TAZ subcellular localization and activity 
When YAP and TAZ are mechanically activated (red), they translocate to the nucleus, where they 
interact with TEA domain family factors (TEAD) to regulate gene expression (top). Schematics 
illustrating how different matrix, geometry and physical conditions influence YAP and TAZ localization 
and activity: the left panels show conditions in which YAP and TAZ are inhibited and localized to the 
cytoplasm, whereas the right panels show conditions that promote YAP and TAZ nuclear localization 
(indicated by red coloring of cell nuclei) (Panciera et al., 2017).  
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cell mechanics and matrix physical properties (Fig. 6). For example cells cultured on 
soft substrate exhibit a cytosolic YAP/TAZ distribution, while those grown on stiff 
microenvironment exhibit a nuclear YAP/TAZ localization and those residing in an 
“in-between” microenvironment stiffness possess an evenly distributed YAP/TAZ 
localization. Therefore, substrate stiffness but also cell shape controls YAP/TAZ 
distribution (Dupont et al., 2011). Yet, how mechanical cues regulate YAP/TAZ 
localization and activity is still unknown, however it is tightly dependent on the F-actin 
organization, contraction and cytoskeletal mechanics (Dupont et al., 2011; Aragona 
et al., 2013). Propagation of tensile forces through the cytoskeleton induced by 
actomyosin network contraction or ECM deformation pulling on cytoskeleton-linked 
integrins leads to YAP and TAZ activation (Taniguchi et al., 2015; Hu et al., 2017). 
The cytoskeleton is also connected to the nucleus; therefore, force propagation 
through the cytoskeleton may also reach the nucleus thereby directly affecting 
nuclear mechanics and the regulation of YAP/TAZ nuclear translocation as detailed 
in the next chapter.  
1.2.3 Nuclear mechanotransduction  
Mechanotransduction is not a process only restricted to “surface” receptors. 
An array of biological processes such as cell migration, programmed necrosis or 
infection trigger nucleus deformation (swelling, squeezing and stretching). For 
example, a transient decrease of extracellular osmotic pressure promotes nuclear 
swelling (Irianto et al., 2013). External mechanical strains can also exert direct 
mechanical forces on the nucleus since it is connected to the cell surface through the 
cytoskeleton via the linker of nucleoskeleton and cytoskeleton (LINK) complex. In a 
metastatic context, tumor cells have to squeeze through the extracellular matrix 
fibers subjecting their nucleus to deformations. Interestingly, the nucleus appears to 
be a good mechanotransduction organelle. Indeed, the nuclear envelope participate 
less to cell trafficking, therefore its overall area fluctuates less. Moreover its 
membrane is more loose and easy to stretch, thus it is more prone to detect external 
strains (Bigay and Antonny, 2012). The nuclear envelope possesses a dynamic 
structure that can rapidly adapt to tensile force by adjusting its stiffness via the 
phosphorylation of proteins of the nuclear envelope such as emerin (Guilluy et al., 
      
 
Figure 7. Mechanosensitive calcium signaling in the nucleus 
 
Figure 8. Proposed model of mechanosensitive nucleoplasmic shuttling 
(Elosegui-Artola et al., 2017)   
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2014). The nuclear envelope serves as scaffold for the activation of important 
peripheral proteins. Hence, nuclear expansion induced by cell swelling leads to the 
recruitment of the phospholipase enzyme cPLA2 and the 5-lipoxygenase (LOX) at the 
inner face of the nuclear membrane. This promotes LOX-dependent generation of 
pro-inflammatory eicosanoids such as leukotrienes, which are key factors in 
inflammatory diseases such as asthma (Peters-Golden and Brock, 2001). Nuclear 
mechanics can also directly control gene expression. Indeed, some MSCs are found 
in the nuclear envelope and mediate Ca2+ release in response to nuclear and 
endoplasmic reticulum stretch induced by cell spreading. For example, the nuclear 
mechanical release of Ca2+ regulates gene expression through the cAMP responsive 
element binding (CREB) and myocyte enhancer factor 2 (MEF2) transcription factor 
phosphorylation by the calmodulin dependent kinase IV (Itano et al., 2003) (Fig. 7). 
Nucleus deformation also alters the integrity of the nuclear pores. Indeed, the 
crossing of molecules through the nuclear envelope via these nuclear pores is a key 
and tightly regulated step of many signaling cascades to achieve the regulation of 
gene expression and by extension the cellular responses. The nucleus deformation 
stretches the nuclear pores thereby decreasing the energy requirement for molecular 
transport through these structures. Nuclear deformation and the consecutive nuclear 
pores stretch have been shown to trigger YAP nuclear translocation and might be a 
more general mechanism for other signaling molecules (Elosegui-Artola et al., 2017) 
(Fig. 8). Finally, harsh nuclear deformation induced by nuclear squeezing during cell 
migration, can result in nuclear membrane damages releasing DNA in the cytoplasm. 
This situation promotes the activation of damage-sensing pathways including cyclic 
GMP-AMP synthase and stimulator of interferon genes (cGAS-STING) pathway and 
triggers the expression of immunomodulatory genes such as interferons (Raab et al., 
2016). 
 
To summarize, mechanical forces generated by external strains can modify 
protein folding and larger complex organization inside the cell, thereby changing their 
biochemical properties and therefore transforming mechanical cues into biochemical 
signals. Nevertheless, studies demonstrated that larger structure such as plasma 
membrane nanodomains called caveolae can also respond to mechanical strains 
applied to the plasma membrane (Sinha et al., 2011).  
      
 
Figure 9. Visualization of the caveolar coat at the plasma membrane of 
myotubes  
Survey view of the cytoplasmic surface of an unroofed myotube presenting caveolae at the plasma 
membrane. Different types of caveolae structures are apparent, ranging from flat (1), circular (2), to 
fully budded (3). Scale 500 nm. Scale bar in insets: 50 nm (from Lamaze et al., 2017) 
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2 The caveolae: specialized plasma membrane structures 
More than sixty years ago, fine plasma membrane structures identified by 
electron microscopy as “caves” or “cave-like indentation of the plasma membrane” 
thereby named caveolae, were first visualized in blood capillaries and mouse gall 
bladder by George E. Palade and Eichi Yamada (Palade, 1953; Yamada, 1955). 
These plasma membrane invaginations are smaller than clathrin coated pits since 
their diameter varies between 50 and 80 nm and they present a striated coat 
(Rothberg et al., 1992) (Fig. 9). Caveolae are also found as interconnected caveolar 
structures named “rosette” (Pelkmans and Zerial, 2005).  Adipocytes, endothelial and 
muscle cells are particularly enriched in caveolae, yet almost all mammalian cell 
types possess caveolae except neurons and lymphocytes despite their expression of 
caveolin-1.  
2.1 Structure and composition 
The first step to fully understand the function of these “cave-like” plasma 
membrane structures was to elucidate their molecular composition. Therefore, since 
the discovery of caveolae, a lot of effort has been put toward the identification of their 
molecular composition and organization. 
2.1.1 Caveolar proteins 
2.1.1.1 Caveolins/
Almost forty years after the first visualization of caveolae, structural studies of 
the caveolae inner face (facing the cytoplasm) revealed a striated coat composed of 
“filaments”. These filaments have been first identified as a 22 kDa substrate for v-src 
tyrosine kinase in virus-transformed chick embryo fibroblasts and therefore called 
caveolin (Rothberg et al., 1992). The same year, a vesicular integral-membrane 
protein of 21 kDa (VIP21) was also found by another team to be an important 
component of the caveolar coat (Kurzchalia et al., 1992). Actually, these two newly 
      
 
Figure 10. Caveolins domains and insertion in the plasma membrane 
(a) Conserved domains of the caveolin protein family. An oligmerization domain encompassing an 8 
amino acids stretch signature motif (FEDVIAEP) and the caveolin scaffolding domain followed by the 
transmembrane domain. Length variability of caveolins -1β, -2 and -3 is the consequence of truncated 
N-terminal part. (b) Proposed model of caveolin-1 (Cav1) topology within the lipid bilayer. Cav1 is 
inserted in the plasma membrane inner leaflet via its TMD conferring a hairpin-shaped topology. Both 
N- and C-termini are facing the cytoplasm (based on Parton and del Pozo, 2013). (c) Computational 
analysis of Cav1 insertion within the plasma membrane. Snapshot of the insertion of Cav182-136 is 
shown in the illustration with the CRAC motif in cyan and putative TMD in magenta as well as the N-
terminus in green. The Cαatoms of G108-P110 are shown in spheres. W98, W115 and W128 are 
shown in sticks. Cholesterol molecules and, ions and water are hidden for clarity (Liu et al., 2016). 
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discovered caveolar proteins appeared to be the same (Glenney and Soppet, 1992). 
Hence, it has been decided that both v-src substrate in Rous sarcoma virus-
transformed fibroblasts and VIP21 would be renamed as caveolin. This is how the 
first member of the caveolin family has been identified thus named as caveolin-1 
(Cav1), shortly followed, by the identification of two homologues: caveolin-2 (Cav2) 
and the muscle restricted isoform: caveolin-3 (Cav3) (Way and Parton, 1995). 
 
Cav1 molecules (and Cav3 in muscle cells) are essential components of 
caveolae. Indeed, these two proteins are required for caveolae biogenesis. Lack of 
Cav1 or Cav3 leads to mis-invagination of the caveolae. Caveolins can form 
structures of higher complexity by homo and hetero-oligomerization into 300 kDa 
complexes (Sargiacomo et al., 1995). All the caveolin isoforms share a signature 
motif of eight amino acids 68FEDVIAEP75 localized in their oligomerization domain 
(Fig. 10a).  
 
Cav1 is the most studied member of the caveolin family. Cav1 is an integral 
plasma membrane protein of 178 amino acids with both N- and C-termini facing the 
cytoplasm (Monier et al., 1995; Aoki et al., 2010) (Fig. 10b). Its structure remains 
debated and mainly relies on predictions based on circular dichroism (CD), nuclear 
magnetic resonance (NMR) and computational analysis. From these studies, we 
know that Cav1 crosses only the inner leaflet of the plasma membrane through a 
putative hairpin-shaped transmembrane domain (TMD) predicted to be from L102 to 
I134 (Razani et al., 2002a). The TMD adopts a helix-break-helix topology (Lee and 
Glover, 2012) (Fig. 10c). Indeed the two α-helices are separated by three residues 
linker regions containing a proline 110 that induces a 50° angle between those two 
helices (Root et al., 2015). The TMD adopts a U-shaped conformation (Aoki et al., 
2010) and plays a key role in the oligomerization ability of Cav1 and Cav2 (Das et al., 
1999). The insertion of the TMD within the inner leaflet of the plasma membrane 
thereby displacing lipids of the inner layer has been proposed to induce membrane 
curvature (McMahon and Gallop, 2005). The Cav1 C-terminal end (K135-I178) is 
involved in plasma membrane attachment, trans-Golgi localization and oligomer-
oligomer interaction (Song et al., 1997; Schlegel and Lisanti, 2000) . Moreover, it 
presents three palmitoylation sites on C133, C153 and C156, which are not required 
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for Cav1 anchorage to the plasma membrane but may influence Cav1 
oligomerization (Dietzen et al., 1995; Monier et al., 1996).  
 
The most prominent domain of Cav1 is the caveolin scaffolding domain (CSD) (Fig. 
10a). Indeed this domain is involved in Cav1 oligomerization, protein-protein 
interaction, and cholesterol recognition/binding (Li et al., 1996; Couet et al., 1997; 
Schlegel et al., 1999). However, the role of the CSD in the control of biological 
processes such as signaling remains somehow controversial (developed in 2.3.4.4 
and discussion)(Collins et al., 2012). The CSD topology is not clear, and was first 
proposed to be a fully amphipathic α-helix that partially lies inside the plasma 
membrane inner leaflet (Le Lan et al., 2006), then later appeared to be a mixture of β 
and α structures (Hoop et al., 2012). More recently, the CSD was proposed to adopt 
a dynamic structure that can be either fully helical or partially unstructured (Liu et al., 
2016). Interestingly, Cav1 also exhibits a high affinity for cholesterol (Murata et al., 
1995). Cholesterol recognition is achieved through the cholesterol 
recognition/interaction amino acid consensus (CRAC) motif within the CSD. Since 
Cav1 has been first discovered as a tyrosine kinase substrate, it was later shown that 
Cav1 can be phosphorylated on its tyrosine 14. More recently, serine 80 has been 
found to be phosphorylated. Yet, the precise function of these two post-translational 
modifications is not well understood. Tyr14 phosphorylation has been recently 
proposed to mediate signaling (Joshi et al., 2012) and Cav1 conformation changes 
(further developed in the discussion) to regulate the CSD accessibility (Shajahan et 
al., 2012; Meng et al., 2017). The Ser80 phosphorylation is required for proper 
caveolae formation (Ariotti et al., 2015) and triggers its binding to the endoplasmic 
reticulum (ER) membrane in the context of regulated secretion of pancreatic cells 
(Schlegel et al., 2001). Finally, Cav1 can be ubiquitinated, a process that mediates 
Cav1 lysosomal degradation (Hayer et al., 2010a).  
 
Cav1 encompasses two isoforms: a full-length α isoform (α-Cav1) and a 
truncated β-isoform (β-Cav1). The β-isoform lack the first thirty-three amino acids, 
hence it cannot be phosphorylated on Tyr14.  
 
Few years after the identification of Cav1, a homologue of α-Cav1 was 
discovered by nucleotide sequence alignment. Cav3 shares common features with 
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Cav1 such as the caveolin signature motif, an oligomerization domain, an 
hydrophobic 102-134 TMD, a CSD and palmitoylation sites (Way and Parton, 1995; 
Tang et al., 1996) (Fig. 10a). Moreover, Cav1 and Cav3 can form hetero-oligomeric 
complexes with Cav1 in cardiac myocytes (Volonte et al., 2008). Cav3 also lacks the 
first twenty-seven aa, hence, neither Cav3 undergoes Tyr14 phosphorylation.  
 
The purification of membrane fractions enriched in caveolae revealed the 
existence of a last member of the caveolin family: caveolin-2 (Cav2). Indeed, this 
isoform shares the common signature motif in its N-terminal part. It has been first 
described to differ from Cav1 from its inability to interact with the heterotrimeric G 
protein (Scherer et al., 1996). Moreover, Cav2 colocalizes with Cav1 indicating that 
Cav2 is a component of the caveolar coat (Scherer et al., 1996; Tang et al., 1996). 
There are two Cav2 isoforms: α-Cav2 and β-Cav2 that are respectively shortened by 
16 and 29 aa compared to α-Cav1 (Fig. 10a). Likewise, Cav2 is not phosphorylated 
on its Tyr14. Unlike the other members of the caveolin family, Cav2 cannot homo-
oligomerize, but it can dimerize and hetero-oligomerize with other caveolins (Scherer 
et al., 1996, 1997). α-Cav2 can be tyrosine phosphorylated on its residues 19 and 27 
and serine phosphorylated on its residues 23 and 36. In addition Cav2 can be fatty 
acylated. However, the function of these post-translational modifications remains 
poorly understood. Cav2 serine phosphorylation participates to caveolae 
morphogenesis (Sowa et al., 2003). On another hand both Cav2 fatty acylation and 
phosphorylation have been reported to play a role in insulin signaling (Kwon et al., 
2009; Kwon and Pak, 2010; Kwon et al., 2015). For example Cav2 phosphorylation 
prevent the interaction between the insulin receptor and a signal terminator (Kwon 
and Pak, 2010).  
 
To conclude, caveolins are integral plasma membrane proteins possessing a 
characteristic hairpin shaped topology with both N- and C-termini facing the 
cytoplasm. They all share a common signature motif in their N-terminal part and an 
oligomerization domain allowing the formation of complex oligomerized structures 
that compose an essential part of the caveolar coat.  
      
 
 
Figure 11. Cavins structure and caveolae morphogenesis 
(a) General structural organization of cavins. Three disordered regions (DR) are separated by two 
coiled coil (ordered) regions (HR) (adapted from Kovtun et al., 2014). (b) Cavins domains. PEST 
domain mediates cavins degradation and Leu-rich domain mediates protein-protein interaction (based 
on Bastiani et al., 2009). Cavin sizes are heterogenous. Cavin-1 is the only member possessing 
nuclear localization sequences. 
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2.1.1.2 Cavins/
Cavins are a family of cytosolic proteins which comprises four members: 
PTRF, SDPR, SRBC and MURC. Their caveolar localization and function pushed the 
scientists to gather these proteins under the name of “cavins” and rename them from 
cavin-1 to cavin-4 (Vinten et al., 2005; Bastiani et al., 2009; McMahon et al., 2009). 
As the caveolin family, the last member of the cavin family (cavin-4) is restricted to 
muscle cells (Ogata et al., 2008). Initially, polymerase 1 and transcript release factor 
(PTRF) was first identified as a regulator of RNA polymerase 1 (Jansa et al., 2001). 
Vinten and colleagues identified a 60 kDa protein associated with the caveolar coat 
in adipocytes. The protein was therefore called cavP60 (Vinten et al., 2001). Three 
years later PTRF has been reported to be enriched at the caveolar coat (Aboulaich et 
al., 2004), shortly after, PTRF and cavP60 appeared to be the same protein and thus 
were renamed cavin (Vinten et al., 2005). 
 
SDPR was first described as a phosphatidylserine binding protein thus named 
PS-p68 (Burgener et al., 1990). When it was involved in serum deprivation response, 
it was renamed serum deprivation-response protein (SDPR) (Gustincich and 
Schneider, 1993). SDPR was shown to associate together with the protein kinase C 
α (PKCα) to the caveolar coat (Mineo et al., 1998). The SDPR-related gene product 
that binds to c-kinase (SRBC) was also involved in the serum deprivation response 
and first identified as a binding partner of PKCδ and thus named protein kinase C 
delta-binding protein (PRKCDBP) (Izumi et al., 1997). Both SRBC and SDPR were 
found in the mass spectrometry analysis that identified cavin-1 (Aboulaich et al., 
2004). 
 
Cavin-1 is required for caveolae formation (Hill et al., 2008; Liu et al., 2008). 
Cavins are proteins from 31 to 47 kDa with 261 to 425 amino acids. The four proteins 
share the same topology (Hansen et al., 2009). In silico analysis revealed that cavins 
possess two conserved α helical regions (HR) that are basic and positively charged. 
These HR regions are separated by acidic and negatively charged disordered 
regions (DR) (Fig. 11a). The HR1 region mediates cavin trimeric oligomerization 
(Kovtun et al., 2014). Indeed, cavin-1 can form trimers with either two cavin-1 or with 
cavin-1 and cavin-2 or with cavin-1 and cavin-3 (Fig. 14). All members of the cavin 
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family except cavin-4 carry a leucine zipper motif in the HR1 region that mediates 
protein-protein interaction (Fig. 11b). These leucine zipper domains are required for 
cavin recruitment at the plasma membrane (Wei et al., 2015b). Moreover all four 
cavins exhibit a short half-life due to the presence of PEST motifs that mediate 
proteasomal degradation (Fig 11b). Cavins have a basic C-terminal domain that 
participates to their membrane anchorage (Parton and del Pozo, 2013). Finally cavin-
1 possesses two nuclear localization signals (Hansen and Nichols, 2010). 
 
All cavins exhibit multiple phosphorylation sites. For example cavin-1 
possesses more than twenty tyrosine and serine phosphorylation sites (Kovtun et al., 
2014). Cavin-1 phosphorylation has been linked to Cav1 phosphorylation in the 
context of insulin signaling (Kruger et al., 2008) and have been suggested to 
participate to the control of cavin-1 fragmentation at the caveolar coat (Aboulaich et 
al., 2004). Cavins binds to phosphatidylserine (Ptdser) (Burgener et al., 1990). In 
addition cavin-1 and cavin-2 exhibit a high affinity for phosphatidyl 4,5 bisphosphate 
(PiP2) (Kovtun et al., 2014). 
 
In summary, cavins are cytosolic proteins associated to the caveolar coat. All 
four cavins present a similar strucuture with a first coiled coil helical region that 
mediates trimeric association and a second coiled coil helical region that mediates 
hetero-association of cavin trimers.   
2.1.1.3 Accessory/proteins/
Several non-essential caveolar components have been also identified since 
then. The F-BAR protein PACSIN2 (Protein Kinase C and Casein Substrate In 
Neurons) also called syndapin 2, which regulates and senses membrane curvature 
and participates to caveolae morphogenesis (Hansen et al., 2011; Senju et al., 
2011). The dynamin2 GTPase and the dynamin-like ATPase Eps15 homology-
domain containing protein 2 (EHD2) oligomers localize at the caveolar neck (Oh et 
al., 1998; Stoeber et al., 2012; Ludwig et al., 2013). While dynamin2 is involved in 
caveolae internalization, EHD2 controls caveolar dynamics and stability at the 
plasma membrane (Morén et al., 2012). In addition EHD2 and other EHDs (1 and 4) 
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are responsible for caveolae clustering into membrane ultrastructure during 
mechanical stress (Yeow et al., 2017). More recently, our laboratory also 
demonstrated that EHD2 links caveolar dynamics to gene transcription, since 
mechanical release of EHD2 in the cytosol leads to its nuclear translocation and 
initiation of transcriptional programs (Torrino et al., 2018, submitted).  
2.1.2 Lipid composition  
Very early, it was shown that caveolae are plasma membrane nanodomains 
enriched in sphingolipids (Tran et al., 1987) and cholesterol (Rothberg et al., 1990). 
Moreover their resistance to detergent treatment (Sargiacomo et al., 1993) primarily 
led the scientists to classify caveolae as “lipid raft” and later as caveolin-enriched 
nanodomains (Simons and Ikonen, 1997; Simons and Sampaio, 2011). The lipid 
composition of caveolae may be explained by the affinity of the caveolar components 
such as Cav1 or cavin-1 for specific lipids. As mentioned in the chapter 2.1.1.1 Cav1 
exhibit a high affinity for cholesterol mediated by its CRAC motif (Murata et al., 1995; 
Thiele et al., 2000; Epand et al., 2005). Cholesterol is an essential caveolar 
component required for bona fide caveolae biogenesis. Indeed, drugs removing 
cholesterol lead to caveolae flattening and disassembly (Rothberg et al., 1992). 
Likewise, cavins binds to Ptdser with high affinity and specificity (Burgener et al., 
1990; Hill et al., 2008), which is a key element of the plasma membrane that 
influences caveolae assembly and dynamics. Indeed, decreased Ptdser induced by 
cavin-1 loss impairs caveolae stability/formation (Hirama et al., 2017). In addition 
Cav1 has been shown to bind in vitro to Ptdser and phosphatidylinositol 4,5 
bisphosphate (PiP2) through its scaffolding domain (Arbuzova et al., 2000; Wanaski 
et al., 2003) which most likely constitute a common binding site for cholesterol, 
Ptdser and PiP2. In addition, caveolae lipid composition not only consists of Ptdser 
and PiP2 but also of sphingolmyelin, glycerophopholipids, and gangliosids such as 
GM1 (Iwabuchi et al., 1998; Ortegren et al., 2004; Sonnino and Prinetti, 2009).  
      
 
Figure 12. Putative model of caveolar coat assembly and organization 
(a) Schematic model of Cav1 topology. Cav1 is inserted into the plasma membrane through the 
caveolin scaffolding domain (CSD; red), an amphipathic helix part of the oligomerization domain 
(diffuse red), and through a second amphipathic helix, the intra-membrane domain (orange). Based on 
Cav3 ternary structure, Cav1 monomers may assemble as a disk-shaped oligomer with the C-terminal 
part oriented toward the center. (b) Cavin monomers exhibit two helical rich domains, HR1 and HR2, 
that may form coil-coiled structures. Cavins, through interaction with the HR1 domain, can form trimers 
consisting of either three cavin-1 or two cavin-1 associated with one cavin-2 or one cavin-3 protein. 
The cavin-1 isoform could be responsible for a more complex assembly through the coiled-coil domain 
2 (cc2) sequence in the HR2 domain. (c) At the plasma membrane, Cav1 oligomers cluster specific 
lipids such as cholesterol, PI(4,5)P2 and phosphatidyl serine involved in the recruitment of cavin 
trimers. This is followed by caveola invagination, a process not completely understood. It has been 
recently suggested that the overall architecture of the caveolar coat made of caveolins and cavins 
would best fit with a polyhedron structure. In this model, Cav1 oligomers position on each pentagonal 
face and cavin complexes align with the vertices and cover the Cav1 oligomers. (from Lamaze et al., 
2017)  
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2.1.3 Caveolar ultrastructure 
For many years not much was known on caveolae ultrastucture. Only very 
recent data allowed the scientists to glimpse the caveolar coat structure. 
Approximately 150 to 200 Cav1 monomers associate with 15-20 cavins trimers to 
form a caveola. It was proposed that the caveolins oligomerize and organize as 
“discs” where N-ter ends are at the periphery of the discs, mediating oligomerization 
and C-ter at the center of the discs. Each disc constitutes a pentagonal face of the 
caveolar dodecahedron. The net of cavins stabilizes the caveolin discs within the 
caveolae (Pelkmans and Zerial, 2005; Ludwig et al., 2013; Gambin et al., 2014; 
Ludwig et al., 2016; Stoeber et al., 2016; Lamaze et al., 2017) (Fig. 12). But still, this 
hypothesis does not perfectly match the organization of the caveolar coat when 
observed with deep-etch EM. 
2.2 Caveolae biogenesis: from protein synthesis to the caveolar bulb 
Caveolae biogenesis requires the recruitment of several essential elements 
(Fig. 12). Cav1 and Cav3 are essential for caveolae biogenesis since their depletion 
causes a complete loss of caveolae in their respective tissues (Drab et al., 2001; 
Galbiati et al., 2001). In contrast Cav2 is not essential for caveolae formation (Razani 
et al., 2002b), however it may participate to caveolae formation in some cell types 
(Lahtinen et al., 2003; Sowa et al., 2003). For several years, Cav1 was believed to be 
sufficient for caveolae biogenesis since exogenous expression of Cav1 generated 
caveolae-like structures at the plasma membrane of lymphocyte and bacteria (Fra et 
al., 1995; Walser et al., 2012).  Nevertheless, cavin-1 identification brought to light a 
new essential component for bona fide caveolae formation. Indeed cavin-1 ablation 
leads also to a loss of caveolae. Yet, due to transcriptional co-regulation of cavin-1 
and all three caveolins, cavin-1 knocked out mice exhibit a markedly decreased 
caveolins expression (Liu et al., 2008). Therefore it was not clear whether this 
phenotype was attributable to cavin-1 loss. By using prostate cancer cells (PC3) and 
notochord cells of zebrafish that have the particularity to express caveolins despite 
the lack of cavin-1 expression, Hill and colleagues observed in the absence of cavin-
1, caveolins! remaining in “flat” caveolae (Hill et al., 2008). From these studies, it 
      
 
 
Figure13. Model of caveolae assembly and biosynthetic trafficking of Cav1 
(Hayer et al., 2010b) 
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clearly appeared that both Cav1/3 and cavin-1 are necessary for de novo caveolae 
formation. Evolutionary studies revealed that caveolins are conserved among 
vertebrates and invertebrates. Nevertheless there are no evidences supporting the 
ability of CeCav1 to form caveolae in C.elegans (Kirkham et al., 2008). In addition the 
absence of orthologues of cavin gene family in invertebrate suggests that this family 
is restricted to vertebrate and that caveolae morphogenesis appeared with cavins 
evolution (Hansen and Nichols, 2010). Furthermore it suggests that caveolins may 
have biological functions independently from caveolae. 
2.2.1 Caveolin-1: Tale of a journey from the ER to the plasma membrane 
During Cav1 mRNA traduction, the signal recognition motif of the newly 
synthetized N-ter protein is recognized by SRP (Signal Recognition Particle), 
allowing Cav1 concomitant ribosomal synthesis and integration into the ER 
membrane (Monier et al., 1995). After its synthesis, Cav1 undergoes a first stage of 
homo-oligomerization of 7-14 Cav1 into 8S complexes in the ER (Monier et al., 1996; 
Hayer et al., 2010b). Caveolins are then transported through COPII vesicles to the 
cis-Golgi apparatus, a process requiring the specific DXE export motif. In the median 
Golgi apparatus, Cav1 further oligomerizes into 140-160 Cav1 complexes of 70S and 
associates with cholesterol and specific lipids generating higher ordered 
nanodomains (Epand et al., 2005; Pelkmans and Zerial, 2005; Pol et al., 2005; Hayer 
et al., 2010b) (Fig. 13). The Cav1-dependent clustering of specific lipids will 
contribute to the recruitment of other caveolar coat components such as cytosolic 
cavins which have high affinity for Ptdser (Kovtun et al., 2014). 
2.2.2 Cavin recruitment and caveolae morphogenesis 
As mentioned above, cavins are cytosolic proteins identified as components of 
the caveolar coat. The striated structure observed in the caveolae cytosolic face has 
been recently proposed to be due to the presence of cavins rather than caveolin 
oligomers (Gambin et al., 2014; Kovtun et al., 2014; Ludwig et al., 2016; Stoeber et 
al., 2016). Cavins are recruited at the very last steps of caveolae morphogenesis; 
only after preassembled Cav1 oligomers are exported to the plasma membrane. 
      
 
 
 
 
 
 
 
 
 
 
Figure 14. Model for the assembly of the cavin coat (Kovtun et al., 2014) 
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Cavins were first believed to be recruited through interaction with Cav1 (Bastiani et 
al., 2009). However recent studies suggest that cavins are rather recruited by Ptdser 
and PiP2 at the caveolar nanodomains at the plasma membrane through 
electrostatic-based interactions between the negatively charged headgroups and the 
HR1 and HR2 cavin domains (Burgener et al., 1990; Hill et al., 2008; McMahon et al., 
2009; Hirama et al., 2017) (Fig. 12 and 14). Cavin-1 is necessary for the recruitment 
of other cavins and plays a key role for caveolae morphogenesis. Recently, cavin-1 
recruitment at caveolae have been suggested to play the role of a “net” that traps 
caveolin discs together and further invaginates the plasma membrane (Stoeber et al., 
2016) (Fig. 12). Cavin-2 is essential for caveolae biogenesis in specific tissues such 
as lung and adipose (Hansen et al., 2013). Cavin-2 recruits cavin-1 and regulates 
membrane curvature as cavin-2 overexpression generates membrane tubulations 
(Hansen et al., 2009). Together with cavin-3; it controls the budding and dynamics of 
caveolae (Nabi, 2009; Mohan et al., 2015). However, cavin-3 is not essential for 
caveolae biogenesis as cavin-3 knock out does not impair caveolae formation in 
mouse model (Liu et al., 2014). In contrast the role of cavin-4 in caveolae 
morphogenesis remains elusive (Bastiani et al., 2009; Hansen and Nichols, 2010). 
2.2.3 Recruitment of accessory proteins 
In addition to essential proteins, a set of accessory proteins is recruited to the 
caveolar coat to control caveolae dynamics. The dynamin-like ATPase EHD2 is 
recruited at the level of the caveolar neck in an ATP binding dependent manner and 
requires its homo-oligomerization. EHD2 is involved in caveolae dynamics since it is 
associated to the static population of caveolae. Indeed, EHD2 depletion leads to an 
increase of caveolar dynamics while EHD2 overexpression induces caveolar 
retention at the plasma membrane (Morén et al., 2012; Stoeber et al., 2012). 
Moreover dynamin 2 is also localized at the caveolar neck and mediates caveolae 
budding and fission (Pelkmans et al., 2002). Caveolar retention by EHD2 is mediated 
by preventing dynamin2 recruitment by both EHD2 and PACSIN2 (Senju and 
Suetsugu, 2015). PACSIN (Syndapin) family members PACSIN2 and the muscle-
restricted isoform PACSIN3 are also localized at the caveolar structures. Their 
mechanism of recruitment remains unknown. However, PACSIN2 phosphorylation 
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modulates its binding to the plasma membrane. Moreover PACSIN2 depletion 
decreases caveolae population and increases caveolins and cavins complexes at the 
plasma membrane (Hansen et al., 2011; Senju et al., 2015).  
2.3 Caveolae functions  
Caveolar accessory proteins participate to the tight regulation of caveolae 
dynamics and mechanics. Moreover, caveolae constitute a large fraction of the 
plasma membrane. Therefore it is not surprising that caveolae play critical roles in 
highly regulated cellular processes. Indeed, as it has been emphasized in the 
literature, many functions have been ascribed to caveolae (Cheng and Nichols, 
2016). New caveolar functions are regularly unveiled and many others remain to be 
discovered.  
2.3.1 Caveolae mediated endocytosis and trafficking 
Due to their resemblance with other vesicular shaped endocytic structures, the 
role of caveolae in cargo internalization has been questioned early (Montesano et al., 
1982). However, studies on caveolae-mediated endocytosis are curbed by the lack of 
caveolae specific cargo and the inaccessibility from the outside of standard reagents 
such as antibodies to caveolar proteins. The simian virus 40 (SV40) has been 
described to enter the host cell through caveolae dependent endocytosis (Pelkmans 
et al., 2001). Nevertheless the specificity of this process has been later challenged as 
new studies suggesting that overexpressed exogenous Cav1 is degraded in the late 
endosome earlier misidentified as “caveosome” and SV40 would rather use another 
clathrin-independent endocytic pathway to enter the host cell (Engel et al., 2011; 
Hayer et al., 2010a). Cholera toxin subunit B (CTxB) and the autocrine motility factor 
receptor (AMFR) can be internalized through caveolae mediated endocytosis 
(Benlimame et al., 1998; Orlandi and Fishman, 1998). However both CTxB and 
AMFR are also internalized through other endocytic pathways therefore complicating 
the studies on their internalization through caveolae (Torgersen et al., 2001; Nichols, 
2002). Moreover, lipids such as lactoceramide and cholesterol can also trigger 
caveolae endocytosis (Pagano, 2003; Sharma et al., 2003; Le Lay et al., 2006). A 
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subpopulation of caveolae also undergoes a “kiss and run” process of cyclic rapid 
appearance/disappearance at the plasma membrane (Pelkmans and Zerial, 2005). In 
addition, like clathrin-coated pits, some caveolae can scission from the plasma 
membrane, a process depending most likely from the dynamin 2 GTPase, which is 
present at the neck of some caveolae (Oh et al., 1998). In contrast to clathrin-coated 
pits, caveolae are less dynamic and their budding frequency is more variable 
(Thomsen et al., 2002; Pelkmans and Zerial, 2005). After caveolae scission from the 
plasma membrane, caveolin enriched vesicles fuse with the early endosome or 
multivesicular bodies (MVBs) (Shvets et al., 2015). The presence of Cav1 in MVBs 
may generate extracellular vesicules (EVs) containing Cav1. Indeed, Cav1 has been 
found in EVs produced by prostate cancer cells (Llorente et al., 2004) and in the 
plasma of melanoma patients (Logozzi et al., 2009). Nevertheless, the role of 
caveolin secretion remains unknown. In addition, a crosstalk between caveolae and 
other endocytic pathways exists: caveolar component such as Cav1, Cav3 and 
cavin-1 can impact clathrin independent carriers (CLIC) and GPI-AP enriched 
compartment (GEEC), independently from the caveolae structure. The inhibition of 
CLIC/GEEC pathway by Cav1 and Cav3 is mediated by their CSD (Chaudhary et al., 
2014). Finally, caveolae have been found to mediate the transcytosis of several 
molecules such as low-density lipoprotein (LDL), albumin and insulin (Vasile et al., 
1983; Ghitescu et al., 1986; Bendayan and Rasio, 1996).  
2.3.2 Lipid homeostasis 
Caveolae sense and regulate plasma membrane composition. Indeed the 
affinity of caveolar components for certain lipid species contributes to the spatial 
organization of lipids within the plasma membrane. For example, the loss of caveolae 
impairs the distribution of Ptdser within the lipid bilayer therefore perturbing Ras 
spatial nano-organization (Ariotti et al., 2014). Moreover caveolae also regulate the 
plasma membrane lipid composition through internalization of lipids such as 
sphingolipids (Shvets et al., 2015). Cav1 has been shown to be essential for fatty 
acids flip-flop (Meshulam et al., 2006). Fatty acids have been proposed to be 
transformed into triacylglycerol, another lipid of caveolae in adipocytes (Ost et al., 
2005). In addition, the loss of caveolae leads to less abundant glycosphingolipids 
      
 
Figure 15. Caveolae mechanical disassembly 
At steady state, caveolae remain invaginated and the integrity of the caveolar coat is intact (left). In 
contrast, upon membrane tension increase induced by a mechanical stress, the caveolar coat 
disassembles. Caveolins are released, cavins are released in the cytoplasm and EHD2 is translocated 
in the nucleus to form a complex with KLF-7 and MOKA cofactors to induce transcriptional programs 
(middle). In recovery, the caveolar coat reform, EHD2 is exported from the nucleus. (from Torrino et 
al., 2018, submitted) 
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(GSL) GM3 and phospholipids such as Ptdser, phosphatidylcholine and 
phophatidylethanolamine due to marked decreased expression of their synthetic 
enzymes (Ariotti et al., 2014). Cav1 has been involved in cholesterol trafficking from 
the lysosome (Mundy et al., 2012). Finally, Cav1 and Cav2 can be associated with 
lipid droplets in adipocytes and other cell types, (Fujimoto et al., 2001; Ostermeyer et 
al., 2001; Pol et al., 2001; Blouin et al., 2008). 
2.3.3 Mechanoprotection  
More than forty years ago Dulhunty and Franzini-Armstrong proposed that 
caveolae might function as a membrane reservoir which functions as a safety valve 
to prevent membrane rupture in muscle cells subjected to mechanical stress. Using 
muscle cells of Rana Pipiens frogs, which are constantly subjected to 
contraction/stretch cycles, the authors observed the opening of the caveolar neck 
upon cell stretch up to non-physiological levels thereby increasing the surface area of 
the cell (Dulhunty and Franzini-Armstrong, 1975; Prescott and Brightman, 1976). 
Thirty-six years later, using “home-made” tools combined with advanced physics and 
biochemical techniques to study caveolae dynamics and mechanics, our laboratory 
definitely established the mechanoprotective role of caveolae and its underlying 
mechanism. Indeed, we demonstrated that upon membrane tension increase 
induced by mechanical stresses such as osmotic cell swelling or cell stretching, 
caveolae rapidly flatten out and disassemble to release the additional excess of 
membrane stored in their invagination thereby “buffering” the membrane tension 
increase (Fig. 15). This process is passive, i.e. it is ATP and actin independent. In 
contrast, caveolae reassembly is reversible and requires both ATP and actin (Sinha 
et al., 2011). Taking this newly discovered caveolar function into account, it is not 
surprising that most of cells within tissue subjected to mechanical stress generated 
by forces such as blood flow, muscular contraction/relaxation, bladder/lung swelling 
etc., have a large amount of caveolae. Interestingly, the mechanoprotective function 
of caveolae has been confirmed in vitro and in vivo as the lack of caveolae induced 
susceptibility to plasma membrane damages, impaired function of muscle cells in 
zebrafish and impaired notochord integrity during zebrafish development and 
endothelial cells integrity during increased cardiac output (Lo et al., 2015; Cheng et 
      
 36 
al., 2015; Garcia et al., 2017; Lim et al., 2017). Considering the wide breadth of 
biological processes controlled by caveolae, the rapid disappearance of those 
structures and the release of caveolar components in the cell may have critical 
consequences by associating these processes to mechanosensing. Based on this 
observation our laboratory hypothesized that caveolae may constitute 
mechanosignaling hubs as these scaffolding structures have been involved in cellular 
signaling (detailed below) (Nassoy and Lamaze, 2012). The first observed 
consequence of the stretch-induced caveolae disassembly was a redistribution of 
Cav1 and a spatial reorganization of GSLs within the lipid bilayer together with c-Src 
activation (Gervasio et al., 2011). More recently, we could show that upon caveolae 
disassembly, the caveolar accessory protein EHD2 accumulates in the nucleus 
where it acts as transcription cofactor (Torrino et al., 2018, submitted) (Fig. 15). 
2.3.4 Cell signaling 
Numerous studies have long associated caveolae to the regulation of cellular 
signaling. Indeed, Cav1 was primarily described as a substrate of the Src kinase and 
heterotrimeric G protein found in Cav1 rich domains. It has been therefore proposed 
early that caveolae might be involved in cell signaling (Lisanti et al., 1994). It is now 
clear that caveolae function as signaling scaffolds for a wide range of signaling 
proteins which are found associated with the caveolar coat or to directly interact with 
caveolar components (Cheng and Nichols, 2016; Lamaze et al., 2017 see annex 2). 
The role of Cav1 in the regulation of intracellular signaling remains however poorly 
understood. 
2.3.4.1 Indirect/regulation/of/signaling/
As mentioned earlier, caveolae play a key role in lipid sorting and 
GSL/cholesterol organization at the plasma membrane. Lipid nanoscale organization 
is a prominent parameter for the dynamics and structural integrity of transmembrane 
proteins such as plasma membrane receptors activation (Rao and Mayor, 2014; 
Blouin et al., 2016). Caveolae dynamics and mechanics could therefore actively 
modulate the activation of some plasma membrane signaling proteins (Nassoy and 
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Lamaze, 2012) (Fig. 17). For example, Cav1 depletion induces a redistribution of 
Ptdser and lipid composition changes within the plasma membrane resulting in the 
spatial reorganization of the lipid anchored Ras GTPase that control cell growth, 
proliferation and differentiation (Ariotti et al., 2014). In addition, stretch-induced 
caveolae disassembly leads to the redistribution of sphingolipids and Cav1 together 
with c-Src activation (Gervasio et al., 2011). On another hand, calcium pumps have 
been localized in caveolae (Fujimoto, 1993), and the mechanical disassembly of 
caveolae led to reduced Ca2+ through changes in Gαq/Cav1 association (Guo et al., 
2015). Since caveolae also mediate endocytosis and cell trafficking, they might also 
modulate the endosomal control of signaling by delivering signaling proteins to this 
compartment (Gonnord et al., 2012). 
2.3.4.2 Cavins=mediated/signaling/
The recently identified cavins such as cavin-1 may also play a role in caveolar 
signaling, as it is required for proper caveolae morphogenesis and functions. Indeed 
cavin-1 control the number of functional caveolae and therefore is a key element for 
the proper targeting of receptors in these structures (Moon et al., 2013; Li et al., 
2014). For example, cavin-3 mediates ERK and Akt signaling by anchoring the 
caveolae at the plasma membrane through the myosin-1c (Hernandez et al., 2013) 
and regulates their dynamics (Mohan et al., 2015). 
2.3.4.3 Signaling/through/Cav2/
Cav2 remains the least studied caveolar component; hence its functions are 
poorly understood. However, Cav2 has been reported to play important roles in 
signaling pathways. Indeed Cav2 is required for proper estrogen receptor α (ER-α) 
activation by 17β estradiol (Totta et al., 2016). Moreover, Cav2 phosphorylation and 
fatty acylation seem to regulate insulin signaling. These two post-translational 
modifications prevent the interaction of the signal terminator SOCS3 with the insulin 
receptor thereby allowing the activation of IRS-1 and STAT3 (Kwon and Pak, 2010; 
Kwon et al., 2009, 2015). Surprisingly, Cav2 has been reported to control the nuclear 
      
 
Figure 16. Cav1 signaling hypothesis 
(a) Schematic of the caveolin signaling as originally proposed by Okamoto and colleagues (Okamoto 
et al., 1998) (based on Collins et al., 2012; Okamoto et al., 1998). (b) Two models of the association 
of Cav1 with the plasma membrane. A first model where the CSD is embedded inside the membrane 
inner leaflet thus poorly accessible as proposed by Kirkham and colleagues (Kirkham et al., 2008) 
(left). A second model where the N-terminus of Cav1 is extended thereby exposing the CSD (right). 
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targeting of signaling proteins such as phosphoERK whose nuclear translocation 
relies on Cav2 motif 154SSV156 (Kwon et al., 2011). 
 
 
2.3.4.4 Remaining/controversies/on/Cav1/signaling//
Cav1 has been extensively reported to interact with signaling proteins 
including endothelial nitric oxide synthase (eNOS), P2X purinoreceptor 7 (P2X7), 
epidermal growth factor receptor (EGFR), transforming growth factor β receptor type 
1 (TGFBR1), heme oxygenase (HO) and many others, (reviewed in Lamaze et al., 
2017). The interaction of Cav1 with these molecules and the modulation of their 
signaling have been suggested to occur through a specific Cav1 domain named 
caveolin scaffolding domain (CSD) (further detailed in 2.1.1.1) (Fig. 16a).  
This domain has been first identified for the interaction and regulation of 
heterotrimeric G proteins, H-Ras and Src (Li et al., 1995, 1996). The role of this 
domain for Cav1 interaction has been confirmed for eNOS, H-Ras and HO (Garcia-
Cardena, 1997; Song et al., 1997; Taira et al., 2011). Furthermore, a caveolin binding 
motif (CBM) has been identified by phage display and found in several Cav1 binding 
partners (Couet et al., 1997a; Garcia-Cardena, 1997; Song et al., 1997; Taira et al., 
2011; Bernatchez et al., 2005; Kirkham et al., 2008) (Fig. 16a). Extensive studies on 
eNOS regulation by Cav1 brought deeper insight on the underlying molecular 
mechanism. These studies revealed that upon eNOS interaction with the Cav1 CSD, 
the lateral chain of phenylalanine 92 (F92) located in the CSD, reaches eNOS 
hydrophobic pocket resulting in an inhibition of its catalytic activity (Bernatchez et al., 
2005; Trane et al., 2014). More recently a similar regulatory mechanism by CBM-
CSD interaction resulting in catalytic inhibition of the target effector has been 
unveiled for HO regulation (Taira et al., 2011). Moreover, the CSD might directly 
mediate the Cav1 inhibitory effect, as peptides that mimic the CSD are sufficient to 
exert a negative effect on the effectors. In contrast, mutated CSD peptides release 
this inhibition most likely by competing with endogenous Cav1 (Bernatchez et al., 
2011). Interestingly, only Cav1-mediated inhibitory effects have been reported across 
the literature, suggesting that Cav1 represses the effector catalytic activities. 
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However the only exception is the positive stimulation of insulin receptor kinase 
activity by Cav1 and Cav3 CSD (Yamamoto et al., 1998). It is possible however that 
this positive effect of the CSD on insulin signaling might be mediated by the inhibition 
of a regulatory intermediate.  
 
Recent studies have questioned this regulatory model. The debate arised from 
Cav1 structural features (further detailed in the discussion). As mentioned in 2.1.1.1, 
the CSD is located from residue 82 to 101, next to the Cav1 TMD thus in close 
proximity with the plasma membrane. In addition, the CSD has been first predicted 
as an amphipathic helix that is partially embedded inside the plasma membrane 
thereby accessible with difficulty to potential binding partners (Kirkham et al., 2008) 
(Fig. 16b). However recent studies suggest that the CSD possesses a dynamic 
topology which is either partially unstructured or fully helical (Liu et al., 2016). 
Considering that the CSD undergoes structural transitions one could assume that 
CSD conformational changes may regulate its accessibility (Fig. 16b). FRAP 
experiments suggest that Cav1 is released from the caveolae upon mechanical 
disassembly (Sinha et al., 2011). It is therefore likely that the CSD conformation and 
thereby its accessibility within non-caveolar Cav1 may also differ from caveolar Cav1. 
In addition, alternative mechanisms may influence the dynamics of CSD accessibility 
to promote interactions with the CSD and their reversibility. Indeed Cav1 undergoes 
several post-translational modifications. Ser80 phosphorylation may results to the 
spreading of the N-ter part of Cav1 away from the plasma membrane due to charge 
repulsion thereby further exposing the CSD (Fig. 16b) (Ariotti et al., 2015; Jung et al., 
2018). Similarly Tyr14 phosphorylation would facilitate CSD binding (Shajahan et al., 
2012; Jung et al., 2018).   
 
Likewise, the functional role of the CBM is also a subject of controversy as 
structural analysis of Cav1 binding partners revealed that this motif is buried in the 
deep interior of their ternary structure, and thus would not be available for protein 
interaction. Moreover the CBM encompasses three putative motifs that only consist 
in (ΦXΦXXXXΦ, ΦXXXXΦXXΦ, or ΦXΦXXXXΦXXΦ; Φ=aromatic residue  (Trp, 
Phe, or Tyr); X=any residue) (Couet et al., 1997a) and therefore poorly discriminative 
and largely found across organism proteomes, including those devoid of caveolins. 
      
 
Figure 17. Molecular and cellular consequences of caveolar flattening induced 
by mechanical stress 
Upon acute mechanical stress (hypo-osmotic swelling or stretching), caveolae flatten out in the 
plasma membrane to provide additional membrane and buffer membrane tension. Caveolar flattening 
releases Cav1 and Cavin-1 from the caveolar structure, increasing the amount of freely diffusing Cav1 
and Cavin-1 at the plasma membrane. On the removal of the force, Cavin-1 and Cav1 rapidly 
reassemble into caveolae in an ATP-dependent process. This cycle represents the primary cell 
response to acute mechanical stress. Non-caveolar Cav1 is likely to be internalized by a clathrin-
independent pathway that remains to be characterized. Endocytosed Cav1 becomes detectable in late 
endosomes (LE) and lysosomes, where it is degraded. It can also accumulate in the recycling 
endosome. Whether Cav1 and Cavin-1 follow identical intracellular routes after their release from 
caveolae by mechanical stress is unknown. It is possible that the endosomal (black arrows) and Golgi 
(orange arrow) pools of Cav1 are solicited during prolonged shear stress when the caveolar density is 
increased several-fold at the plasma membrane. Another possibility is that the released Cavins (green 
arrow) activate cellular processes to induce caveolar biogenesis, thereby increasing membrane 
reservoir size. Caveolar flattening can modulate mechanosignaling by several non-mutually exclusive 
mechanisms (lightning arrows). Released Cav1 and Cavins may interfere with the organization and 
dynamics of membrane microdomains and associated signaling molecules at the plasma membrane 
and endosomes. Gene transcription may be activated as a result of the nuclear translocation of 
released cavins. Magnification shows insertion of Cav1 and the Cav1 scaffolding domain (CSD) into 
the caveolar structure. The Cav1 CSD would form an in-plane amphipathic helix buried within the 
membrane in assembled caveolae. Many signaling molecules including several receptors and non-
receptor tyrosine kinases and their downstream effectors, have been shown to interact with the Cav1 
CSD in vitro (from Nassoy and Lamaze, 2012).  
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Moreover no particular CBM-containing protein enrichment has been found in Cav1 
interactome (Byrne et al., 2012; Collins et al., 2012).  
 
To conclude, considering the mechanoprotective role of caveolae. Our 
laboratory hypothesized that signaling through the multiple caveolar components 
could be coupled to caveolae mechanics. Therefore, the mechanical cycle of 
caveolae disassembly/reassembly would constitute a mechanical switch for several 
signaling pathways (Fig. 17).   
2.4 Caveolae pathophysiology  
Considering the multiple functions of caveolae, it is not surprising that any 
physical, biochemical and genetic perturbations impairing caveolar integrity, 
mechanics or dynamics would result in pathological situations. Indeed, there is a 
large literature on the pleiotropic phenotypes induced by deficient caveolar 
components. In the context of this work, it is interesting that the alteration of caveolae 
integrity mostly affects cell types chronically subjected to mechanical stress such as 
adipocytes, endothelial cells and myocytes. Deletion or mutation of caveolar 
components have been associated with multiple caveolinopathies such as 
lipodystrophy, vascular dysfunction, musculopathies (Ariotti and Parton, 2013) and 
cancer (Goetz et al., 2008). 
2.4.1 Lipodystrophy 
Cav1 or cavin-1 deficiency results in a lipodystrophic phenotype. Caveolae 
loss induced by cavin-1 deletion results in glucose intolerance and markedly 
decreased fat mass. Cavin-1 null mice have normal weight but exhibit 
hypertriglyceridemia and hyperinsulinemia which are characteristic of the 
lipodystrophic phenotype (Liu et al., 2008). Similarly Cav1 null mice have problems 
with lipid metabolism and adipocytes functions. These mice are small and lean. They 
show a resistance to diet-induced obesity with elevated triglycerides and free fatty 
acid levels. Moreover, these mice are insulin resistant which is consistent with the 
role of Cav1 and Cav3 as activators of insulin signaling (Yamamoto et al., 1998). In 
      
 41 
agreement with Yamamoto and colleagues, Cav2 deletion in mice did not impair 
insulin signaling (Cohen et al., 2003). In addition Cav1 is found at the plasma 
membrane of key lipid storage organelles: adipocytes and lipid droplets (Blouin et al., 
2008). Since insulin stimulation induces lipid uptake within the adipocytes, it is not 
surprising that Cav1 null mice have adipose atrophy (Londos et al., 1999). In 
humans, a rare case of homozygous nonsense mutation of Cav1 (p.Glu38X) results 
in Berardinelli-Seip-Congenital Lipodistrophy (BSCL) (Kim et al., 2008). Likewise, a 
homozygous frame shift mutation (c.696_697insC) of cavin-1 has been identified in 
another human lipodystrophy example (Hayashi et al., 2009). Other heterozygous 
frame shift mutations of Cav1 have been later found in patients with lipodystrophy 
c.88delC and p.l134fsdel1-X137 (Cao et al., 2008) and p.Phe160X (Schrauwen et al., 
2015). Similarly, another heterozygous cavin-1 frame shift mutation consisting in a 
deletion in cavin-1 gene c.947delA in a child with myopathy results in congenital 
lipodistrophy (Ardissone et al., 2013). Altogether these studies emphasize the 
prominent role of caveolae in lipid homeostasis and the maintenance of physiological 
processes (Lamaze et al., 2017). 
2.4.2 Vascular dysfunction 
As caveolae are important structures for the control of NO and calcium 
signaling (Isshiki and Anderson, 2003) (2.3.4) it is not unexpected that Cav1 
disruption in mice leads to impaired NO and Ca2+ signaling in the cardiovascular 
system. This impairment results in altered contraction/relaxation and maintenance of 
the myogenic tone of the endothelium (Drab et al., 2001). Accordingly, eNOS activity 
is upregulated in Cav1 null mice, consistent with the inhibitory role of Cav1. In 
addition, loss of Cav1 caused endothelial cell proliferation and fibrosis (Razani et al., 
2001). Cav1 ablation in mice also results in decreased angiogenic response to basic 
fibroblast growth factor (bFGF) (Woodman et al., 2003). In vivo treatment with CSD 
mimicking peptides decreased acetylcholine-induced vasodilatation and NO 
production. CSD peptides treatment also markedly decreases inflammation and 
vascular leak at the same extent as glucocorticoids. These results emphasize the 
prominent role of this Cav1 domain in the control of cell signaling and its potential 
therapeutic targeting (Bucci et al., 2000). Moreover high level of Cav1 expression has 
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been involved in atherosclerosis development (Fernandez-Hernando et al., 2010). 
Endothelial cells experience shear stress within the vessels due to blood flow. Loss 
of Cav1 in mice vascular endothelial cells induces susceptibility to acute rupture 
under high cardiac output (Cheng et al., 2015). Caveolae are mechanosensitive 
organelles that regulate vascular functions, therefore with a key role in vessels 
remodeling induced by shear stress (Yu et al., 2006). 
2.4.3 Muscular dystrophies and cardiomyopathies 
Mutations of Cav3, cavin-1 and cavin-4 have been associated with multiple 
musculopathies from dystrophies to cardiomyopathies (Hayashi et al., 2009). Thirty 
Cav3 mutations have been identified. These mutations lead to skeletal muscle 
dysfunction resulting in several musculopathies: limb-girdle muscular dystrophy, 
rippling muscle disease, distal myopathy and hyperCKemia. Cav3 mutations have 
been associated with sarcolemmal membrane alterations, disorganization of T-tubule 
network and cell signaling deregulation (Galbiati et al., 2001; Gazzerro et al., 2010). 
Since caveolae play a key role in membrane protection and lipid homeostasis, lack of 
caveolae would directly impair the cell response to mechanical stress (Cheng et al., 
2015; Lo et al., 2015; Sinha et al., 2011). More recently our lab discovered that two 
mutations of Cav3 P28L and R26Q lead to Cav3 Golgi retention preventing caveolae 
formation at the plasma membrane. Hence myotubes with these Cav3 mutations are 
more prone to membrane rupture under mechanical strains. In addition, the central 
muscle signaling pathway IL-6/STAT3 is impaired in this context (Dewulf et al., 2018 
under revision, see annex 3). Other muscle related signaling pathways such as those 
involving Ca2+, p38MAPK and Akt might be affected by the absence of caveolae 
(Capanni et al., 2003; Weiss et al., 2008; Stoppani et al., 2011). Finally, Cav3 
mutations alter the expression and trafficking of proteins participating to membrane 
integrity or membrane repair such as dysferlin and the Tri-partite motif (TRIM) protein 
mitsugumin 53 (MG53) (Capanni et al., 2003; Hernandez-Deviez et al., 2006; Cai et 
al., 2009). 
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2.4.4 Cancer 
Caveolae have pleiotropic functions that have been implicated in multiple 
essential cancer processes such as cell migration, cell cycle progression, cell 
death/survival, cell transformation, angiogenesis and multidrug resistance (MDR). 
Hence, several studies have involved caveolae and caveolar processes in tumor 
development. In particular, Cav1 have received a lot of attention as it plays an 
important but complex role in tumor progression. Indeed, no consensus has been 
reached so far on the role of Cav1 in cancer. Dual and contradictory roles have been 
ascribed to Cav1 as it acts both as oncogene and tumor suppressor depending on 
the pathological context (Goetz et al., 2008; Lamaze and Torrino, 2015). The ability 
of Cav1 to control cell signaling (as described in 2.3.4.4) may play an important role 
in the regulation of oncogenic processes. The first evidence of the tumor suppressor 
effect came from the inhibition of anchorage-independent cell growth of transformed 
cells by recombinant Cav1 expression (Engelman et al., 1997). The tumor 
suppressor effect was then further confirmed by the ability of fibroblasts depleted for 
Cav1 to form tumors in mouse model through p42/44MAPK hyper activation (Galbiati 
et al., 1998). Similarly, pancreatic carcinoma cells overexpressing Cav1 had reduced 
tumor formation due to MAPK inhibition and decreased anchorage-independent 
growth (Han et al., 2009). Moreover, consistently with the tumor suppressor role of 
Cav1, decreased Cav1 levels have been reported in breast, lung, ovary, thyroid and 
mesenchymal cancers. Nevertheless, Cav1 can also play an opposite role depending 
on cancer types. Indeed, Cav1 has oncogenic effects as it promotes tumor 
progression in prostate cancer in mouse models (Williams et al., 2005). In addition, 
clinicopathological analysis of human bladder, breast, renal, brain, lung and prostate 
cancers revealed that Cav1 upregulation is correlated with reduced survival 
(reviewed in Williams and Lisanti, 2005; Goetz et al., 2008)).  Therefore, Cav1 
expression has been proposed as reliable prognosis and diagnosis marker. On 
another hand, as Cav3 mutation P104L leading to musculopathies, Cav1 mutation 
P132L has been identified in some human breast cancers. This mutation is involved 
in cell transformation and MAPK activation, promoting cell invasion (Hayashi et al., 
2001). Six other Cav1 mutations have been identified and associated with ER-α 
positive breast cancers (Li et al., 2006). Cav1 play also a key role in the tumor 
microenvironment. Indeed loss of Cav1 expression in stromal cells has been 
      
 
 
Figure 18. Potential role of caveolae in tumor progression  
Potential role of caveolae in tumor progression. Tumors are often characterized by enhanced rigidity 
and stiffness and recent evidence shows that tumor progression is associated with alterations in tissue 
and cell mechanics. Caveolin-1 (Cav1), the main constituent of caveolae, is clearly involved in tumor 
progression. A biphasic expression pattern could be correlated with distinct Cav1 functions. It was 
shown that Cav1 expression is low during the first stage of tumor progression. However, Cav1 is 
overexpressed during the advanced cancer phases, including metastatic process. Thus, Cav1 would 
act as a tumor suppressor at early stage of transformation and tumor progression while it would play 
an oncogenic role inducing migration and metastasis at later stages. Our hypothesis is that the dual 
role of Cav1 in tumor progression may be explained by their recently discovered new function as 
mechanosensors that adapt the cell response to mechanical forces. Thus, in in situ carcinoma, when 
proliferative tumor cells become confined by the basal membrane, functional caveolae respond as 
mechanosensors with cycles of caveolae disassembly/reassembly induced by external forces. In 
invasive carcinoma, tumor cells break down the basal membrane and invade the extracellular matrix. 
Tumor cells are thus exposed to mechanical forces generated by the extracellular matrix and tissue 
stiffness. Increased mechanical environment may overwhelm and alter the functional cycle of 
caveolae disassembly/reassembly. This in turn may impair the caveolae mechanical response and 
Cav1 dependent mechanosignaling thereby promoting migration and metastasis formation. (Lamaze 
and Torrino, 2015)  
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associated with poor prognosis in breast cancer and correlates with the upregulation 
of ECM components in the tumor microenvironment (Witkiewicz et al., 2009; Trimmer 
et al., 2011). In addition, stromal expression of Cav1 contributes to the remodeling of 
the microenvironment, which facilitates tumor invasion and metastasis (Goetz et al., 
2011). However, the mechanism underlying the role of Cav1 in tumor development 
might be more complex than a matter of level and pattern of expression. Indeed, 
recent studies emphasize the prominent role of mechanical strains generated by the 
microenvironment of the tumor (Kai et al., 2016). Therefore, considering the essential 
role of caveolae in cell mechanoresponse, how caveolae dynamics and mechanics 
are affected by these mechanical strains should be investigated as well as the 
biological processes they mediate in the context of tumor progression, such as 
signaling (Fig. 18) (Lamaze and Torrino, 2015). 
3 Type I interferon-induced JAK-STAT signaling 
JAK-STAT is one of the most studied signaling cascades of the cell. This 
pathway is used by a wide array of cytokines and growth factors to transduce a 
multitude of signals and generate accurate gene responses. JAK-STAT signaling is 
involved in a wide breadth of biological processes such as hematopoiesis, innate and 
adaptive immunity, cell proliferation, differentiation, migration and apoptosis (Igaz et 
al., 2001; O’Shea et al., 2002; Villarino et al., 2017).  
3.1 Interferons 
Among the different cytokines that activate the JAK-STAT cascade, interferons 
(IFNs) are among the most studied. They represent the prototypical example of JAK-
STAT signaling. Most cell types bind IFNs with a large variability in binding affinity 
and numbers of binding sites (200-103/cell) (Langer and Pestka, 1988). IFNs are 
secreted cytokines with a broad range of biological activities such as antiviral, 
antibacterial, cytotoxic and antiproliferative effects. Hence, these molecules 
constitute an essential element of the line of defense against viral infections and of 
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the immunosurveillance for cancer cells (Gresser and Belardelli, 2002; Santini et al., 
2002). Thus, over the last three decades, recombinant IFNs have been used for 
clinical applications. Indeed, IFN-α2 used to be administrated in treatment of hepatitis 
C virus infection (Pfeffer et al., 1998) and IFN-β has been shown to be effective in 
multiple sclerosis (Paty and Li, 1993; Prosperini et al., 2014). Recombinant human 
IFNs have shown effectiveness for cancer treatment for the first time with hairy cell 
leukemia and for Kaposi’s sarcoma. Since then, human IFNs have been approved for 
the treatment of a wide breadth of cancers such as metastatic malignant melanoma 
(Di Trolio et al., 2015).  
3.1.1 Classification  
More than 60 years ago, Isaac and Lindenmann discovered a secreted factor 
that prevents viral replication in chicken embryonic cells (Isaac and Lindenmann, 
1957). Indeed, this factor was described as a “product of influenza viral interference” 
therefore named interferon, giving rise to the first member of the interferon family. On 
the basis of their structural, biological properties and their cognate receptors, IFNs 
are divided into three subfamilies: IFNs type I (IFN-α/-β), type II (IFN-γ) and type III 
(IFN-λ) (Platanias, 2005; Davidson et al., 2016). Indeed, IFNs type I share a common 
receptor named interferon alpha receptor (IFNAR), type II binds to interferon gamma 
receptor (IFNGR) and type III to IL28RA/IL-10Rβ. The first family of IFNs 
encompasses sixteen members: twelve IFN-α subtypes and IFN-β, -ε -κ, -ω. IFN-δ 
and IFN-τ have been described only in pigs and cattle and do not have human 
homologues (Pestka et al., 2004). 
3.1.2 Specificity 
 IFNs type I perfectly illustrate the paradox of signaling, as they all possess 
similar structures and bind to the same receptor, yet result in distinct biological 
outcomes (Brierley and Fish, 2002). In addition to cellular mechanisms such as 
clathrin-dependent endocytosis that mediates signal specificity between type I and 
type II IFNs (Marchetti et al., 2006), signal specificity can also be achieved within the 
type I subfamily through the binding strength of the cytokine to one of the IFNAR 
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chains (Lamken et al., 2004). Indeed, an engineered IFN-α2 mutant with 30 fold 
higher affinity for IFNAR1 (in the range of IFN-β affinity) induces an IFN-β-like cellular 
response (Jaitin et al., 2006). In addition, this specificity can be also mediated 
through IFNAR endosomal sorting (Ng et al., 2015; Chmiest et al., 2016; Zanin et al., 
2018).  
3.2 Interferons receptors 
IFNAR belongs to the family of helical cytokine receptors (hCR) class II, which 
thereby includes IFNGR and IL-10Rβ. IFNAR is a non-tyrosine kinase receptor. 
Indeed IFNAR1 and IFNAR2 do not possess intrinsic kinase activity and must be 
associated with cytosolic kinases to transduce signals.  
3.2.1 IFNAR1, IFNAR2 and their isoforms 
The IFNAR chains were first discovered in 1990 with the emergence of cloning 
techniques. Indeed, Uzé and colleagues identified one of the IFNAR chains as the 
receptor of human IFN-α8 (Uze et al., 1990). Four years later, another IFNAR chain 
(IFNAR2), that physically associates with a tyrosine kinase and later identified as 
IFNAR2c was described as a universal ligand-binding receptor to human IFN-α/-β 
(Novick et al., 1994). Finally, two truncated isoforms of IFNAR2 generated by 
alternative splicing, exon skipping or different polyadenylation sites were 
characterized: IFNAR2a and a secreted, thus soluble isoform IFNAR2b (Lutfalla et 
al., 1995). Due to the truncation of the cytosolic part, thereby isolating the receptor 
from downstream effectors, both isoforms do not process signal transduction (de 
Weerd et al., 2007). These non-functional IFNAR2 isoforms may serve to negatively 
regulate the signaling pathway (Gazziola et al., 2005). Another IFNAR1 isoform has 
been reported in cancer cells, however, it results most likely from an artifact or 
aberrant mRNA (Abramovich et al., 1994).   
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Figure 19. Structure and dynamics of IFN-IFNAR ternary complex formation 
(a) Ligand-induced conformational changes in IFNAR (based on a comparison of unbound and bound 
structures). The bound conformation is in blue. (Piehler et al., 2012) (b) Two-step assembly of the 
ternary IFN-receptor complex in the plasma membrane (orange, IFN; blue, IFNAR2; green, IFNAR1): 
rapid and high-affinity binding of IFN to IFNAR2 is followed by recruitment of IFNAR1 into the ternary 
complex. (Piehler et al., 2012) 
  
a
b
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3.2.2 Structure and mechanism of activation 
IFNAR is composed of two transmembrane proteins IFNAR1 and IFNAR2 with 
a structure similar to the immunoglobulin constant domain (Bazan, 1990). Both 
chains are heavily glycosylated resulting in a high molecular weight (120-130 kDa) 
despite their relatively short amino acid sequence length:  IFNAR1 (557 aa) and 
IFNAR2c (515 aa) (Ling et al., 1995). Under no stimulation, IFNAR1 and IFNAR2 
remain separated at the plasma membrane. IFNAR1 and IFNAR2 clustering requires 
binding of IFN (Cohen et al., 1995). The binding affinity of IFNs to IFNAR1 differs 
from IFNAR2. Indeed, Scatchard analysis revealed that IFNAR possess two binding 
sites: a low affinity site (of micromolar range) corresponding to IFNAR1 and a high 
affinity site (nanomolar range) corresponding to IFNAR2. The IFNAR1 extracellular 
domain (ECD) of 409 aa is subdivided into four domains named SD1 to SD4, each 
one harboring a fibronectin type III (FNIII)-like domain. SD1 contains residues 
responsible for plasma membrane glycosphingolipid binding (Ghislain et al., 1994). 
SD1-3 are essential for the cytokine binding and SD4 is essential for the ternary 
complex (IFNAR1-ligand-IFNAR2) formation (Lamken et al., 2005). According to a 
proposed model, upon IFN binding the N-terminal SD1 folds to form a lid above the 
bound IFN (Cajean-Feroldi et al., 2004; de Weerd et al., 2007; Piehler et al., 2012; 
Schreiber, 2017) (Fig. 19a). On the other hand, IFNAR2 ECD is composed of only 
two FNIII-like domains referred as D1 and D2 that are both involved in IFN binding. 
Finally, a two step assembly mechanism has been proposed for the formation of the 
ternary complex (Lamken et al., 2004; Gavutis et al., 2005; Piehler et al., 2012): A 
first step of ligand binding to IFNAR2 chain and a consecutive association of IFNAR1 
chain to the preformed IFNAR2-ligand complex (Fig. 19b). Since IFNAR1 and 
IFNAR2 bind on the opposite sides of IFN, the newly formed ternary complex adopts 
a unique orthogonal shape (Piehler et al., 2012) (Fig. 19a). For type 1 IFN, studies 
suggest that the initiation of the signal transduction is rather induced by IFNAR 
dimerization than IFN-binding-induced rearrangement of ECD propagating to the 
cytosolic tail (Wilmes et al., 2015). 
 
As mentioned earlier, IFNARs lack intrinsic kinase activity and thus their 
cytosolic tails need to be constitutively associated with cytosolic kinases to transduce 
the signal subsequently to formation of the ternary complex.  
      
 
 
Figure 20. JAKs general structure and regulation 
(a) JAK1 domains organization (based on Haan et al., 2006). (b) The two prevailing models for 
regulation of JAK kinase domain catalytic activity by the pseudokinase domain: (top) in cis; (bottom) in 
trans. In the in cis inhibition model (top), the pseudokinase domain binds the kinase domain within the 
same JAK monomer, leading to a suppression in catalytic activity. The in trans model for inhibition 
(bottom) involves the binding of the pseudokinase domain from one JAK to the kinase domain of 
another within a receptor-assembled JAK dimer to suppress the kinase domain's catalytic activity. 
Activation of JAK in either model involves reorientation of the JAKs to facilitate mutual trans- 
phosphorylation and thus activation of the JAK kinase domains. (from Babon et al., 2014) 
   
FERM
JAKs JH7 JH6 JH4 JH3 Pseudokinase (JH2) Kinase (JH1)5
SH2
a
b
N C
      
 48 
3.3 JAK: Just another kinase... 
JAK kinases are members of the large family of protein tyrosine kinases (PTK). 
The first two members of the JAK family (JAK1 and JAK2) were first discovered by 
Andrew Wilks from a PCR-based screen, aiming at identifying new PTKs. Therefore, 
these two proteins were initially termed “Just Another Kinase” (Wilks, 1989). These 
kinases have the particularity to carry both a functional kinase domain and a non-
functional (pseudo) kinase domain, defining a new class of PTKs (Wilks et al., 1991). 
This singularity, prompted A. Wilks to rename this family “Janus Kinase” referring to 
the two-faced roman god of Gates (Wilks, 2008). In the meantime another member of 
the JAK family: TYK2 was identified (Krolewski et al., 1990; Firmbach-Kraft et al., 
1990; David et al., 1995). JAK3 was later identified due to its restriction to 
hematopoietic cells (Kawamura et al., 1994).  
3.3.1 Structural features  
JAK kinases exhibit a high molecular weight (130-140 kDa). All four members 
share seven characteristic domains (Wilks et al., 1991), which are named JAK 
homology (JH) domains (Haan et al., 2006). In addition, the N-terminal part (JH3-
JH7) comprises a Src homology domain-2 (SH2), and a 4.1, Ezrin, Radixin, Moesin 
(FERM) domain that targets JAKs to the membrane-proximal region of cytokine 
receptors (Fig. 20a). Both mediate their non-covalent association with the cytosolic 
tail of the receptor (Wallweber et al., 2014). Indeed, JAKs have been reported to be 
predominantly found at the plasma membrane, pre-associated to different cytokine 
receptors (Behrmann et al., 2004; Haan et al., 2006), which are required for JAK 
targeting at the plasma membrane.  
 
The non-functional kinase domain JH2 is critical for the modulation of the 
catalytic domain (JH1) and are both positioned at the C-terminal part of the protein. 
The pseudokinase domain presents high structural similarities with the tyrosine 
kinase domain JH1 (Toms et al., 2013), yet it lacks essential residues involved in 
catalytic activity and substrate binding (Wilks et al., 1991; Saharinen et al., 2000). 
Hence, it has been hypothesized that the pseudokinase domain has a regulatory role 
      
 
Figure 21. JAK-STAT signal transduction 
At steady state IFNAR1 and IFNAR2 remain separated within the plasma membrane. Upon cytokine 
binding to IFNAR2, IFNAR1 is recruited to form the ternary complex resulting in JAK1 and TYK2 
juxtaposition, which leads to their reciprocal transphosphorylation inducing their full activation. Fully 
activated JAKs phosphorylate IFNARs that become a docking platform for latent cytosolic STATs. 
IFNAR-docked STATs are thereby phosphorylated by JAKs and released in the cytosol where they 
dimerize to be imported into the nucleus and initiate specific transcriptional programs.  
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within the JAKs. Indeed, JH2 deletion from TYK2 impaired IFN signaling (Velazquez 
et al., 1995). Multiple studies support the regulatory role of the pseudokinase domain, 
showing that JH2-deleted JAK2 and JAK3 exhibit an increased basal activity 
(Saharinen and Silvennoinen, 2002).  
3.3.2 Mechanism of activation 
The precise molecular mechanism of JAKs activation remains unclear. 
However it is clear that the pseudokinase domain acts as a protein interaction 
module that inhibits the tyrosine kinase activity of the JH1 domain. Two models have 
been proposed where autoinhibition occurs either in cis (within the same JAK protein) 
or in trans where both JAKs mutually inhibit their JH1 domain with their JH2 domain 
(Babon et al., 2014) (Fig. 20b). Nevertheless, considering that IFNAR chains remain 
separated in absence of ligand, it is unlikely that trans inhibition occurs in this 
context. Moreover, crystal structure analysis of the pseudokinase-kinase tandem of 
TYK2 support the model of cis inhibition (Lupardus et al., 2014).  
 
The mechanism triggering the dissociation between JH2 and JH1 (JAK 
activation) is unknown and may result from conformational changes induced by JAKs 
juxtaposition and/or transphosphorylation on their kinase domain activation loop 
(Yamaoka et al., 2004). On the other hand, autoinhibition of JAK2 slightly differs from 
the other JAKs. Indeed, the JAK2 pseudokinase domain possesses a weak catalytic 
activity that autophosphorylates itself on two autoinhibitory residues (Ser523 and 
Tyr570) (Ungureanu et al., 2011). These two autoinhibitory residues are not 
conserved among the other JAKs. 
 
Upon ligand binding to IFNAR, both chains associate within the ternary complex and 
undergo conformational changes that propagate to their respective cytosolic tail. 
These events lead to JAKs juxtaposition and repositioning of their respective 
pseudokinase domain, relieving autoinhibition (Babon et al., 2014). This repositioning 
may be triggered by reciprocal transphosphorylation on both kinase domain 
activation loop (Feng et al., 1997). These last steps drastically enhance the kinase 
catalytic activity leading to IFNAR tyrosine phosphorylation (IFNAR1 Y466 and 
      
 
Figure 22. STAT domains structure and protein binding sites 
(a) The core structure (amino acids ~130–712) shows binding of a STAT1 dimer to DNA and the 
location of binding sites of various proteins in various domains. The amino-terminal structure, the 
placement of which in the intact structure is undefined, also interacts with various partners, as does 
the carboxy-terminal transactivation domain, the structure of which is unknown. CBP, CREB binding 
protein; IRF, interferon regulatory factor; Mcm, minichromosome maintenance; Nmi, N-Myc interactor; 
PIAS, protein inhibitor of activated STAT. (b) STAT structure. STAT, signal transducer and activator of 
transcription. SH2, Src- homology-2 domain ( from Levy and Darnell, 2002). 
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IFNAR2 Y337/542) (Abramovich et al., 1994; Constantinescu et al., 1994; Platanias 
et al., 1994). Therefore, the new motifs constituted by phosphorylated tyrosines 
harbored by IFNAR become docking sites for the latent cytosolic signal transducers 
and activators of transcription (STATs) (Zhong et al., 1994) (Fig. 21).  
3.4 Signal Transducers and Activators of Transcription 
The family of cytosolic STAT proteins encompasses seven members: STAT1, 
2, 3, 4, 5a, 5b and 6. The STATs have been characterized based on their sequence 
homology and their functional ability to activate distinct sets of genes in response to 
growth factor and cytokine stimulation (Leaman et al., 1996). The STAT family 
shares conserved domains: a N-terminal part which is involved in the regulation of 
STAT activity, a coiled coil domain involved in receptor and regulatory proteins 
interaction, an SH2 domain that mediates STATs interaction with the tyrosine 
phosphorylated receptor, a DNA binding domain and a variable C-ter transactivation 
domain involved in the modulation of gene transcription (Kisseleva et al., 2002) (Fig. 
22). In addition, STATs are substrates of JAKs and undergo phosphorylation on a 
conserved tyrosine residue. This tyrosine phosphorylation triggers STAT homo or 
heterodimerization (through reciprocal SH2-phosphotyrosine interactions) and their 
subsequent nuclear translocation relying on the importin-α5 and the Ran import 
pathway (Kisseleva et al., 2002). STAT phosphorylation promotes their nuclear 
retention. Inside the nucleus, depending on the composition of STAT dimers, it 
eventually form complexes with other co-trancritption factors such as the IFN 
regulatory factor 9 (IRF9) and binds to DNA consensus sequences such as the IFN 
response elements (ISREs) or IFN-γ activated sequence (GAS) elements in the 
promoter of IFN-stimulated genes (ISGs) to initiate transcriptional programs (Darnell 
et al., 1994; Schreiber and Piehler, 2015). Signal termination is mediated by STAT 
dephosphorylation and their subsequent nuclear export (Mertens and Darnell, 2007). 
DNA bound STATs are protected from phosphatases and thereby remain in the 
nucleus to process the transcriptional program (Meyer et al., 2003) (Fig. 22). 
      
 
Figure 23. Negative regulation of JAK-STAT signaling 
(a) Schematic diagram of cytokine-induced JAK-STAT signaling. SOCS proteins are targets for STAT-
induced up-regulation, whereupon they inhibit signaling, forming a negative-feedback loop. The two 
most potent members of the SOCS family, SOCS1 and SOCS3, act by directly inhibiting the catalytic 
domain (JH1 domain) of JAK2 (left). SOCS3 (green, cartoon representation) docks on to the GQM 
motif of JAK (electrostatic surface representation) and places its KIR in the substrate-binding groove. 
The numbering indicates the exact fragments present in the crystal structure of PDB code 4GL9 (left). 
Close-up of the JAK–KIR interaction with a substrate peptide (white) modeled. The asterisk (*) 
indicates that ATP and substrate are modeled on the basis of the IRK–substrate–ATP structure (PDB 
code 1IR3). The KIR of SOCS3 (green) blocks substrate binding, the first residue of the KIR, Leu22, is 
located where the P+1 residue would reside; this is indicated schematically in (boxed) (adapted from 
Kershaw et al., 2013b). (b) Negative regulators of IFN-induced JAK-STAT signaling (from Arimoto et 
al., 2018) 
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3.5 JAK-STAT regulation 
As mentioned above, JAK-STAT is a key signaling pathway that allows the 
control of major cellular processes in response to extracellular stimuli. Therefore, a 
tight regulation is essential to avoid any undesirable responses that would give rise to 
dramatic consequences at the whole organism scale. Hence, a multitude of 
regulatory mechanisms have been setup at each milestone of the signaling pathway 
to ensure correct activation, signal termination and desensitization.  
3.5.1 Upstream regulation 
JAK-STAT can be regulated at the level of the cytokine receptors. Indeed, 
serine phosphorylation on IFNAR1 residue 535 by different sets of kinases such as 
protein kinase D2 (PDK2) or casein kinase α (CKα) induces the recruitment of F-box 
protein E3 ubiquitin ligase subunit β transducing repeats-containing protein 2 (β-
Trcp2) resulting in IFNAR1 ubiquitination and its subsequent degradation 
(Marijanovic et al., 2006; Bhattacharya et al., 2010; Zheng et al., 2011). Similarly, 
ubiquitin-specific peptidase 18 (USP18) interacts with IFNAR2 displacing the 
associated JAK1 (Malakhova et al., 2006). This interaction results in a destabilization 
of IFN-α binding to IFNAR2 (Francois-Newton et al., 2011, 2012). 
3.5.2 Downstream regulation 
JAK kinases are key effectors of the JAK-STAT signal transduction. Therefore, 
JAKs catalytic activity or activation (i.e. phosphorylation) is naturally targeted by 
regulatory mechanisms. Hence, the JAK-STAT regulatory toolbox includes a wide 
range of inhibitory proteins including phosphatases (Arimoto et al., 2018).  
  
One of the most well known families of JAK-STAT regulatory proteins is the 
SOCS family. They were identified on the basis of their ability to bind JAKs and 
inhibit cytokine signaling. SOCS are part of a negative feedback loop induced by 
JAK-STAT signaling (Endo et al., 1997; Naka et al., 1997; Starr et al., 1997).  There 
are eight members of the SOCS family. They all contain an SH2 domain and a SOCS 
      
 
 
Figure 24. JAKs and STATs with associated cytokines and phenotypes (O’Shea 
et al., 2015) 
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box domain. They function as E3 ubiquitin ligase that promotes cytokine receptors 
and their associated JAKs ubiquitination and their subsequent degradation. However 
SOCS1 and SOC3 mechanism differ from other SOCS as they directly inhibit JAKs 
catalytic activity (Yasukawa et al., 1999). Indeed SOCS1 and SOCS3 carry a kinase 
inhibitory region (KIR) that sits on and occludes JAK substrate-binding sites upon 
receptor-SOCS1/3-JAK interaction (Kershaw et al., 2013a) (Fig. 23a). 
 
 Protein tyrosine phosphatases are also important regulators of JAK-STAT. For 
example, PTP1B is an SH3 and phosphatase containing protein that 
dephosphorylates both JAK2 and TYK2 (Myers et al., 2001). PTP1B inhibits IFN-α 
and IFN-γ signaling by dephosphorylating the activation loop of JAK2 and TYK2. A 
similar protein named T-cell protein phosphatase (TCPTP) has been reported to 
dephosphorylate JAK1 and JAK3 (Simoncic et al., 2002). In addition Src homology 
region 2 domain-containing phosphatase 1 and 2 (SHP1 and SHP2) are 
phosphatases that directly bind to and dephosphorylate JAK1, JAK2 and TYK2 
(David et al., 1995; Yetter et al., 1995; Jiao et al., 1996). Their SH2 domain allows to 
specifically target activated JAKs by binding to the phophotyrosine of their activation 
loop. 
 
Finally, STAT-induced transcription can be inhibited by the interaction with a 
protein inhibitor of activated STAT (PIAS) (Fig. 22a). PIAS are composed of four 
members: PIAS1, 3, x and y. For example, PIAS1 inhibits STAT1 binding to DNA, 
thus it prevents STAT1-induced gene transcription (Liu et al., 2004). In addition, the 
IFN-regulatory factor 2 competes with other IRFs such as IRF9 for ISRE binding 
thereby preventing ISRE-mediated genes induction (Taki, 2002). 
3.6 JAK-STAT in tumor progression 
Due to the wide array of physiological processes mediated by JAK-STAT, gain 
or loss of function mutations in genes encoding for JAKs, STATs and their regulatory 
proteins are associated with a broad range of human diseases (reviewed in O’Shea 
et al., 2015) (Fig. 24). For example inactivating mutations of JAK kinases have been 
reported in patients with immunodeficiencies (Casanova et al., 2012). On the other 
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hand, mutations resulting in constitutively active JAKs were early involved in 
myeloproliferative diseases and tumor development such as leukemia/lymphoma and 
solid tumor development including breast cancer (Leonard and O’Shea, 1998). In this 
chapter, I will further develop how non-functional JAK-STAT signaling may drive 
breast cancer development. 
 
All members of the STAT family have important role in mammary gland 
development. For example, STAT3 is a prominent factor for self-renewal of 
pluripotent stem cells (Niwa et al., 1998). Moreover, STAT3 mediates inflammatory 
signaling, tissue remodeling and triggers apoptosis by regulating the expression of 
phosphoinositide-3 kinase (PI(3)K) regulatory subunits during mammary gland 
development. STAT6 induces expression of cytokines and important factors for the 
maintenance of luminal alveolar cells. STAT5 mediates lactation and STAT1 has 
been reported to be phosphorylated during tissue remodeling of the gland (Abell et 
al., 2005; Hughes and Watson, 2012). As JAKs and STATs regulate cell proliferation 
and survival in the mammary gland, it is not surprising that those proteins are 
involved in breast tumor progression, with either oncogenic or tumor suppressor 
roles. Somatic mutations of JAK1, JAK2 and JAK3 have been reported in patients 
with breast cancer (Jeong et al., 2008; Caffarel et al., 2012). Moreover STAT3 and 
STAT5 are well-known oncogenic factors of the mammary gland that are found to be 
hyperactivated in a high proportion of breast tumors (Cotarla et al., 2004; Diaz et al., 
2006). Indeed, gain of function V617F mutation of JAK2 leads to constitutive STAT5 
activation and increased survival and cell proliferation (Caffarel et al., 2012). 
However, unlike many other oncogenes, mutations in JAKs or STATs are very rare 
and the mechanisms leading to JAK-STAT subversion are not well understood. In 
most cancers, STAT1 has paradoxical activities as it is either considered as a tumor 
suppressor or oncogene depending on the context. For example, in postmenopausal 
breast cancer, STAT1 acts as a tumor suppressor while it promotes malignancy in 
premenopausal breast tumors (Haricharan and Li, 2014). Indeed, STAT1 is 
repressed during breast cancer progression, while highly expressed in surrounding 
tissues of benign breast tumors (Chan et al., 2012). In addition, STAT1 expression in 
ER-/human epidermal growth factor receptor 2-positive (HER2+) and HER2- breast 
cancer is correlated with better prognosis (Desmedt et al., 2008). In contrast, in some 
cases, high STAT1 expression is associated with metastasis and drug resistance 
      
 
Figure 25. Therapeutic inhibitors of JAKs and STATs (O’Shea et al., 2015) 
  
      
 54 
(Weichselbaum et al., 2008). On the other hand, STAT3 is an oncogene that is 
constitutively activated in a wide array of cancers. Indeed, STAT3 hyperactivation is 
often reported in primary breast cancers and is associated with poor prognosis 
(Charpin et al., 2009). Aberrant STAT3 activation leads to tumor formation as 
phosphoSTAT3 transactivates a large numbers of oncogenes such as c-Myc, Cyclin 
D1, prosurvival factors Bcl-xL and survivin together with angiogenesis and invasion 
factors v-EGF and klf-8 (Bromberg et al., 1999; Diaz et al., 2006). Therefore, 
transcriptional program initiated by STAT3 results in highly metastatic tumors. Mice 
with constitutively activated STAT3 exhibit significantly more aggressive tumors 
(Barbieri et al., 2010). In addition STAT3 also regulates miR-21 and miR-181-b1 
transcription via PTEN generating inflammatory signaling, which results in cell 
transformation through epigenetic mechanisms (Iliopoulos et al., 2010). STAT3 
activation also induces stem-cell like phenotype by activating Sox2 expression or 
CCL2 production that in turn activates NOTCH1 signaling in tumor cells (Tsuyada et 
al., 2012; Yang et al., 2013). Moreover, STAT3 activation affects the tumor 
microenvironment by stimulating the secretion of various cytokines that recruits T-
helper and tumor associated macrophages promoting growth and differentiation of 
tumor cells and inhibition of antitumor immunity (Hynes and Watson, 2010). 
 
The clear role of JAK-STAT signaling in tumor progression makes this pathway 
an attractive therapeutic target for antitumor treatment. Indeed clinical targeting of 
JAK-STAT has been proven to be efficient in clinical trials in patients with solid 
tumors. For example, Ruxolitinib, developed by Novartis, which targets JAK1 and 
JAK2 is used for a wide range of solid tumors. Other JAKs inhibitors such as 
INCB39110 and INCB047986 (InCyte corp.) that blocks JAK1 phosphorylation are 
currently in advanced clinical trials (Buchert et al., 2016) (Fig. 25). Similarly STATs 
inhibitors are being developed, yet STATs blockade is much more challenging than 
blocking kinases and may not be as efficient due to STATs redundancy (O’Shea et 
al., 2015). However small-molecules and oligonucleotide based inhibitor targeting 
STAT3 and STAT5 are promising (Furqan et al., 2013).  
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Results  
4 Caveolae Mechanics Control JAK-STAT signaling 
4.1 Objectives and summary 
 
Mechanoprotection is the last function ascribed to cavolae. Indeed, our 
laboratory demonstrated that caveolae have the ability to flatten out upon membrane 
tension increase induced by a mechanical stress, thereby providing additional 
plasma membrane surface in order to prevent cell damages. On another hand it has 
been established that caveolae are key signaling organelles. Therefore our lab 
hypothesized that the mechano-dependent cycle of caveolae 
disassembly/reassembly constitutes a mechanical switch for signaling pathways 
(Nassoy & Lamaze 2012). In the present work, we hypothesized that the caveolae 
mechanical disassembly leads to the release of non-caveolar Cav1 in the plasma 
membrane. Considering the ability of Cav1 to modulate the activity of signaling 
molecules, we further hypothesized that the mechanical release of non-caveolar 
Cav1 modulates major signaling pathways. Indeed, using high throughput screening 
we identified JAK-STAT as a signaling pathway that is modulated by caveolae 
mechanics. Hence, the aim of this work is to identify the molecular mechanisms 
underlying the control of JAK-STAT signaling by caveolae mechanics.  
 
Single molecule localization revealed that “free” Cav1 is released in the lipid 
bilayer upon membrane tension increase induced by osmotic cell swelling. Moreover, 
consistently with high throughput screening results, biochemical assay and cell 
imaging confirmed that IFN-α-induced STAT3 activation is decreased upon cell 
stretch. Study of STAT3 activation profile in mouse endothelial cells WT (WT MLEC) 
and knock out for Cav1 (Cav1-/- MLEC), revealed that caveolae/Cav1 are negative 
regulators of STAT3 activation. Using mouse embryonic fibroblast (MEF) lacking 
cavin-1 expression (cavin-1-/- MEF) we could demonstrate that non-caveolar Cav1 
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negatively regulates JAK-STAT signaling. Immunoprecipitation and pulldown 
experiments revealed that Cav1 interacts with JAK1, which is a key effector of the 
JAK-STAT signaling pathway. In addition, Cav1-JAK1 interaction depended on 
membrane tension. It has been proposed that Cav1 modulates signaling events via 
direct binding and inhibition of signaling molecules through its caveolin scaffolding 
domain (CSD). Nevertheless, this model remains debated. In the present work, we 
definitely show that Cav1 CSD has a prominent role in the Cav1-mediated JAK-STAT 
control. Indeed, mutation of this domain on amino acids F92 and V94 prevents Cav1 
interaction with JAK1 resulting in the abolishment of Cav1 negative effect on JAK-
STAT. Furthermore, the CSD is sufficient to mimic Cav1 negative effect on STAT3 
activation and directly impairs JAK1 catalytic activity as JAK1-mediated ATP 
conversion in-vitro could be decreased by CSD mimicking peptide.  
 
The detailed results of this work are presented below, under the form of an 
article in preparation for submission.  
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Abstract   
Caveolae are small invaginations of the plasma membrane that have been classically 
involved in membrane trafficking and signaling. These multifunctional organelles 
were recently shown to play a key role as mechanosensors that adapt the cell 
response to mechanical stress. Here, we investigated the role of caveolae mechanics 
in the control of the JAK-STAT signaling pathway. Single molecule imaging 
experiments revealed that caveolae disassembly induced by mechanical stress led to 
a drastic increase of caveolin-1 diffusion at the plasma membrane. This promoted the 
direct interaction of the caveolin-1 scaffolding domain with the tyrosine kinase JAK1, 
inhibiting its catalytic activity and thereby the activation by IFN-α of the JAK1 
downstream effector STAT3. These results therefore establish caveolae as 
mechanosignaling hubs that couple the sensing of mechanical stress to the 
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regulation of intracellular signaling through the release of free caveolin-1 at the 
plasma membrane. 
 
 
Introduction 
Since their first visualization by electron microscopy more than 60 years ago (Palade, 
1953; Yamada, 1955) the small cup-shaped plasma membrane invaginations named 
caveolae have been extensively investigated. Caveolae are shaped by a protein 
complex composed of caveolin and cavin proteins. Among the three mammalian 
caveolins, caveolin-1 (Cav1) is the only isoform required for the assembly of 
caveolae in non-muscle cells. (Parton et al., 2006; Rothberg et al., 1992; Scherer et 
al., 1996). The second group of caveolae proteins is represented by a family of four 
cytosolic proteins named cavins (cavin-1 to -4) (Aboulaich et al., 2004). Cavin-1 is 
essential for caveolae morphogenesis in all cell types whereas Cav3 and cavin-4 are 
strictly restricted to muscle cells (Bastiani et al., 2009; Way and Parton, 1995). 
Recent electron microscopy and X-ray crystallography studies gave a further insight 
into the stoichiometric organization of the characteristic striated coat observed on the 
outer cytoplasmic side of caveolae. It has been calculated that 150-200 Cav1 
monomers associate with 50-60 cavins organized as trimers to form a caveola 
(Gambin et al., 2014; Ludwig et al., 2013; Stoeber et al., 2016). Several proteins, 
albeit less well characterized, have also been localized at the neck of caveolae, 
including dynamin 2, PACSIN2 (syndapin 2) and the ATPase EHD2 (Hansen et al., 
2011; Morén et al., 2012).  
Caveolae, which are particularly abundant in adipocytes, endothelial cells and 
muscle cells, are multifunctional organelles that have been classically involved in 
membrane trafficking and cell signaling (Cheng and Nichols, 2016; Lamaze et al., 
2017). Mutations or impaired expression of caveolins and cavins have been 
associated with several human diseases including lipodystrophy, vascular 
dysfunction, cancer and muscle dystrophies (Lamaze et al., 2017). If caveolae have 
long been associated with the control of intracellular signaling, the mechanisms 
underlying this control remain poorly understood and often debated (Collins et al., 
2012). Caveolae are likely to regulate the activation of signaling effectors by several 
non-mutually exclusive means (Lamaze et al., 2017). Owing to the strong affinity of 
Cav1 for cholesterol and sphingolipids, caveolae can locally modulate the lipid 
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composition and thereby the nanoscale organization of the plasma membrane, a key 
parameter for the activation of transmembrane receptors and associated signaling 
molecules (Blouin et al., 2016). This process was recently illustrated for the control of 
Ras signaling (Ariotti et al., 2014). Caveolae can also function as nanodomains 
themselves to confine signaling effectors locally at the plasma membrane as shown 
for the regulation of calcium signaling through the localization of the Ca2+ pump into 
caveolae (Fujimoto, 1993). Finally, caveolae can regulate cell signaling through direct 
interaction of Cav1 with its signaling partners. In this context, it was shown that Cav1 
carries a specific caveolin scaffolding domain (CSD), which is able to interact with 
and regulate the activity of several signaling molecules bearing a corresponding 
caveolin binding motif (CBM), a consensus signature motif found in several Cav1 
binding proteins (Couet et al., 1997a; Lisanti et al., 1995; Okamoto et al., 1998). If 
this interaction has been described in several studies, more recent structure- and 
sequence-based data on Cav1-CSD and CBMs have questioned the direct regulation 
of cell signaling by caveolae through protein-protein interaction with Cav1 (Byrne et 
al., 2012; Collins et al., 2012) 
We established a new function of caveolae as mechanosensing organelles 
that protect cells from rupture of the plasma membrane under mechanical stress 
(Sinha et al., 2011). Under various conditions where membrane tension is increased, 
caveolae immediately flatten out and disassemble to release the membrane stored in 
their invagination and buffer membrane tension variations. The essential role of 
caveolae in cell mechanoprotection was confirmed in several cell types in vitro and in 
vivo (Cheng et al., 2015; Lim et al., 2017; Lo et al., 2015). It has been proposed that 
the classical functions of caveolae should be reconsidered through their new function 
in cell mechanics (Cheng and Nichols, 2016; Nassoy and Lamaze, 2012). Here we 
revisited the role of caveolae on intracellular signaling by investigating the effects of 
the mechano-dependent cycle of caveolae disassembly/reassembly on cell signaling. 
We identified the Janus kinase/signal transducers and activators of transcription 
(JAK-STAT) signaling pathway to be directly regulated by caveolae mechanics. Upon 
mechanical stress, we found that Cav1 was rapidly released from caveolae into the 
plasma membrane. The pool of released Cav1 was able to directly interact via its 
CSD with the JAK1 tyrosine kinase, leading to the inhibition of its catalytic activity 
and preventing thereby the activation of JAK-STAT signaling by interferon-α (IFN-α). 
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Our study unveils a new mechanism by which caveolae couple mechanosensing with 
the control of cell signaling under mechanical stress. 
 
Results  
 
Mechanical stress drastically increases the diffusion of Cav1 at the plasma 
membrane. 
We previously demonstrated that caveolae have the ability to flatten out and 
disassemble in response to increased membrane tension (Sinha et al., 2011). Yet, 
the fate of the caveolar components following the disassembly of caveolae under 
mechanical stress remains unclear. Single-molecule fluorescence analysis revealed 
that changes in membrane tension led to the release of the cavin coat from flattened 
caveolae as two distinct cavin-1/cavin-2 and cavin-1/cavin-3 cytosolic subcomplexes  
(Gambin et al., 2014). Less is known about the topology of Cav1 oligomers after 
caveolae flattening. Caveolins could remain organized as a flat caveolar structure, as 
observed by deep-etch electron microscopy (Sinha et al., 2011), or released as non-
caveolar Cav1 oligomers. Indeed, FRAP experiments showed that the mobile fraction 
of Cav1 was increased upon mechanical stress, suggesting a higher number of Cav1 
molecules freely diffusing outside of caveolae (Sinha et al., 2011). We performed 
high-resolution single particle tracking (sptPALM) together with total internal 
reflection fluorescence microscopy (TIRF) to monitor with higher spatiotemporal 
resolution the fate of Cav1 molecules that are released from disassembled caveolae. 
This allowed us to measure the diffusion coefficient (D) of Cav1 fused to phospho-
switchable mEOS3.2 after photoactivation in mouse lung endothelial cells (MLEC). At 
steady state, the Cav1-mEos trajectories remain confined around static Cav1-mEOS 
objects, whose characteristics indicate that they are most likely confined within 
caveolae. Under membrane tension increase induced by hypo-osmolarity, we 
observed dramatic changes in the diffusion parameters of Cav1-mEOS with Cav1-
mEOS trajectories increasing in length and exploring a wider area (Fig. 1a). The D 
coefficient of Cav1-mEOS is redistributed as well, and translated a faster diffusion of 
Cav1-mEOS (Fig. 1b). Importantly, the logarithmic value of the diffusion coefficient 
increased with the time of exposure to hypo-osmolarity (Fig. 1c). In contrast, the D 
coefficient of Cav1-mEOS3.2 returns to a iso-osmotic-like distribution in shocked 
cells back to iso-osmolarity, which translate a return to a confined state for Cav1-
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mEOS (Fig. 1d).  Altogether, these results clearly indicate that after caveolae 
disassembly by mechanical stress, Cav1 molecules are released from the caveolar 
coat and freely diffuse at the plasma membrane. This process is dynamic and 
reversible. 
 
Caveolae can control several signaling pathways under mechanical stress 
We have hypothesized that the mechano-dependent cycle of caveolae 
disassembly/reassembly may constitute a mechanical switch by which caveolae and 
/or caveolins could control intracellular signaling (Nassoy and Lamaze, 2012). We 
therefore investigated whether the pool of freely diffusing Cav1 released under 
mechanical stress could impact the activation of some signaling pathways. To 
identify some of these signaling pathways, we ran a screening experiment based on 
the reverse phase protein assay (RPPA), a miniaturized high throughput dot-blot 
technology for proteomic analysis allowing the analysis of protein expression, post-
translational modifications and identification of activated or altered signaling 
pathways. The RPPA was performed on MLEC cells having (WT) or not caveolae 
(Cav1-/-), in resting condition or under uniaxial stretching. We also stimulated the cells 
by IFN-α so as to analyze the JAK/STAT signaling pathway. Results from the RPPA 
screening revealed several signaling pathways that were affected by cell uniaxial 
stretching as exemplified by the stretch dependent activation of MAPK and Akt 
pathways. As expected, IFN-α stimulation led to the tyrosine phosphorylation of 
STAT3 and STAT1 (Fig. 2a). Interestingly, the level of STAT3 phosphorylation was 
strongly decreased upon cell stretching, in a Cav1 dependent manner, whereas 
STAT1 activation was not affected. Other signaling pathways such as MAPK are 
activated by stretch independently from caveolae (Fig. 2a). 
 
Mechanical stress impairs the JAK/STAT signaling pathway  
We further investigated the role of caveolae mechanics on the JAK/STAT signaling 
pathway activated by IFN-α. JAK-STAT signaling represents one of the major 
signaling pathways of the cell. It is used by a wide array of cytokines and growth 
factors to transduce signal and generate accurate gene responses. It governs 
multiple biological processes as diverse as hematopoiesis, innate and adaptive 
immune function, cell proliferation, differentiation, migration and apoptosis (Villarino 
et al., 2017). The activation of JAK-STAT signaling by IFN-α relies on the ubiquitous 
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IFNAR receptor composed of two non-tyrosine kinase receptor subunits IFNAR1 and 
IFNAR2. IFN-α binding to IFNAR2 allows the formation of a ternary complex with 
IFNAR1, where the two IFNAR-associated JAK1 and TYK2 tyrosine kinases are 
mutually activated by trans-phosphorylation. These conformational changes trigger 
the full activation of JAK1 and TYK2, which in turn create tyrosine phosphorylated 
docking sites on IFNAR1 and IFNAR2 subunits where cytosolic STAT molecules 
(STAT1, STAT2 or STAT3) are recruited. The tyrosine phosphorylation by JAK1 and 
TYK2 allows the release of STATs in the cytosol and their dimerization before their 
translocation to the nucleus where they induce a transcriptional program specific to 
IFN-α (Schreiber and Piehler, 2015). 
We confirmed the data obtained through RPPA screening by monitoring 
STAT3 activation by IFN-α that is, phosphorylation at tyrosine 705, a key step 
required for the formation of active transcriptional complexes (Kaptein et al., 1996). 
We measured by immunoblotting the level of STAT3 phosphorylation and its 
consecutive nuclear translocation in WT MLEC or Cav1-/- MLEC cells stimulated with 
IFN-α under 25% uniaxial stretching. We found that the level of STAT3 tyrosine 
phosphorylation was decreased by about 43% in stretched WT MLEC cells (Fig. 3a). 
The decrease of STAT3 activation translated into a defect of STAT3 nuclear 
translocation in stretched cells (Fig. 3b). As observed above in the RRPA screening, 
the level of STAT3 tyrosine phosphorylation remained unchanged when Cav1-/- 
MLEC cells were stretched, indicating that this regulation requires functional 
caveolae (Fig. 3a). Again, we found that STAT1 activation by IFN-α was insensitive 
to mechanical stress since pSTAT1 nuclear translocation occurred normally in 
stretched cells (Fig. 3b). 
 
Non-caveolar Cav1 mediates STAT3 inhibition 
Our data indicate that caveolae and mechanical stress can control the activation of 
STAT3 by IFN-α. We next asked whether this control could occur in unstimulated 
cells. As expected, in the absence of stimulation by IFN-α, no activation of STAT1 
and STAT3 were detected in WT MLEC (Fig. 4a, b). In contrast, we observed a 
strong activation of STAT3 in unstimulated Cav1-/- MLECs. The absence of caveolae 
had no effect on the level of phosphorylated STAT1 at steady state in agreement with 
the RPPA and nuclear translocation data (Fig. 4b). The constitutive activation of 
STAT3 was dependent on the activity of the JAK1 tyrosine kinase since siRNA-
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mediated JAK1 depletion completely abolished STAT3 activation in stimulated and 
unstimulated Cav1-/- MLEC cells (Fig. 4c, d). These data indicate that caveolae 
and/or caveolins are negative regulators of STAT3 activation at steady state.  
 A key question in the field of caveolae is to distinguish the role of caveolae 
from the role of caveolins (Lamaze et al., 2017). Since we showed that mechanical 
stress released a pool of freely diffusing Cav1 at the plasma membrane (Fig. 1), we 
sought to investigate the role of non-caveolar Cav1 on STAT3 activation. To do so, 
we took advantage of mouse embryonic fibroblasts (MEF) knocked out for cavin-1. 
Indeed, in the absence of cavin-1, Cav1 is unable to assemble into morphologically 
distinguishable caveolae and remains as a pool of non-caveolar Cav1 with increased 
lateral mobility at the plasma membrane (Hill et al., 2008).  We therefore measured 
the level of STAT3 phosphorylation in unstimulated and IFN-α-stimulated cavin-1-/- 
MEF cells. As expected, STAT3 was not activated in unstimulated cavin-1-/- MEF 
cells (Fig. 5a). However, the stimulation of cavin-1-/- MEF cells by IFN-α failed to 
activate STAT3. The rescue of cavin-1 expression in cavin-1-/- cells (cavin-1-/- + 
cavin-1) allowed again the activation of STAT3 by IFN-α (Fig. 5b). These results 
suggest that the pool of non-caveolar Cav1 is responsible for the lack of STAT3 
activation by IFN-α. Indeed, the treatment of WT MLEC cells with methyl-β-
cyclodextrin, which disrupts caveolae by removing cholesterol at the plasma 
membrane, led also to a significant decrease of the level of STAT3 activation by IFN-
α (Supplementary fig. 1).  Finally, we measured the level of STAT3 activation in 
cavin-1-/- MEF expressing increasing amounts of non-caveolar Cav1 and found a 
dose dependent inhibition of IFN-α-induced STAT3 activation (Fig. 5c). Altogether 
these data indicate that an excess of non-caveolar Cav1 inhibits the activation of 
STAT3 by IFN-α. 
 
The level of Cav1 and JAK1 interaction is tuned by mechanical stress 
STAT3 is the direct downstream effector of JAK1 and TYK2 kinases that are 
associated to the IFNAR complex (Platanias, 2005). It is therefore likely that the 
inhibition of IFN-α-induced STAT3 tyrosine phosphorylation by non-caveolar Cav1 
occurs through interaction with the JAK kinases. We found indeed that Cav1 could 
interact with JAK1 in pull-down experiments performed in Cav1-/- MLECs cells 
expressing Cav1-RFP  (Fig. 6a). Our data showing on one hand that mechanical 
stress both releases non-caveolar Cav1 from caveolae and prevents the activation of 
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STAT3 by IFN-α, and on the other hand that non-caveolar Cav1 prevents the 
activation of STAT3 by IFN-α, led us to postulate that mechanical stress could 
regulate the interaction between Cav1 and JAK1. We thus applied a 30 mOsm hypo-
osomotic shock for 5 min so as to disassemble caveolae and promote the release of 
non-caveolar Cav1 at the plasma membrane. Under this condition, we observed an 
increase by about 65% of the amount of JAK1 co-immunoprecipitated with Cav1 (Fig. 
6b). Furthermore, the increase of Cav1 and JAK1 interaction under mechanical 
stress, was correlated with a concomitant 80% decrease of STAT3 activation by IFN-
α (Fig. 6c). Importantly, upon return to iso-osmotic conditions, when caveolae have 
been reassembled to initial numbers (recovery) (Sinha et al., 2011), both the levels of 
Cav1 interaction with JAK1 and STAT3 activation by IFN-α resumed to the levels 
measured before hypo-osmotic shock. These data indicate that the level of Cav1-
JAK1 interaction is tuned by the amount of Cav1 released from caveolae that are 
disassembled to buffer the increase of membrane tension induced by hypo-osmotic 
shock. Moreover, it shows that the inhibition of STAT3 activation by IFN-α is 
correlated with the level of Cav1 interaction with JAK1 suggesting that JAK1 
inhibition is tuned by the amount of Cav1 that binds to JAK1.  
 
JAK1 inhibition is mediated by the caveolin scaffolding domain 
Early studies have identified a so-called caveolin scaffolding domain that was 
involved in the direct regulation, mostly inhibitory, of several signaling molecules by 
Cav1 including eNOS or heterotrimeric G proteins and lastly heme oxygenase (Couet 
et al., 1997b; Garcia-Cardena, 1997; Taira et al., 2011). Interestingly, we found that 
the tyrosine kinase JAK1 carries several CBMs, the caveolin binding motifs that may 
be involved in the recognition by the Cav1 CSD. One is localized in the pseudokinase 
domain, one putative CBM is in the kinase domain (Jasmin et al., 2006) and another 
CBM can be found in the FERM domain of JAK1. The phenylalanine 92 and valine 
94 residues play a key role in the CSD/CBM interaction (Nystrom et al., 1999; Trane 
et al., 2014). To test whether the interaction between Cav1 and JAK1 was mediated 
by the Cav1 CSD, we expressed a Cav1 CSD construct mutated for the F92 and V94 
residues (F92A/V94A Cav1) in Cav1-/- MLEC cells. In agreement with previous 
experiments, we found JAK1 in pulled-down lysates from WT Cav1 expressing cells. 
In contrast, no JAK1 could be detected in pulled-down fraction from lysates of 
F92A/V94A Cav1 expressing cells (Fig. 7a), which indicates that the interaction 
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between Cav1 and JAK1 requires the CSD phenylalanine 92 and valine 94 residues. 
In addition the CSD shares primary sequence similarities with the pseudosubstrate 
domain of SOCS1 and SOCS3, which is the domain that mediates JAKs inhibition by 
SOCS1 and SOCS3 (Jasmin et al., 2006; Kershaw et al., 2013). 
 To test whether the inhibitory role of Cav1 on JAK1 activity was mediated by 
the CSD, we examined the level of pSTAT3 nuclear translocation induced by IFN-α 
stimulation in Cav1-/- MLEC cells expressing either WT or F92A/V94A Cav1 
(Bernatchez et al., 2011; Meng et al., 2017; Nystrom et al., 1999). While the nuclear 
translocation of pSTAT3 occurred normally in non-transfected cells, cells 
overexpressing Cav1 WT showed a defect of pSTAT3 nuclear translocation in 
agreement with the inhibitory role of Cav1 on JAK1 activity. It was reported indeed 
that the overexpression of Cav1 generates a pool of non-caveolar Cav1 at the 
plasma membrane, which is likely due to a stoichiometric imbalance between the 
number of Cav1 molecules and the other caveolar components required for caveolae 
assembly (Hayer et al., 2010; Moon et al., 2013). On the contrary, in cells expressing 
the F92A/V94A mutated Cav1 CSD, we observed a normal nuclear translocation of 
pSTAT3 induced by IFN-α stimulation, indicating that F92A/V94A Cav1 lost the ability 
to negatively regulate STAT3 activation, most likely through its inability to interact 
with JAK1 (Fig. 7b). In agreement with the lack of regulation of STAT1 activation by 
mechanical stress and caveolae, the nuclear translocation of pSTAT1 induced by 
IFN-α was not affected whether cells express WT Cav1, F92A/V94A Cav1 or none 
(Supplementary fig. 2).  
We further established the role of the Cav1 CSD using two CSD mimicking 
peptides, a peptide named CavTratin corresponding to the Cav1 CSD (Cav1 
82DGIWKASFTTFTVTKYWFYR101) and a dominant negative peptide named 
CavNoxin (Cav1 82DGIWKASFAAATVTKYWFYR101) where key amino acids have 
been replaced by alanines thereby abolishing its inhibitory effect (Bernatchez et al., 
2011). WT MLEC cells treated with CavTratin showed a significant decrease of 
STAT3 tyrosine phosphorylation upon IFN-α stimulation, indicating that the caveolin 
domain CSD is sufficient to mimic the negative regulation of STAT3 activation by 
Cav1. Conversely, cells treated with CavNoxin showed a significant increase of 
STAT3 tyrosine phosphorylation upon IFN-α stimulation (Fig. 7c). These data confirm 
that increasing the amount of Cav1 that is able to interact with the JAK1 kinase inhibit 
STAT3 activation whereas the mutated Cav1 CSD peptide relieves the JAK1 
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inhibition, most likely by competing with endogenous Cav1. We could definitely 
establish the direct role of the Cav1 CSD on JAK1 catalytic activity by assessing in a 
cell free assay, the effect of CSD binding on the ability of JAK1 to catalyze ATP 
hydrolysis. We measured in vitro the catalytic activity of a human recombinant JAK1 
by measuring the conversion of ATP to ADP. We found that increasing 
concentrations of a control peptide did not affect the catalytic activity of JAK1 as ADP 
production was maintained. In contrast, JAK1 dependent ADP production 
significantly decreased in a dose dependent manner when CavTratin was added to 
the reactional mix (Fig. 7d). These data therefore demonstrate that the negative 
regulation of STAT3 activation by Cav1 results from direct binding of the Cav1 CSD 
to JAK1, which inhibits JAK1 catalytic activity.  
 
Discussion 
Over the past decades, many functions have been ascribed to caveolae (other 
reviewed here: Lamaze et al., 2017). The discovery of the role of caveolae in cell 
mechanics in 2011 (Sinha et al., 2011) led the field to revisit the classical functions of 
caveolae in this new context (Cheng and Nichols, 2016). In this study, we 
investigated the fate of Cav1 upon caveolae mechanical disassembly and its impact 
on caveolae dependent signaling. Upon membrane tension increase, we could 
visualize by single molecule microscopy the appearance of a highly mobile pool of 
non-caveolar Cav1 at the plasma membrane. Considering the established role of 
caveolae in signaling (Parton and Simons, 2007; Patel et al., 2008), we exanimated 
the effect of non-caveolar Cav1 release on cell signaling pathways. High throughput 
screening revealed that the JAK-STAT signaling pathway was modulated by cell 
stretching in a caveolae dependent manner. We could demonstrate that non-caveolar 
Cav1 generated by caveolae mechanical disassembly, binds directly to the JAK1 
tyrosine kinase and inhibits its catalytic activity in a CSD-dependent manner. Cav1 
binding to JAK1 results in impaired activation of STAT3 by IFN-α. Importantly, we 
further show that the level of Cav1-JAK1 interaction and thereby the downregulation 
of IFNα-induced STAT3 activation, is modulated by mechanical stress. Finally, based 
on CSD mimicking peptides and CSD-mutated Cav1, we could demonstrate that the 
Cav1 CSD domain is required for the interaction of Cav1 with JAK1 and directly 
mediates the inhibitory effect of Cav1 on JAK1 catalytic activity.  
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Numerous studies have involved Cav1 as an essential component of the 
signal transduction function of caveolae, based on its ability to interact with many 
signaling proteins (Couet et al., 1997b; Gangadharan et al., 2015; Garcia-Cardena, 
1997; Li et al., 1996; Nystrom et al., 1999; Taira et al., 2011). The mechanisms by 
which caveolae control signaling remains poorly understood and some aspects are 
still debated (Lamaze et al., 2017). Early work has involved the Cav1 CSD domain in 
the control of Cav1 interaction with signaling effectors (Li et al., 1995; Li et al., 1996). 
The corresponding CBM domains have been found in many downstream signaling 
effectors that bind to Cav1 (Couet et al., 1997a). Indeed, sequence analysis showed 
that JAK1 displays three domains that could correspond to putative CBMs: one in the 
FERM domain (157YLFAQGQY164), one in the pseudokinase domain 
(777WSFGTTLW784) and a last one in the kinase domain (1065WSFGVTLH1072) 
(Supplementary fig. 3). While the role of these motifs has not been investigated in 
this work, our data involve most likely the CBM2 or CBM3 since it is the only CBMs 
present in the recombinant JAK1 kinase used in the cell free assay. Although the 
CSD-CBM interaction has been extensively investigated for the interaction of Cav1 
with signaling proteins such as insulin and trimeric G protein receptors, eNOS or 
Heme Oxygenase (Bernatchez et al., 2005; Nystrom et al., 1999; Taira et al., 2011; 
Trane et al., 2014), its role in signaling has been regularly questioned. The debate on 
the CSD-CBM interaction has been fueled by the recent structural features of Cav1 
(Lamaze et al., 2017). The CSD consists in an amphipathic helix that is partially 
embedded in the inner leaflet of the plasma membrane, which would make it not 
suitable to mediate interaction (Byrne et al., 2012; Collins et al., 2012; Kirkham et al., 
2008).  
In this study, we show nevertheless that the Cav1-JAK1 interaction is directly 
mediated by the CSD and that this interaction is tuned by mechanical stress. One 
could therefore hypothesize that the mechanical release of Cav1 from caveolae 
triggers the exposition of the CSD by Cav1 conformation changes induced by the 
mechanical release of Cav1. In this context, it is interesting that previous studies 
reported that the CSD is not static and presents instead a dynamic structure, that is 
either fully helical or partially unstructured and could determine CSD accessibility (Liu 
et al., 2016). In addition, one or the other conformation would be favored by the lipid 
environment (Hoop et al., 2012; Le Lan et al., 2006). It is therefore possible that non-
caveolar Cav1 may experience a different lipid environment, hence its increased 
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mobility, resulting in a different CSD conformation. Finally, it cannot be excluded that 
Cav1 and/or JAK1 post-translational modifications induced by the mechanical 
release of Cav1 could mediate this interaction. Indeed, Cav1 is phosphorylated on 
Tyr 14 and Ser 80 by different sets of kinases. The introduction of negative charges 
in the N-terminal part of Cav1, may induce a kink in Cav1 structure by further pushing 
away the N-ter end from the plasma membrane due to charge repulsion (Ariotti et al., 
2015; Meng et al., 2017; Shajahan et al., 2012).  
An unresolved question in the field is the role of caveolae versus non-caveolar 
Cav1 in signaling (Cheng and Nichols, 2016; Lamaze et al., 2017). Our study unveils 
a regulatory role of caveolae in JAK-STAT signaling based on the mechanical control 
of the balance between non-caveolar Cav1 (high stress) and caveolar Cav1 (low 
stress). This process allows the fine mechanical tuning of JAK-STAT signaling as the 
level of non-caveolar Cav1 is below detection under resting conditions (Hill et al., 
2008; Sinha et al., 2011). We have identified here and elucidated the molecular 
mechanism underlying the selective control of JAK-STAT signal transduction by 
caveolae mechanics. Interestingly, this mechanism selectively targets JAK1 
dependent STAT3 activation, while at steady state, IFN-α indifferently induces both 
STAT1 and STAT3 activation (Platanias, 2005). The molecular basis driving this 
signal specificity needs to be further investigated. Our data showing that STAT3 was 
activated in Cav1 knocked out cells in the absence of IFN-α and that the Cav1 CSD 
interacted directly with JAK1 and inhibited its catalytic in the absence of IFN-α 
indicate that this control is not restricted to IFN-α and could be extended to other 
cytokines activating JAK1. Williams and colleagues, recently revealed that proper 
JAK-STAT signal suppression through SOCS3 requires bona fide caveolae and 
stable cavin-1 (Williams et al., 2018). Hence one could hypothesize that mechanical 
disassembly of caveolae and the destabilization of cavin complexes, would result in 
impaired SOCS3 mediated JAK-STAT signal termination. Therefore, under 
mechanical stress, the release of free Cav1 might lock the JAK-STAT signaling 
pathway to prevent aberrant JAK-STAT signaling.  
The physiological role of JAK-STAT signaling control by caveolae mechanics 
remains unclear. The deregulation of STAT3 activation has been involved in many 
human pathologies including Crohn’s disease, psoriasis, Hyerglobulin E syndrome 
and cancer (O’Shea et al., 2015). This process could be involved in tumor 
development and may partially explain the ambivalent role that Cav1 plays in tumor 
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growth (Goetz et al., 2008; Lamaze and Torrino, 2015). On one hand, STAT3 is a 
well-known oncogene targeted by many anti-cancer therapies (Beebe et al., 2018). 
On the other hand, STAT1 is a tumor suppressor (Koromilas and Sexl, 2013). This 
new aspect of caveolae functioning as mechanosignaling hubs may play a critical 
role during tumor growth. Indeed the mechanical forces encountered by cancer cells 
during tumor progression (Kai et al., 2016), may perturb caveolar dynamics that in 
turn would impair the fine tuning of the STAT3/STAT1 activation balance through 
caveolae mechanics.  
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Figure 1. High resolution analysis of Cav1 diffusion under mechanical stress  
(a) Left panel, wide field images of Cav1-GFP under iso-osmolarity (300 mOsm) and 
hypo-osmolarity (30 mOsm) in MLEC cells. Right panel, Cav1-mEOS3.2 trajectories 
(green) and Cav1-mEOS3.2 objects (red) acquired using TIRF-sptPALM. (b) 
Distribution of log(D) for Cav1-mEOS3.2 in iso-osmotic condition (blue) and hypo-
osmotic condition (orange). (c) Distribution of log(D) for Cav1-mEOS3.2 in hypo-
osmotic from 0 minute (deep blue) to 30 minutes (light blue). (d) Distribution of log(D) 
for Cav1-mEOS3.2 in hypo-osmotic condition (orange) and recovery condition 
(green). 
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Figure 2. High throughput screening of signaling pathways modulated by 
caveolae mechanics 
(a) Heat map of signaling effectors activation in WT and Cav1-/- MLEC cells under 
resting condition or uniaxial stretch and with type I IFN stimulation or not. (b) STAT1 
and STAT3 activation under type I IFN stimulation (left). STAT1, STAT3, p42/44 
MAPK and Akt phosphorylation level under uniaxial stretch.  
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Figure 3. Uniaxial stretching controls IFN-α induced STAT3 activation 
(a) STAT3 phosphorylation level induced by IFNα stimulation in Cav1-/- MLEC cells 
submitted or not to stretch. Representative immunoblot. Immunoblot quantification of 
signal ratio relative to “No stretch” condition. Mean value ± SEM. Statistic were 
processed using two tailored unpaired t test. *P<0,05.  (b) Analysis of the nuclear 
translocation of pSTAT1 (green) and pSTAT3 (red). WT MLEC were stretched or not 
and prior to stimulation with IFNα for 20min. After fixation the nuclear distribution of 
pSTAT1 and pSTAT3 was detected by immunofluorescence. 
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Figure 4. Cav1 negatively regulates the JAK1-dependent STAT3 activation 
(a) STAT3 basal phosphorylation level in WT MLEC compared to Cav1-/- MLEC. 
Representative immunoblot. (b) STAT1 basal phosphorylation level in WT MLEC 
compared to Cav1-/- MLEC. Representative immunoblot. (c) STAT3 basal 
phosphorylation level in Cav1-/- MLEC upon control (CTRL) or JAK1 siRNA 
treatment. Reprensentative immunoblot. (d) IFNα induced STAT3 phosphorylation 
level in Cav1-/- MLEC upon CTRL or JAK1 siRNA treatment. Representative 
immunoblot. Immunoblot quantification of (pSTAT/Tubulin)/(STAT/Tubulin) signal 
ratio relative to control condition. Mean value ± SEM. Statistics was performed using 
two tailored unpaired t test. *P<0,05; **P<0,01. 
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Figure 5. Non-caveolar Cav1 inhibits IFN-α-induced STAT3 phosphorylation in 
a concentration dependent manner 
(a) STAT3 basal level of activation of cavin-1-/- MEF cells and cavin-1-/- MEF cells 
transfected with cavin-1 (+ cavin-1). Quantification of signal ratio relative to “cavin-1-/-
” condition. Representative immunoblot. (b) IFN-α-induced STAT3 level of activation 
in cavin-1-/- MEF cells and cavin-1-/- MEF cells + cavin-1. Representative immunoblot. 
Quantification signal ratio relative to “cavin-1-/-“ condition. (c) IFN-α-induced STAT3 
phosphorylation level in cavin-1-/- MEF cells with either low, medium or high Cav1 
expression. Representative immunoblot. Quantification of signal ratio relative to “low” 
condition. (a, b, c) mean values ± SEM. Statistics were processed using unpaired t 
test (a, b) and multi-comparison one-way ANOVA (c). *P<0,05; **P<0,01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 111 
 
 
 
JAK1
Cav1
Input Iso Hypo Reco Beads
130 KDa
25 KDa
IP
Iso Hypo Reco
0.0
0.5
1.0
1.5
2.0
2.5
pS
TA
T3
/S
TA
T3
 (A
.U
.)
**
ns
Iso Hypo Reco
0.0
0.5
1.0
1.5
2.0
2.5
C
av
1 
- J
AK
1 
in
te
ra
ct
io
n 
(A
.U
.)
*
ns
a
b c
d e
Iso Hypo Reco
pSTAT3
STAT3
α-Tubulin
JAK1
Cav1
RFP
130 KDa
55 KDa
55 KDa
25 KDa
 R
FP
 
Ca
v1
-R
FP
 
Ca
v1
-R
FP
  
RF
P 
Input IP
IFN-α
      
 76 
 
Figure 6. Mechanical stress determines Cav1 interaction with JAK1  
(a) RFP-trap pull down experiment in Cav1-RFP expressing Cav1-/- MLEC cells. 
Representative immunoblot. (b) Immunoprecipitation experiment of endogenous 
Cav1 in iso-osmotic (Iso), hypo-osmotic (Hypo) and successive hypo-osmotic shock 
and iso-osmotic condition (Rec). Representative immunoblot. Quantification of 
(JAK1/Cav1) signal ratio relative to “Iso” condition. (c) STAT3 phosphorylation level 
in WT MLEC upon IFNα stimulation under iso-osmotic (Iso), hypo-osmotic (Hypo) 
and successive iso and hypo-osmotic shock (Rec). Representative immunoblot. 
Quantification of immuno-staining upon Iso-, Hypo- and Recovery osmotic shock. (b, 
c) mean value ± SEM, statistics were processed using multi-comparison one-way 
ANOVA. *P<0,05; **P<0,01.  
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Figure 7. The caveolin scaffolding domain is required for Cav1-JAK1 
interaction and Cav1 negative effect 
(a) immunoblot of RFP-trap pulldown experiment performed on Cav1-/- MLEC cells 
expressing either WT Cav1-RFP or F92A/V94A Cav1-RFP or RFP (left). 
Quantification of JAK1/Cav1 signal ratio relative to “WT Cav1-RFP” condition (right). 
(b) Analysis of nuclear translocation of pSTAT3 (green) of IFN-α stimulated Cav1-/- 
MLEC expressing either exogenous WT Cav1-RFP or F92A/V94A Cav1-RFP (red) 
(left). Quantification of nuclear/cytosol pSTAT3 signal ratio in CTRL, WT Cav1 and 
F92A/V94A Cav1 (right). After fixation, the nuclear distribution of pSTAT3 was 
detected by immunofluorescence. (c) IFN-α-induced STAT3 phosphorylation level of 
WT MLEC cells upon either control peptide and CavTratin treatment (left) or control 
peptide and CavNoxin treatment (right). Representative immunoblots. (d) Graph 
representing in vitro JAK1 ADP production relative to peptide log concentration (µM), 
control peptide (black curve) or CavTratin (red curve). (a, b, c) mean values ± SEM. 
Statical analysis were processed using one-way ANOVA (a, b) and two tailored 
unpaired t test (c). *P<0,05; **P<0,01; ***P<0,001; ****P<0,0001. 
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Figure 8. Molecular model of the control of JAK-STAT signaling by caveolae 
mechanics 
Left panel: At steady state, Cav1 is entirely caveolar and its localization is restricted 
to invaginated caveolae. Upon IFN-α stimulation, signal transduction occurs through 
the JAK-STAT pathway, activating STAT3 phosphorylation and its consecutive 
nuclear translocation. Right panel: Upon mechanical stress, membrane tension 
increases, which leads to rapid caveolae flattening and disassembly. Caveolae 
disassembly dramatically increases the diffusion of non-caveolar Cav1 oligomers that 
are able to bind to JAK1 via its CSD.  This results in the direct inhibition of the 
tyrosine kinase catalytic activity. JAK1 inhibition mediated by Cav1 interaction 
prevents signal transduction of JAK-STAT pathway when stimulated by IFN-α. 
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Supplementary figure 1. Caveolae disruption by cyclodextrin treatment 
decreased IFN-α-induced STAT3 phosphorylation 
STAT3 phosphorylation level of WT MLEC stimulated by IFN-α upon mβCD 
treatment. Representative immunoblot. Quantification of (PSTAT3/Tub)/(STAT3/Tub) 
signal ratio relative to control condition. Mean values ± SEM. Statical analysis were 
processed using two tailored unpaired t test, ***P<0,001. 
 
 
 
Supplementary figure 2. IFN-α induced STAT1 nuclear translocation.  
Analysis of the nuclear translocation of pSTAT1 (green) of IFN-α stimulated Cav1-/- 
MLEC expressing either exogenous WT Cav1-RFP or F92A/V94A Cav1-RFP (red). 
After fixation the nuclear distribution of pSTAT1 (green) was detected by 
immunofluorescence. Quantification of nuclear/cytosol pSTAT3 signal ratio in CTRL, 
WT Cav1 and F92A/V94A Cav1. Statistics were processed using standard one-way 
ANOVA. 
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Supplementary figure 3. CBM localization on JAK1 structure 
(a) Putative CBM localization in JAK1 primary structure. (b) CBM1 (highlighted lateral 
chains, red arrow) localization in the tridimensional structure of the FERM domain of 
JAK1 (PDB 5IXI). (c) CBM2 (highlighted lateral chains, red arrow) localization in 
JAK1 pseudokinase tridimensional structure (PDB 4L00). Pseudokinase and kinase 
domains are structurally identical. The putative CBM3 has a localization similar to the 
CBM2 but within the kinase domain. 
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Materials & Methods 
 
Cell lines.  
WT MLEC and Cav1-/- cell lines were characterized by Sessa’s team (Murata et al., 
2007) and kindly provided by Radu V.Stan (Darthmouth Mediac School, NH, USA). 
These mice lung endothelial cells were immortalized using polyomavirus T antigen 
and selected according to CD31, VE-Cadherin and PV1 expression.  
 
Cell culture.  
All cells were grown at 37°C under 5% of CO2. WT MLEC and Cav1-/- MLEC cell 
lines were cultured in Enothelial Balal Medium (EBM2) from Lonza supplemented 
with 15% Hyclone FCS, 4mM glutamine, 5mM sodium pyruvate, 0,01 % penicillin 
streptomycin (v/v), 0.04% hydrocortisone (v/v), 0.4% hEGF-B (v/v), 0.1% VEGF (v/v), 
0.1% R3-IGF-1 (v/v), 0.1% ascorbic acid (v/v), 0.1% hEGF (v/v), 0.1% GA-1000 (v/v), 
0.1% heparin (v/v) (EGM2 singlequote, Lonza). MEF cells were cultured in DMEM 
high-glucose glutamax (Gibco, Life Technologies), supplemented with 10% SVF 
(v/v), 0.01% penicillin streptomycin (v/v) and 5mM sodium pyruvate.  
 
Antibodies and reagents.  
Mouse anti-αTubulin (Sigma-Aldrich, clone B512, T5168, 1/1000 for WB); mouse 
anti-chlatrin heavy chain (BD Transduction, 610500, 1/5000 for WB) rabbit anti-
caveolin-1 (Cell Signaling 3238S, 1/1000 for WB); mouse anti-caveolin-1 (BD 
Transduction, 610407, 10µg/condition for IP); mouse anti-PTRF (BD Biosciendes 
611258, 1/1000 for WB); mouse anti-STAT3 (Cell signaling, clone 124H6, 9139, 
1/1000 for WB); rabbit anti-pSTAT3 (Cell signaling, clone D3A7 9145, 1/1000 for WB, 
1/100 for IF); rabbit anti-STAT1 (Cell signaling, 9172, 1/1000 for WB); mouse anti-
pSTAT1 (Cell Signaling, 9167, 1/1000 for WB, 1/100 for IF); rabbit anti-JAK1 (Cell 
Signaling, 3332S, 1/1000 for WB); Secondary antibodies conjugated to Alexa 488, 
Cy3 or horse radish peroxidase (Beckman Coulter or Invitrogen). 
 
RNA interference-mediated silencing.  
WT MLEC cells were transfected with small interfering RNAs (siRNAs) using using 
HiPerFect (Qiagen) according to manufacturer’s protocol. Experiments were 
performed 24 hours after transfection, on validation of silencing efficiency by 
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immunoclot analysis using specific antibodies and normalizing to the total level of α-
tubulin used as loading control. 20 nM SMART pool siRNA targeting JAK1 mRNA 
(GE healthcare/Dharmacon, L-040117-00-0005) was used for JAK1 knock down. 
Control siRNA (QIAGEN, 1022076) was used at the same concentration and served 
as reference point. 
 
Immunoblotting.  
Cells were lysed in sample buffer (62.5 mM Tris/HCl ph 6.0, 2% SDS (v/v), 10% 
glycerol (v/v), 40 mM dithiothreitol and 0.03% phenol red (w/v)). Lysates were 
analyzed by SDS-PAGE and Western blot analysis and immunoblotted with the 
indicated primary antibodies and horseradish peroxydase-conjugated secondary 
antibodies. Chemiluminescence signal was revealed using PierceTM ECL Western 
Blotting Substrate, SuperSignal West Dura Extended Duration Substrate or 
SuperSignal West Femto Substrate (Thermo Scientific Life Technologies). 
Acquisitions were performed with the ChemiDoc MP Imaging System (BioRad). 
Samples for the detection of phospho and non-phospho proteins were loaded on two 
different gels. The ratio of the signal detection for targeted protein/loading control 
was determined for each membrane. The overall ratio of (phosphoprotein/loading 
control)/(protein/loading control) was determined.  
 
Immunofluorescence.  
Transfected Cav1-/- MLEC cells were seeded on 12 mm coverslips 24h before the 
pSTAT nuclear translocation assay. After IFNα stimulation, cells are fixed and 
permeabilized with cold methanol for 15 min at -20°C. Cells are washed with PBS 
0.2% BSA (v/v) then sequentially incubated with idicated promary antibody and 
fluorescence-conjugated secondary antibody in PBS 0.2% BSA (v/v) for 1h at room 
temperature. Coverslips are mounted in Fluoromount-G mounting medium 
(eBioscience) supplemented with 2 µg/mL DAPI (Sigma-Aldrich). Pictures were 
acquired on a Leica DM 6000B inverted epifluoresence microscope equipped with a 
HCX PL Apo 63X NA 1.40 oil immersion objective and an EMCCD camera 
(Photometrics CoolSMAP HQ); Camera: CCD 1392x1040; objective 40x or 63x. 
Quantification of pSTATs nuclear translocation by calculating the nucleocytoplasmic 
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ratio of phospho-STAT1-3 signal (nuclei masks were realized with the DAPI staining) 
with image J software 1.49a (NIH) and plugins bundle proposed by the McMaster 
Biophotonics Faclity (http://www.macbiohotonics.ca). 
 
 
 
Single particle tracking. 
WT MLEC cells were transfected using the AMAXA electroporation setup with Cav1-
mEOS3.2 and Cav1-GFP 24h prior experiment. Cells were grown in Ringer media 
and 30mOsm hypo-osmotic shock was applied during acquisition. Images were 
acquired using sensitive EMCCD and Nikon CFI Apo TIRF 100x oil, NA 
1.49 objective.  
 
Transfection.  
For single particle tracking experiment WT MLEC and Cav1-/- were transfected using 
Lonza AMAXA. Adapted settings for mice cells (MEF) were provided in the AMAXA 
setup. Lonza provided specific reagent for AMAXA mice cells transfection. Double 
transfection of 5ug of Cav1 mEOS3.2 and 1ug of Cav1 GFP on 1 million cells was 
performed 24h prior experiment. For pSTATs nuclear translocation upon Cav1 
expression, cells were electroporated using a pulse of 220 V and 975 µF with a Gene 
Pulser® the BioRad setup. 
 
IFN-α stimulation.   
Cells were treated with or without 1000 U/ml IFNα at 37°C for the indicated times. 
For biochemical analysis, cells were washed with PBS and lysed in SDS Sample 
Buffer 1X. Total lysates were analyzed by SDS-PAGE and Western blot analysis and 
immunoblotted with the indicated antibodies. Chemiluminescence detection was 
performed with SuperSignal West Dura Extended Duration Substrate or with 
SuperSignal West Femto Substrate (Thermo Scientific Life Technologies). 
Phosphorylated and total forms of the proteins are quantified and normalized to 
clathrin heavy chain or tubulin levels in the same lysate. Phosphorylated protein over 
total ratio is determined for each condition. 
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High throughput screening.  
25 µg/mL fibronectine diluted in NaOH 100 mM pH 8.6  is incubated on a PDMS 
layer at 37°C. 70k WT MLEC or Cav1-/- MLEC cells were seeded and incubated for 4 
hours at 37°C in complete MLEC media. Cells were stretched by 25% for 2 minutes 
then while stretch is maintained, cells media is replaced by stimulation media (EBM-2 
no SVF with IFNα 1000 U/ml) for 20min at 37°C. Cells were washed with PBS and 
lysed with hot laemmli 1X sample buffer (50 mM Tris pH=6.8, 2% SDS, 5% glycerol, 
2mM DTT, 2,5 mM EDTA, 2.5mM/EGTA, 2.5mM/EGTA, 2x Phosphatase inhibitors 
(Halt Phosphatase inhibitor cocktail 100x, Perbio, Ref. 78420), Protease inhibitors 
(Protease inhibitor cocktail, complete MINI EDTA-free, Roche, Ref. 1836170), 1 
tablet/5mL (or by RR : 1/1000 PIC), 4 mM Sodium Orthovanadate, 20 mM Sodium 
Fluoride). 
 
Co-immunoprecipitations.  
Cells were lysed in 1% NP-40 in TNE (10 mM Tris/HCl pH 7.5, 150 mM NaCl, 0.5 
mM EDTA) with protease inhibitors cocktail (Roche) for 30 min at 4°C. Cleared 
lysates (16,000g, 10 min, 4°C) were incubated overnight at 4°C under rotation with 1 
µg/ml of the indicated antibody followed by incubation for 1 hour with 25 µl of protein 
A/G magnetic beads (Thermo Scientific) in the case of endogenous proteins. In the 
case of tagged proteins, 25 µl GFP-Trap or RFP-Trap beads (Chromotek) were used. 
After 3 washes in TNE, immunoprecipitated beads were eluted following the 
manufacturers’ instructions. 
 
Osmotic shock and uni-axial stretch. 
For osmotic shock, cells were seeded 24h before experiment, then complete media 
was replaced by 30 mOsm media (10% media and 90% H2O) for 5 minutes, cells 
were immediately lysed or hypo-osmmotic media was replaced by normal iso-
osmotic media (recovery) before lysis. For cell stretch, cells were seeded on a 100 
um thick PDM sheet (12x7 mm) coated with fibronectin 4 hours prior experiment. The 
PDMS sheet was linearly stretched using a homemade setup motorized (P1, 
Karlsruhe, Germany). Cells were pre-stretched by 25% for 2 minutes and stretch was 
maintained during IFNα stimulation.  
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CSD mimicking peptides  
CSD mimicking peptides were synthetized from biomatik. Control peptide HHHHHH-
RQIKIWFQNRRMKWKKWGIDKASFTTFTVTKYWFRY; CavTratin HHHHHH-
QIKIWFQNRRMKWKKDGIWKASFTTFTVTKY; CavNoxin HHHHHH-
RQIKIWFQNRRMKWKKDGIWKASFAAATVTKWYFYR. Cells were treated for 6 
hours with 1µM CSD mimicking peptide resuspended in endothelial basal medium 
0,2% PBS/BSA (v/v) 
 
Invitro Kinase activity measurement. 
Invitro kinase assay was performed using purified JAK1 (ProQinase 1480-0000-1 
JAK1 aa583-1154), RBER-IRStide (ProQinase 0863-0000-1). Kinase reaction was 
performed in Kinase reaction buffer ([ATP] 100 µM, RBER-IRStide 80 µg/ml, DMSO 
according to peptide concentration) at 30°C for 1h. Measurement of ADP production 
was performed using Promega ADP-Glo™ Kinase Assay. Luminescence 
measurement was performed using BMG Labtech FLUOstar Omega plate reader.  
 
Drug treatment  
WT MLEC cells were treated 1% with methyl β cyclodextrin (w/v) (sigma aldrich 
C4555) for 20 minutes and stimulated with 1000 U/ml IFNα at 37°C for 10 minutes. 
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Discussion  
5 Discussion and perspectives  
5.1 Caveolar Cav1 versus “free” Cav1 
My laboratory previously demonstrated that upon mechanical stress resulting in 
membrane tension increase, caveolae rapidly flatten out to “buffer” the membrane 
tension increase in order to conserve the plasma membrane integrity (Sinha et al., 
2011). However, the precise molecular aspect of the caveolar disassembly has 
remained unclear until now. In this study, super resolution imaging clearly shows that 
upon mechanical disassembly of caveolae, Cav1 diffusion drastically increases 
indicating the release of “free” i.e. non-caveolar Cav1 oligomers at the plasma 
membrane. We further demonstrate that upon caveolar mechanical disassembly, 
Cav1 interacts with JAK1 and thereby negatively regulates its catalytic activity. In the 
present work, based on the applied mechanical stress, cholesterol depletion, Cav1 
overexpression and cavin-1 knocked out cells, we hypothesized that the free Cav1 
released from the disassembling caveolae is the one that interacts with JAK1. 
However, caveolae may not totally disassemble and some Cav1 oligomers may 
remain within the flat Cav1-enriched nanodomain of the former curved caveolae (Hill 
et al., 2008; Tachikawa et al., 2017; Yang and Scarlata, 2017; Khater et al., 2018). 
One can hypothesize that among the many possible mechanisms that mediate CSD 
accessibility; caveolae flattening may be one possible mechanism to induce Cav1 
conformation changes and CSD exposure for protein-protein interaction (detailed 
below). Therefore, IFNAR2-JAK1 complexes would be recruited and immobilized into 
flat confined Cav1-enriched domains. To verify this hypothesis, we generated JAK1-
mEOS3.2 to assess the diffusion rate of JAK1 upon membrane tension increase. 
Confined JAK1 in Cav1-enriched plasma membrane domain would be a good 
indicator of JAK1 recruitment at the flat caveolae. On the contrary, high diffusion of 
JAK1 together with Cav1 or confinement outside the caveolae upon membrane 
tension increase would favor the hypothesis of JAK1 interacting with “free” Cav1.  
      
 
 
Figure 26. Proposed topology of free Cav1 
At steady state Cav1 oligomers within the caveolar coat: Cav1 topology as proposed by Kirkham and 
colleagues (Kirkham et al., 2008). The CSD is not available for protein interaction (left). Upon 
caveolae flattening, Cav1 oligomers are released in the plasma membrane and encounter different 
membrane curvatures, lipid environment; lipid X or Y and/or might undergo posttranslational 
modifications such Tyr14 and Ser80 phosphorylation leading to Cav1 conformational changes that 
trigger CSD exposure allowing interactions with Cav1 partners (right). 
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5.2 CSD dependent regulation of JAK1  
Cav1 CSD mutants, CSD mimicking peptides and in vitro kinase assay clearly 
demonstrate the prominent and direct role of the CSD in Cav1-JAK1 interaction and 
the resulting inhibitory effect by Cav1. These new results strengthen the line of 
evidences that support a regulatory mechanism exerted by Cav1 on some signaling 
molecules. As discussed in 2.3.4.4, the regulation of signal transduction through 
CSD-mediated direct Cav1 interaction with signaling proteins is controverted. The 
keystone of this controversy relies on the Cav1 predicted ternary structure. Indeed, 
the CSD has a predicted structure of α-helix that is amphipathic and therefore, it is 
partially embedded in the inner lipid layer of the plasma membrane. Thus, this 
configuration would not favor the CSD interaction with the Cav1 putative binding 
partners (Collins et al., 2012; Ariotti et al., 2015). Interestingly, the CSD should not be 
considered static within the Cav1 structure. Indeed recent computational analysis of 
Cav1 structure within the lipid bilayer, revealed that the CSD possesses a dynamic 
secondary structure either partially unstructured or fully helical (Liu et al., 2016). 
Hence, one could hypothesize that this dynamic secondary structure may control the 
relative position of the CSD to the plasma membrane. Whether parameters such as 
Cav1 lipid environment influence the structural dynamics of the CSD should be 
investigated. Indeed the CSD inserted in POPC/Cholesterol adopts a mixture of β-
stranded and α-helical structure while the CSD inserted in DPC micelles adopts a 
fully helical structure (Le Lan et al., 2006; Hoop et al., 2012). Therefore, the 
conformation of Cav1 within a flat caveolae or non-caveolar Cav1 oligomers diffusing 
in the lipid bilayer, thus experiencing different membrane curvatures and lipid 
environments, may differ from Cav1 within fully a budded caveola, where the CSD is 
poorly accessible (Fig. 26). Alternative mechanisms have also been proposed to 
mediate CSD exposure. Indeed, N-ter phosphorylation on Tyr14 and/or Ser80 may 
push away the whole N-ter end including the CSD from the plasma membrane 
because of charge repulsion within the inner leaflet of the lipid bilayer (Shajahan et 
al., 2012) (Fig. 26). This mechanism may also mediate Cav1-JAK1 interaction 
reversibility, which is a key parameter in cell signaling. However, variations of Cav1 
Tyr14 phosphorylation upon membrane tension increase could not be detected, 
suggesting that this Cav1 post-translational modification is not involved in this 
mechanism (Fig. 27). Nevertheless, our laboratory observed a similar control of 
      
 
 
Figure 27. Cav1 tyrosine phosphorylation upon hypo osmotic shock 
Western blot analysis of tyrosine phosphorylation of immunoprecipitated endogenous Cav1 in iso-
osmotic, hypo-osmotic and successive hypo-osmotic shock and iso-osmotic condition (Recovery) from 
WT MLEC cells lysate. 
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IL6/STAT3 pathway in muscle cells only expressing Cav3 (see annex 3). Considering 
that Cav3 cannot be phosphorylated on Tyr14, it is unlikely that Tyr14 
phosphorylation is involved in this mechanism. However, variations of Cav1 Ser80 
phosphorylation upon mechanical stress still need to be investigated. For example, 
immunoprecipitation of non-phosphorylable or phosphomimetic mutants of Cav1 
should be performed to assess whether S80 phosphorylation is involved in Cav1-
JAK1 interaction. 
 
On another hand, in the context of Cav1-JAK1 interaction triggering and 
reversibility, JAK1 post-translational modifications such as tyrosine S-nitrosylation 
should be investigated. Indeed, it has been reported that another member of the JAK 
family; JAK2 can be S-nitrosylated on two tyrosine residues. Nitrosylated JAK2 
interacts with Cav1 and eNOS (Elsasser et al., 2007). JAK2 nitrosylation is 
performed through NO generation by proteins such as eNOS. Interstingly, Cav1 
regulates eNOS activity. Similarly a regulatory mechanism of RhoA activation via S-
nitrosylation of its GTPase activating protein (GAP) mediated by the Cav1-regulated 
eNOS-dependent NO production has been described (Rizwan Siddiqui et al., 2011). 
It would be therefore important to assess JAK1 nitrosylation upon mechanical stress 
by western blot using anti-nitrosylated tyrosine antibodies. Moreover, the effect of 
mechanical stress on NO production using NO probes and whether NO treatment 
triggers or prevents Cav1-JAK1 interaction would be interesting questions to 
address. 
 
Finally, another aspect of the regulatory mechanism via the CSD-mediated 
Cav1 inhibition of signaling proteins largely contributed to the rise of the controversy. 
Indeed, the CBM, a putative CSD interaction motif has been early identified by phage 
screening (Couet et al., 1997a). However, structural analysis of Cav1 binding 
partners, revealed that most of them carry a CBM in their core thereby poorly 
available for interaction with the CSD (Collins et al., 2012). In addition, this motif 
encompasses three highly degenerated motifs. Hence, CBM containing proteins are 
largely found through the proteome of different organisms, even those devoid of 
caveolins. Therefore, the presence of CBMs in proteins primary structure might not 
be predictive of Cav1 interaction. Nevertheless, a CBM is found in most of Cav1 
binding partners and although being non-predictive, some of them may still mediate 
      
 
 
Figure 28: CBM localization on JAK1 structure 
(a) localization  of the putative CBMs in JAK1 primary structure. (b) CBM1 (highlighted lateral chains, 
red arrow) localization in the tridimensional structure of the FERM domain of JAK1 (PDB 5IXI). (c) 
CBM2 (highlighted lateral chains, red arrow) localization in JAK1 pseudokinase tridimensional 
structure (PDB 4L00). Pseudokinase and kinase domains are structurally identical. The putative CBM3 
has a localization similar to the CBM2 but within the kinase domain. 
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the interaction with Cav1. All JAKs carry several CBMs. JAK1 has three putative 
CBMs: a first one is located in the JH6 region corresponding to the FERM domain 
(157YLFAQGQY164), another in the JH2 pseudokinase domain (777WSFGTTLW784) 
and a last one in the JH1 kinase domain (1065WSFGVTLH1072) (Fig. 28a). JAK1 CBMs 
are located on three α-helices that are buried inside JAK1 ternary structure. Hence, 
all motifs seem to be poorly accessible (Fig. 28b, c). However, to address whether 
one of these CBMs are required for JAK1 interaction with Cav1, we generated three 
JAK1 mutants with alanine replacement of each CBM (JAK1-CBM1, JAK1-CBM2 and 
JAK1-CBM3). Preliminary pulldown experiments of JAK1-CBM1 in HeLa cells 
overexpressing Cav1 (to generate an excess of non-caveolar Cav1) revealed that 
mutations in the CBM located in the FERM domain did not affect its ability to interact 
with Cav1. These data suggest therefore that the first CBM is not required for Cav1-
JAK1 interaction (Fig. 29). In addition, in vitro kinase assay has been performed 
using recombinant JAK1 containing only the pseudokinase-kinase tandem, therefore 
it only contains the CBMs located in the pseudokinase and kinase domain (CBM2 
and CBM3). These two domains are sufficient to undergo inhibition of catalytic 
activity by the CSD mimicking peptide. Experiments to definitely establish the role of 
CBM2 and CBM3 in Cav1-JAK1 interaction are currently ongoing.  
 
 
To conclude, the precise molecular mechanism underlying the CSD-mediated 
inhibition of JAK1 remains unknown. However, our results emphasize the prominent 
role of Cav1 F92 and V94, since their Ala replacement relieves Cav1 inhibitory effect. 
Moreover the pulldown experiment clearly demonstrates that F92 and V94 are 
required for Cav1-JAK1 interaction. Whether F92 or V94 lateral chain sit  in an 
important domain of JAK1 such as the regulation model established for eNOS is 
unknown. However, Cav1 interaction with JAK1 may also results in the stabilization 
of JAK1 inactive conformation, by preventing JH1 (pseudokinase domain) extension. 
Structural studies of the Cav1-JAK1 complex or at least, CSD-JAK1 would bring 
deeper insight on the molecular mechanism mediating the resulting inhibition. 
Interestingly, it has been suggested that caveolins may have a SOCS role in JAK-
STAT signaling. Indeed sequence alignment revealed that the CSD shares a 
common motif with the KIR domain of SOCS1 and SOCS3 (Jasmin et al., 2006) (Fig. 
30).  Therefore, one could hypothesize that upon Cav1-JAK1 interaction the CSD 
      
 
Figure 29: CBM1-mutated JAK1 pulldown 
Immunoblot of JAK1-mCherry pulldown of HeLa cells expressing exogenous Cav1 and either WT-
JAK1 or CBM1-mutated JAK1 (JAK1-CBM1). 
 
 
 
 
 
 
Figure 30. Sequence alignment of SOCS1 and SOCS3 KIR domains with 
caveolins  
The Cav1 scaffolding domain shares primary sequence similarities with the SOCS-1 pseudosubstrate 
domain. The conserved domains are identified by the consensus sequence Φ xTFxxS/T(+) xxxY(+), 
where Φ is a hydrophobic or aromatic amino acid and (+) is a positively charged residue (from Jasmin 
et al., 2006). 
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would occlude the substrate binding site of JAK1, the same way SOCS inhibit JAK1 
(as detailed in 3.5.1) preventing thereby JAK1 catalytic activity. 
5.3 Signal specificity  
An intriguing aspect of this work is that caveolae disassembly induced by a 
mechanical stress results in the specific inhibition of IFN-α-induced STAT3 activation. 
Surprisingly STAT1 activation by IFN-α is not affected by the caveolar mechanics. 
The molecular mechanism driving this specificity still needs to be addressed. Indeed, 
IFN-α stimulation normally induces both STAT1 and STAT3 activation. IFN-α binding 
to IFNAR leads to JAK1 and TYK2 cross-activation, which result in both STAT1 and 
STAT3 activation.  A logical hypothesis would consist in the selective targeting of 
JAK1 by Cav1 that would result in STAT3 inhibition. In the meantime, TYK2 would 
remain activated and would mediate STAT1 activation. Nevertheless, there are no 
evidences of such JAK specificity for STAT activation. In addition, JAKs are activated 
by mutual transphophorylation, therefore, there is a reciprocal interdependency 
between JAK1 and TYK2. Thus, according to the consensus mechanism of JAKs 
activation, the targeting of one of the two kinases would inevitably prevents the 
activation of the other one. However, it has been reported that TYK2 plays a 
restricted role in IFN-α signaling. Moreover lack of TYK2 does not prevent JAK1 
activation (Shimoda et al., 2000).  
 
 
On another hand, caveolar mechanotransduction is not restricted to IFN-α 
induced JAK-STAT signal transduction. This process may constitute a general 
regulatory mechanism for JAK-STAT signaling, disregarding the receptors or the 
ligands. Indeed, basal STAT3 activation in Cav1-/- MLEC cells and in vitro kinase 
assay revealed that this mechanism directly targets JAK1 regardless of upstream 
signaling molecules. Hence, it is not unexpected that it can be extended to other 
cytokines and receptors that use JAK-STAT such as the IL6 pathway. My laboratory 
found that caveolae mechanics also control the IL6/STAT3 pathway through a similar 
Cav3 release in the context of muscle physiology (Dewulf et al., 2018 under revision 
see annex 3). It suggests that the muscle specific isoform of Cav3 that also carries a 
      
 
 
Figure 31. Specific inhibition of STAT3 by Cav1 in human breast cancer cells  
Immunoblot of kinetics of IFN-α-induced STAT3 and STAT1 activation in MCF10A cells upon siCTRL 
or siCav1 treatment (left). Immunoblot quatification (right). 
 
  
pSTAT3
STAT3
α-Tubulin
Cav1
siC
TR
L
siC
TR
L
siC
TR
L
siC
av
1
siC
av
1
siC
av
1
IFN-α (min) 0 5 20
0.0
0.5
1.0
1.5
pS
TA
T3
/S
TA
T3
 (A
.U
.)
2.0
0 5 20
siCTRL
siCav1
siC
TR
L
siC
TR
L
siC
TR
L
siC
av
1
siC
av
1
siC
av
1
0 5 20
pSTAT1
STAT1
α-Tubulin
Cav1
0.0
0.5
1.0
1.5
pS
TA
T1
/S
TA
T1
 (A
.U
.)
0 5 20
siCTRL
siCav1
IFN-α (min)
      
 98 
CSD, may compensate the absence of Cav1 and play a similar signaling role in 
muscular tissues.  
5.4 Caveolae mechanotransduction: role in tumor progression  
Our results clearly demonstrate that caveolae mechanics exert a control over 
JAK-STAT signaling. As discussed above, only STAT3 activation is affected by 
caveolae mechanics. As described in the introduction, STAT3 has oncogenic 
activities while STAT1 has, in most of situations, tumor suppressor activities. 
Therefore, mechanical forces encountered by cancer cells during tumor progression 
may regulate signal interpretation and modulate STAT3/STAT1 activation balance 
through caveolae mechanics. This mechanism may partially explain the ambivalent 
role of Cav1 during tumor progression. Moreover, any perturbations affecting the 
integrity of caveolae mechanotransduction may result in STAT3/STAT1 activation 
imbalance. For example, Cav1 knock down in breast cancer cells also induces 
STAT3 activation in response to IFN-α most likely because of the lack of negative 
regulation of JAK1 by non-caveolar Cav1 (Fig. 31). In addition, tumor cells submitted 
to hypo-osmotic shock exhibit this characteristic pSTAT3 inhibition (Fig. 32). Non-
aggressive tumor cells HS578T grown as multicellular spheroids in agarose and 
submitted to tumor-like compressive forces by compressing them with an 
hyperosmotic solution also exhibit the characteristic decrease of IFN-α-induced 
STAT3 activation (Fig. 33). It would be tempting to propose that the caveolae-
dependent mechanical control of JAK-STAT constitutes a physiological regulatory 
mechanism of cell proliferation in response mechanical strains generated by situation 
such as space limitation found in the tumor mass. Hence, impaired caveolar 
mechano-response would result in cell growth and other caveolae-related processes. 
 
To conclude, considering the wide breadth of Cav1 binding partners, it is likely 
that caveolae mechanotransduction plays a key role during tumor progression by 
tuning several major cell signaling pathways. Moreover the release of non-caveolar 
Cav1 may modulate signaling cascades through other mechanism than CSD 
interaction. For example, non-caveolar Cav1 mechanically released from caveolae 
disassembly can regulate the lipid composition of receptors microenvironment, which 
      
 
 
Figure 32: IFN-α-induced STAT3 activation of breast cancer cells upon hypo-
osmotic shock  
Immunoblot of IFNα-induced STAT3 phosphorylation in breast cancer cell lines (MCF10A, HS578T 
and MDA-MB-231) upon either steady-state, hypo-osmotic shock or recovery. 
 
 
Figure 33: IFN-α-induced STAT3 activation of breast cancer cell under 
compression 
Immunoblot of IFNα-induced STAT3 phosphorylation of encapsulated breast tumor cells HS578T.  
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is a key parameter for their activation (Rao and Mayor, 2014; Blouin et al., 2016). 
Indeed, high throughput screening revealed that other signaling pathways seem to be 
modulated by caveolae mechanics. Therefore, defective caveolae such as those 
found in many tumor cell lines like prostate cancer cells PC3 that exhibit constitutive 
non-caveolar Cav1 due to a lack of cavin-1 expression may lead to impaired 
mechanoresponse and signaling. Nevertheless, the physiological role of such 
mechanisms remains elusive. Williams and colleagues, recently revealed that proper 
JAK-STAT signal suppression through SOCS3 requires bona fide caveolae and 
plasma membrane associated cavin-1 (Williams et al., 2018). Hence one could 
hypothesize that mechanical disassembly of caveolae and the destabilization of cavin 
complexes, would result in impaired SOCS3 mediated JAK-STAT signal termination. 
Therefore, under mechanical stress, the release of free Cav1 might lock the JAK-
STAT signaling pathway to avoid aberrant JAK-STAT signaling. On another hand, as 
presented in the introduction, wide breadths of biological processes are governed by 
the interplay between cell mechanics and the physical properties of the 
microenvironment. Mechanoreciprocity and establishment of mechanically regulated 
cell processes are achieved thanks to conserved tools such as mechanotransducers. 
Considering the multitude of Cav1 binding partners, caveolae mechanotransduction 
may therefore constitute a general mechanism. It may tunes the overall cell signaling 
upon mechanical stress induced by external physiological or pathological strains 
such as those experienced by cells within the tumor mass. Alternatively, it could 
locally regulate signaling events depending on local plasma membrane tension 
variations generated by membrane deformation during processes such as cell 
migration through the ECM. 
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Materials and methods of the discussion  
 
 
Cell culture 
All cells were grown at 37°C under 5% of CO2. HS578T, MDA-MB-231 cells were 
grown in DMEM GlutaMAX (Gibco, Life Technologies) supplemented with 10% FCS 
(Gibco, Life Technologies), 5 mM pyruvate (Gibco, Life Technologies) and 1% 
penicillin-streptomycin (Gibco, Life Technologies). MCF10A cells were grown in 
DMEM GlutaMAX (Gibco, Life Technologies) supplemented with 5% (v/v) horse 
serum; 20 ng/mL EGF; 100 ng/mL CTx; 0.01mg/mL human insulin; 500 ng/mL 
hydrochortisone. WT MLEC cells were cultured in Enothelial Balal Medium (EBM2) 
from Lonza supplemented with 15% Hyclone FCS, 4mM glutamine, 5mM sodium 
pyruvate, 0,01 % penicillin streptomycin (v/v), 0.04% hydrocortisone (v/v), 0.4% 
hEGF-B (v/v), 0.1% VEGF (v/v), 0.1% R3-IGF-1 (v/v), 0.1% ascorbic acid (v/v), 0.1% 
hEGF (v/v), 0.1% GA-1000 (v/v), 0.1% heparin (v/v) (EGM2 singlequote, Lonza). 
 
Antibodies and reagents.  
Mouse anti-αTubulin (Sigma-Aldrich, clone B512, T5168, 1/1000 for WB); mouse 
anti-chlatrin heavy chain (BD Transduction, 610500, 1/5000 for WB) rabbit anti-
caveolin-1 (Cell Signaling 3238S, 1/1000 for WB); mouse anti-caveolin-1 (BD 
Transduction, 610407, 10µg/condition for IP); mouse anti-STAT3 (Cell signaling, 
clone 124H6, 9139, 1/1000 for WB); rabbit anti-pSTAT3 (Cell signaling, clone D3A7 
9145, 1/1000 for WB); rabbit anti-STAT1 (Cell signaling, 9172, 1/1000 for WB); 
mouse anti-pSTAT1 (Cell Signaling, 9167, 1/1000 for WB); rabbit anti-JAK1 (Cell 
Signaling, 3332S, 1/1000 for WB); rabbit anti-phosphoTyrosine (Santa Cruz, sc-
7020, 1/1000 for WB). 
 
Immunoblotting.  
Cells were lysed in sample buffer (62.5 mM Tris/HCl ph 6.0, 2% SDS (v/v), 10% 
glycerol (v/v), 40 mM dithiothreitol and 0.03% phenol red (w/v)). Lysates were 
analyzed by SDS-PAGE and Western blot analysis and immunoblotted with the 
indicated primary antibodies and horseradish peroxydase-conjugated secondary 
antibodies. Chemiluminescence signal was revealed using PierceTM ECL Western 
Blotting Substrate, SuperSignal West Dura Extended Duration Substrate or 
SuperSignal West Femto Substrate (Thermo Scientific Life Technologies). 
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Acquisitions were performed with the ChemiDoc MP Imaging System (BioRad). 
Samples for the detection of phospho and non-phospho proteins were loaded on two 
different gels. The ratio of the signal detection for targeted protein/loading control 
was determined for each membrane. The overall ratio of (phosphoprotein/loading 
control)/(protein/loading control) was determined.  
 
Compression  
Multicellular spheroids are formed in 48-well plates using a classical agarose cushion 
protocol. When the MCS is formed, Dextran (molecular mass ¼ 100 kDa; Sigma-
Aldrich, St. Louis, MO) is added to the culture medium to exert mechanical stress, as 
previously described in Montel et al., 2011 at a concentration of 55 g/L to exert 5 
kPa, and 80 g/L to exert 10 kPa. 
 
RNA silencing 
Cav1 knock down in MCF10A cells was achieved using smart pool siRNA from 
Eurogentec: 5’-GCAAAUACGUAGACUCGGA55-3’; 5’-
GCAGUUGUACCAUGCAUUA55-3’; 5’-CUAAACACCUCAACGAUGA55-3’. Cells 
were transfected using OzBiosciences  SilenceMag MagnetofectionTM according to 
manufcturer’s protocol. Control siRNA (QIAGEN, 1022076) was used at the same 
concentration and served as reference point. 
 
Co-immunoprecipitations.  
Cells were lysed in 1% NP-40 in TNE (10 mM Tris/HCl pH 7.5, 150 mM NaCl, 0.5 
mM EDTA) with protease inhibitors cocktail (Roche) for 30 min at 4°C. Cleared 
lysates (16,000g, 10 min, 4°C) were incubated overnight at 4°C under rotation with 1 
µg/ml of the indicated antibody followed by incubation for 1 hour with 25 µl of protein 
A/G magnetic beads (Thermo Scientific) in the case of endogenous proteins. In the 
case of tagged proteins, 25 µl GFP-Trap or RFP-Trap beads (Chromotek) were used. 
After 3 washes in TNE, immunoprecipitated beads were eluted following the 
manufacturers’ instructions. 
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Osmotic shock 
For osmotic shock, cells were seeded 24h before experiment, then complete media 
was replaced by 30 mOsm media (10% media and 90% H2O), cells were 
immediately lysed or hypo-osmmotic media was replaced by normal iso-osmotic 
media (recovery) before lysis. 
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The caveolae dress code: structure and signaling
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Ste´phane Vassilopoulos2 and Ce´dric M Blouin1
Abstract
Over the past decade, interest in caveolae biology has peaked.
These small bulb-shaped plasma membrane invaginations of
50–80 nm diameter present in most cell types have been
upgraded from simple membrane structures to a more complex
bona fide organelle. However, although caveolae are involved
in several essential cellular functions and pathologies, the
underlying molecular mechanisms remain poorly defined.
Following the identification of caveolins and cavins as the main
caveolae constituents, recent studies have brought new insight
into their structural organization as a coat. In this review, we
discuss how these new data on caveolae can be integrated in
the context of their role in signaling and pathophysiology.
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The caveola robe
Caveolins
It took almost 40 years after caveolae were first visualized
by electron microscopy (EM) in the 1950s to identify the
caveolar protein components [1,2]. Caveolin-1 (Cav1) was
identified in 1992 [3,4] followed by the two others homo-
logues caveolin-2 (Cav2) [5] and the muscle specific
caveolin-3 (Cav3) [6,7]. The three caveolin isoforms
contain a family signature constituted by a single stretch
of eight amino acids 68FEDVIAEP75 localized in the N-
terminal cytosolic oligomerization domain (Figure 1a) [7].
Cavins
Although Cav1 and Cav3 were initially thought to be
necessary and sufficient for caveolae morphogenesis [8],
several studies in the past decade have uncovered addi-
tional constituents. Thus, the identification of the cavin
protein family brought precious insights into caveolae
ultrastructure and assembly opening new avenues for
better understanding the cellular functions of this intrigu-
ing organelle. The assembly of a bona fide caveola requires
both Cav1 and cavin-1 (also called PTRF) [9,10]. In
mammals, cavin-2 (SDPR), cavin-3 (SRBC) and the mus-
cle-restricted cavin-4 (MURC) complete this four-mem-
ber family, which has emerged as essential to caveolae
formation and functions (Figure 1b) [11–13].
Purified cavins when added on phosphatidylserine (PS)
enriched liposomes or when overexpressed in mammalian
cells induce membrane tubulation, leading to the
assumption that cavins may play a role in the initiation
of the caveola invagination [11,14,15!!]. Accordingly,
cavin-1 depletion results in loss of caveolae while caveo-
lae are not morphologically detectable in the prostate
cancer PC3 cell line and in the nematode Caenorhabditis
elegans, which both express Cav1 but not cavin-1 [9,16].
Nevertheless, it was reported that caveolae could be
assembled in Escherichia coli independently from cavin-
1 [17].
Accessory proteins
Several non-essential proteins have also been involved in
caveolae biogenesis. PACSIN-2, also called Syndapin2, is
the only F-BAR protein representative, proteins regulat-
ing membrane curvature, that has been involved in
caveolae morphology [18,19]. The dynamin-2 GTPase
and the dynamin-like ATPase EHD2 have been localized
at the neck of caveolae [20,21]. EHD2 has been shown to
stabilize caveolae by controlling their dynamics and asso-
ciation with the actin cytoskeleton [22]. Dynamin-2 how-
ever is not present in all caveolae and whether it plays a
role in caveolae scission similarly to its classical role in
clathrin-dependent endocytosis remains to be
established.
A tailored coat
Caveolins bind lipids and organize membrane
nanodomains
The assembly process is initiated by the export of caveo-
lin-enriched vesicles from the Golgi apparatus to the
plasma membrane [23]. Little is known about this first
step except for a critical role of lipids and particularly
cholesterol, which is essential for both caveolin oligomer-
ization at the Golgi apparatus and caveola invagination at
the plasma membrane [3]. Cav1 binds cholesterol with a
Available online at www.sciencedirect.com
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1:1 stoichiometry [24,25], probably through a cholesterol
recognition/interaction amino acid consensus (CRAC)
motif (94VTKYWFYR101) located in the vicinity of the
plasma membrane [26]. Caveolin oligomers trigger the
clustering of specific lipids thereby constructing special-
ized lipid nanodomains at the plasma membrane [27].
They include sphingolipids (sphingomyelin, GD3 and
GM1 gangliosides), phospholipids such as PS and phos-
phoinositides such as phosphatidylinositol (4,5)-bispho-
phate (PI(4,5)P2).
Cavins are recruited to caveolin-induced lipid
nanodomains
Interestingly, PS and PI(4,5)P2 were recently involved in
caveola formation through electrostatic interactions
between the negatively charged headgroups and two
specific domains of cavins (HR1 & HR2)
[9,12,14,15!!,28]. Thus, cytosolic cavins form higher-
order heterotrimers consisting of either three cavin-1 or
two cavin-1 with one cavin-2 or one cavin-3, through their
HR1/cc1 coiled-coil domain, that further polymerize
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Putative model of caveolar coat assembly and organization.
(a) Schematic model of Cav1 topology. Cav1 is inserted into the plasma membrane through the caveolin scaffolding domain (CSD; red), an
amphipathic helix part of the oligomerization domain (diffuse red), and through a second amphipathic helix, the intra-membrane domain (orange).
Based on Cav3 ternary structure [108], Cav1 monomers may assemble as a disk-shaped oligomer with the C-terminal part oriented toward the
center. (b) Cavin monomers exhibit two helical rich domains, HR1 and HR2, that may form coil-coiled structures [14]. Cavins, through interaction
with the HR1 domain, can form trimers consisting of either three cavin-1 or two cavin-1 associated with one cavin-2 or one cavin-3 protein. The
cavin-1 isoform could be responsible for a more complex assembly through the coiled-coil domain 2 (cc2) sequence in the HR2 domain [15]. (c)
At the plasma membrane, Cav1 oligomers cluster specific lipids such as cholesterol, PI(4,5)P2 and phosphatidyl serine involved in the recruitment
of cavin trimers. This is followed by caveola invagination, a process not completely understood. It has been recently suggested that the overall
architecture of the caveolar coat made of caveolins and cavins would best fit with a polyhedron structure [15,30]. In this model, Cav1 oligomers
position on each pentagonal face and cavin complexes align with the vertices and cover the Cav1 oligomers.
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upon association with assembling caveolae (Figure 1c)
[14,21,29].
Flat versus curved: the interplay between caveolins and
cavins
At the plasma membrane cavins and caveolins invariably
form characteristic stripes surrounded by a proteinaceous
crescent made of globular proteins whose identity
remains elusive (Figure 2). To date, it is still unclear
whether caveolae assemble as flat structures that will then
bud inward and produce the typical stable cup-shaped
caveolae or if pre-formed caveolae emanating from intra-
cellular compartments most likely the trans-Golgi net-
work fuse with the plasma membrane.
Recent EM and X-Ray crystallography studies revealed
that the characteristic striated coat that is observed on the
outer cytoplasmic side of caveolae may be organized by
cavins rather than caveolin oligomers alone as originally
proposed [14,15!!,21,29,30!!]. These striations are
observable on deep etch electron micrographs of caveolae
presenting various degrees of invagination from flat to
fully budded (Figure 2).
It has been estimated that 150–200 Cav1 monomers
associate with 50–60 cavins ("15–20 trimers) to form a
caveola [15!!,21,29,31]. The overall architecture of caveo-
lae was recently proposed to fit with a polyhedron most
likely a dodecahedron structure formed by cavin com-
plexes aligned with the vertices but also covering the
caveolin oligomers positioned on each pentagonal face
(Figure 1c) [15!!,30!!]. It is however difficult to visualize a
dodecahedron organization when observing caveolae en
face on deep-etch electron micrographs, and further
efforts will be needed to validate this model with proteins
which have been purified from more physiological sys-
tems than insect cells and bacteria.
Signaling regulation through direct interaction
with Cav1
Over the years, caveolae have been associated with vari-
ous physiological and pathological contexts in relation
with their cellular functions in lipid homeostasis, signal
transduction, endocytosis and transcytosis. If some debate
still exists [32], early consensus suggested that caveolae
could regulate cellular signaling by organizing specific
signaling platforms at the plasma membrane [33].
Thus, a broad variety of growth factor and signaling
receptors, kinases, enzymes and other signaling mole-
cules have been localized into caveolae and/or co-immu-
noprecipitated with Cav1 including but not limited to
eNOS [34], the insulin [35], EGF [36], TGF-b [37!] and
P2X7 [38] receptors, Src tyrosine kinase [39], H-Ras and
K-Ras [40], the heme oxygenase [41]. Caveolae have also
been associated with bona fide mechanosignaling path-
ways including MAP kinase, Akt, Src kinases, Rho and
Rac small GTPases [42].
The central role of the caveolin scaffolding domain
A first study identified a domain responsible for the direct
regulation of heterotrimeric G proteins by Cav1 [43]. This
interaction was further confirmed for H-Ras, the Src and
Fyn tyrosine kinases, and the endothelial nitric oxide
synthase eNOS [35,40,41].
This specific feature of Cav1 resides in a particular
a-helical domain (residues 82–101) called the caveolin
scaffolding domain (CSD) so named because it is also
required for Cav1 oligomerization. The CSD is localized
on the N-terminal part but its relative position to the
plasma membrane remains unclear. The CSD would
exert an inhibitory role on signaling effectors by binding
directly to a putative corresponding caveolin binding
motif (CBM) identified in several of these effectors
[35,40,41,44,49]. Indeed, biochemical studies on eNOS
revealed the critical role of the CSD phenylalanine resi-
due 92, which, by extending its lateral chain, allows to
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Visualization of the caveolar coat at the plasma membrane of
myotubes.
Survey view of the cytoplasmic surface of an unroofed mouse
myotube presenting caveolae at the plasma membrane. Different
types of caveolae structures are apparent, ranging from flat (1),
circular (2), to fully budded (3). Scale bar: 500 nm. Scale bar in insets:
50 nm.
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reach the hydrophobic pocket of eNOS to inhibit its
catalytic activity [44,45]. A similar example was provided
by the heme oxygenase 1 whose activity is inhibited
through direct binding between its CBM domain and
the CSD [41]. Furthermore, a small CSD-mimicking
peptide inhibits eNOS activity whereas the correspond-
ing mutated peptide increases eNOS activity most likely
by competing with endogenous Cav1, which suggests a
direct Cav1-CSD mediated inhibitory effect [46].
Controversy on CSD accessibility
However, new studies have recently undermined the
model of signaling regulation through direct CBM/CSD
interaction. The CBM motif was found to be poorly
discriminative as it is also found in species such as
Saccharomyces cerevisiae that do not express caveolins.
No particular enrichment in proteins with the CBM
sequence was found in the Cav1 interactome and the
structural analysis of different CBM domains revealed
that this domain was likely to be buried inside the
proteins and therefore not readily available for interacting
with the CSD [47,48]. Likewise, the CSD would also be
an amphipathic helix and thus partially embedded inside
the plasma membrane hence not accessible [49].
Alternative mechanisms could also be considered. Thus, a
new study proposed that the CSD is a dynamic structure
that can be either fully helical or partly unstructured,
which may change its accessibility [50!]. Furthermore,
the conformation of Cav1 could vary with the oligomeri-
zation state and the organization of the caveola compo-
nents (cavin isoforms or lipids). In this context, mechani-
cal stress by promoting the release of Cav1 from
disassembled caveolae [51] could not only control the
ratio of caveolar vs. free Cav1 but also the accessibility to
its CSD.
Yet the mechanisms controlling the reversibility of these
interactions, a key parameter in signaling, remain to be
explored. In this context, the post-translational modifica-
tions of Cav1 may be particularly relevant. Phosphoryla-
tion on Cav1 Ser 80 would result in a more versatile
topology exposing the CSD because of charge repulsion
between the inner leaflet of the plasma membrane and
the phosphorylated residue [52]. A similar mechanism
was proposed for Cav1 Tyr 14 phosphorylation that would
form a stable structure facilitating binding to the CSD
[53]. Cav1 Tyr 14 phosphorylation was also shown to
prevent the direct binding of Cav1 on Egr1 [54]. Whether
Cav1/Egr1 interaction occurs through the CSD is how-
ever unknown.
Indirect regulation of signaling by caveolae
Through caveolae
In addition to the direct inhibitory effect of Cav1 on
signaling effectors, caveolae can also indirectly modulate
intracellular signaling. Caveolae interact with the actin
cytoskeleton and contribute to lipid sorting and delivery
to the plasma membrane through their enrichment in
glycosphingolipids and cholesterol [55]. Caveolae can
thus modulate the nanoscale plasma membrane organiza-
tion, a key parameter in transmembrane receptor activa-
tion [56]. Once again this process could also be actively
controlled by caveolae dynamics in response to mechani-
cal strains [51,57]. In this regard, stretch-induced caveolae
disassembly led to the redistribution of Cav1 and sphin-
golipids at the plasma membrane together with c-Src
activation [58]. Furthermore, Cav1 depletion led to per-
turbations in Ras spatial nano-organization and signaling
through changes in lipid composition and PS distribution
[59!]. In agreement with the localization of calcium
pumps in caveolae [60], the mechanical disassembly of
caveolae led to reduced Ca2+ responses through changes
in Gaq/Cav1 association [58,61]. Finally, as for clathrin-
mediated endocytosis, caveolae endocytosis, while lim-
ited under resting conditions, might also contribute to the
endosomal control of signaling by delivering activated
receptors to this compartment [62].
Through Cav2
The role of Cav2, which is not required for caveolae
formation, remains enigmatic. Cav2 expression is
required for activating the estrogen receptor a by 17b-
oestradiol [63]. The insulin signaling pathway can be
regulated by Cav2 fatty acylation and phosphorylation,
two successive post-translational modifications that pre-
vent the interaction of the SOCS3 phosphatase with the
insulin receptor allowing the activation of IRS-1 (Insulin
Receptor Substrate-1) and the nuclear translocation of
activated STAT3 [64–66]. Cav2 was allegedly reported to
mediate signaling from the plasma membrane to the
nucleus, as phospho-ERK nuclear translocation induced
by insulin relied on Cav2 154SSV156 C-terminal sequence
[67].
Through cavins
Finally, the recently identified cavins may also contribute
to caveolae signaling. Cavin-1 being essential to caveolae
assembly, it controls the number of functional caveolae
and thereby the localization of activated receptors in
these structures [68,69]. Cavin-3 mediates ERK activa-
tion by anchoring caveolae to the plasma membrane via
myosin-1c [70] and regulates their dynamics [71!]. Like-
wise CAVIN-1/-2/-3 KO mice display a certain degree of
heterogeneity among endothelial caveolae depending on
tissues and cavin-2 expression [72].
Caveolinopathies
Because of the multiple functions of caveolae and their
impact on signaling, it is not unexpected that several
pathologies have been associated with caveolae dysfunc-
tion. With the notable exception of neurons and lympho-
cytes, caveolae are ubiquitously found in most cells and
are particularly enriched in adipocytes, endothelial and
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muscle cells. Accordingly, mutations or deregulation of
caveolae components expression have been associated
with lipodystrophy, vascular dysfunction, musculopathies
[73] or cancer [74]. It is certainly no coincidence that, all
chronically experience mechanical forces in their envi-
ronment [1,51,75,76]. Whether these diseases can be
related to defects in caveolae mechanosensing and
mechanotransduction remains however to be tested.
Lipodystrophy
In mice, Cav1 or cavin-1 deficiency leads to a similar
lipodystrophic phenotype consisting in important loss of
fat mass associated with hypertriglyceridemia [10,77]. A
p.Glu38X stop codon CAV1 homozygous mutation result-
ing in caveolae loss was first identified in a patient
suffering from Berardinelli-Seip congenital lipodystrophy
[78] followed by the identification in lipodystophic
patients of a homozygous frame shift mutation
(c.696_697insC) in the PTRF gene coding for cavin-1
[79]. Other human mutations are found in Cav1 and
cavin-1, including heterozygous frame shift mutations
in the CAV1 gene (88delC and p.I134fsdelA-X137 in
Ref. [80], p.Phe160X in Ref. [81!]) and a single deletion
in PTRF gene (c.947delA in Ref. [82]), leading again to a
similar phenotype. These studies and others emphasize
the central role of caveolae in lipid metabolism. Lipody-
strophy could be ascribed to the loss of caveolae-depen-
dent lipid storage capacities by adipocytes as mice lacking
Cav1 or cavin-1 remain lean under high fat diet [77,80,83].
Cav1 is found at the plasma membrane of adipocytes and
at the surface of lipid droplets, the key lipid storage
organelle [84]. Thus, the absence of Cav1 will affect both
lipid uptake and associated caveolae-dependent signaling
events together with lipid droplet composition [85,86].
Lipid uptake results also in rapid swelling of adipocytes, a
mechanical stress that may require functional caveolae for
efficient membrane mechanoprotection.
Vascular dysfunction
In addition to lipodystrophy, mice lacking Cav1 and
cavin-1 experience vascular dysfunction [87–89]. Defects
in stimulated contractility, myogenic tone and endothe-
lium-dependent relaxation of arteries have been observed
in CAV1 KO mice [87] that could be related to the control
of NO and calcium signaling by Cav1 [90,91]. The
phenotype of CAV2 KO mice, which still have caveolae,
is surprisingly restricted to lung dysfunction through
increased lung endothelial cell proliferation [92]. Again
shear stress is intrinsically associated with endothelial
cells in vessels and caveolae are likely to be involved
in several shear-related functions [93].
Muscular dystrophies and cardiomyopathies
Mutations of muscle-specific Cav3, cavin-1 and cavin-4
have been associated with several forms of muscular
dystrophies and cardiomyopathies [79,94]. The observed
symptoms could be ascribed to several defects in muscle
physiology. A lack of functional caveolae could lead to
defective formation of the excitation contraction coupling
machinery and disorganization of the T-tubule network
[94,95]. It could also result in lipid homeostasis and
mechanosensitivity defects upon muscle contraction,
which in turn would directly affect the response of the
sarcolemmal membrane to mechanical strains. Moreover,
non-mutually exclusive caveolae-dependent defects have
also been reported for signaling pathways important for
muscle physiology such as those mediated by calcium,
Akt or MAP kinases [96–98], or in the expression or
localization of key proteins involved in membrane integ-
rity or repair such as dysferlin [99], and also in mechan-
oprotection [51,100!].
Cancer
Several thousand studies have addressed the role of Cav1
in this broad-spectrum pathology that is cancer. Yet this
role remains complex with studies describing Cav1 as a
tumor suppressor and others as an oncogene. The nature
of this role may vary with the type and stage of cancer [74]
and is probably related to a deregulation of signaling
pathways involved in tumor progression. The other com-
ponents of caveolae have been less studied. In breast and
prostate cancers [101,102], Cav2 expression was increased
whereas cavins, with lower expression, were more likely
to be tumor suppressors [68,103,104]. The role of caveo-
lae in cancer should be reconsidered through their
mechanosensing function as recent data have shed light
on the key role of mechanical forces in tumor progression
[105].
Other pathologies including pulmonary arterial hyperten-
sion [106], fibrosis [87] or atherosclerosis [107] have also
been associated with caveolae deficiency or deregulated
Cav1 expression. These pathologies can also be analyzed
in the context of mechanical dysfunction [32].
Conclusion and unresolved questions
Obviously more than 60 years after the first description of
caveolae, many fundamental questions remain unan-
swered. It is intellectually challenging to reconcile the
diversity of their cellular functions with a unique organ-
elle that is mostly stable at the plasma membrane. The
absence or deregulation of this ubiquitous organelle
results likewise in a rather specific set of pathologies. A
major unresolved question concerns the mechanisms by
which caveolae can control so many signaling circuits.
The recent structural description of the caveolar coat has
been a major step forward that will allow to better
understand how signaling effectors can associate with
the different components of this compact structure.
The resolution of the ternary structure of Cav1, as
recently achieved for Cav3 [108], will bring new answers
as well.
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One could also speculate that the different Cav1 and
cavin isoforms may assemble subpopulations of caveolae
differing in their composition/structure thereby allowing
customized signaling and local reactivity to mechanosen-
sing in different cells and tissues. At the ultrastructural
level, various degrees of caveolar invaginations can be
observed (Figure 2). Whether these structures co-exist
independently or are in dynamic exchange is unknown. It
will be important to analyze the distribution of caveolin
and cavin isoforms in these structures. Live cell imaging
of caveolae with higher spatiotemporal resolution
approaches such as super-resolution microscopy should
also provide a better understanding of their significance
[109!!].
The rapid exchange of cavins and Cav1 from caveolae in
response to mechanical constrains is potentially a new
mechanism by which caveolae could control signaling in a
highly dynamic and integrated manner
[51,55,57,100,110!,111,112]. In this context, it is interest-
ing that in most caveolae-associated pathologies, cells and
tissues are subjected to increasing mechanical stress that
may induce aberrant cellular mechanosignaling [105,113].
Thus, the miscellaneous functions of caveolae could be
reunified through a central mechanoprotective role rely-
ing on mechanosensing and mechanosignaling. Thanks to
the new conceptual and technological advances applied to
caveolae biology during the past decade, we start to
understand how this multifunctional organelle is capable
of integrating and translating an array of various external
stimuli into the regulation of distinct cellular functions.
The next challenge is to translate this knowledge in vivo
in order to design tailored therapeutics for treating caveo-
lae-associated diseases.
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Abstract  
Caveolin-3 is the major structural protein of caveolae in muscle cells. Mutations in 
the CAV3 gene cause different types of myopathies that are characterized by several 
defects altering membrane integrity and repair, expression of muscle proteins, and 
regulation of muscle signaling pathways. We show here that myotubes derived from 
patients bearing the CAV3 P28L and R26Q mutations present a dramatic decrease 
of caveolae at the plasma membrane, which results in an abnormal response to 
mechanical stress. Mutant myotubes were unable to buffer the increase in 
membrane tension induced by mechanical stress. This resulted in impaired 
regulation of the IL6/STAT3 signaling pathway leading to IL6/STAT3 constitutive 
hyperactivation and increased expression of muscle related genes. These defects 
were fully reversed by reassembling a pool of functional caveolae through 
expression of wild type caveolin-3. Our study reveals that under mechanical stress 
	 2	
the regulation of mechanoprotection by caveolae is directly coupled with the 
regulation of IL6/STAT3 signaling in muscle cells and that this regulation is absent in 
muscle cells from Cav3-associated dystrophic patients. 
 
 
Introduction 
Caveolae are cup-shaped plasma membrane invaginations that were first observed 
in the 50’s by Palade and Yamada on electron micrographs from vascular and gall 
bladder tissues1,2. Caveolae present a specific protein signature involving two main 
families of proteins, caveolins (caveolin-1, -2 and -3), and cavins (cavin-1, -2, -3 and 
-4)3,4,5,6,7,8,9. Caveolins and cavins are expressed in almost every cell type, except for 
caveolin-3 (Cav3) and cavin-4, whose expression is restricted to smooth and striated 
muscle cells9,10. Cav3, like Cav1 in non muscle cells, is necessary for the formation 
of caveolae at the plasma membrane of muscle cells11. 
Caveolae have long been associated with several important cellular functions 
including endocytosis, lipid metabolism and cell signaling, albeit with several 
persistent controversies12,13. More recently, a new function of caveolae was 
established as mechanosensors that play an essential role in cell mechanoprotection 
both in vitro and in vivo14,15,16,17,18. Mutations or abnormal expression of caveolae 
components have been associated with lipodystrophy, vascular dysfunction, cancer 
and muscle disorders13,19. The molecular mechanisms underlying caveolin-
associated diseases are still poorly understood. 
In this study, we explored the mechanical role of caveolae in human muscle 
cells and their possible deregulation in caveolinopathies, a family of muscle genetic 
disorders involving mutations in the CAV3 gene. These diseases affect both cardiac 
and skeletal muscle tissues, and share common characteristics including mild 
muscle weakness, high levels of serum creatine kinase, variations in muscle fiber 
size and an increased number of central nuclei20,21,22,23. We focused our 
investigations on the human CAV3 P28L mutation responsible for hyperCKemia24, 
and CAV3 R26Q, which is responsible for ripple muscle disease, hyperCKemia and 
limb-girdle disease 1C25. Studies with transgenic mice and zebrafish or cells 
overexpressing the Cav3 mutants have linked the P28L and R26Q CAV3 mutations 
to deregulations in distinct signaling pathways25,26, defects in membrane repair27,28 
and mechanoprotection of the muscle tissue16. Nevertheless, the role of the 
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caveolae mechanoresponse in human myotubes and its possible deregulation in 
dystrophy-associated Cav3 mutations have not yet been addressed.  
We show here that the Cav3 P28L and Cav3 R26Q myotubes are unable to 
assemble sufficient amounts of functional caveolae at the plasma membrane, 
leading to a loss of membrane tension buffering and membrane integrity under 
mechanical stress. The absence of functional caveolae in mutant myotubes 
uncouples the regulation of IL6/STAT3 signaling with mechanical stress, which 
results in the constitutive hyperactivation of the IL6/STAT3 signaling pathway and 
the upregulation of several muscle related genes. Finally, the expression of WT 
Cav3 in mutant myotubes was sufficient to restore a functional pool of caveolae and 
to rescue the coupling of caveolae mechanosensing with IL6/STAT3 signaling. 
These results establish caveolae as central connecting devices that adapt 
intracellular signaling to mechanical cues in muscle cells. The loss of this function in 
Cav3-associated mutations may be responsible for some of the clinical symptoms 
described in human dystrophic patients. 
 
Results 
 
Drastic decrease in the number of caveolae at the plasma membrane of Cav3 
mutant myotubes. 
To address the impact of Cav3 mutations in human muscle disorders, we analyzed 
wild type (WT), Cav3 P28L and Cav3 R26Q myotubes derived from immortalized 
myoblasts, which were isolated from healthy or Cav3 mutant patients and 
differentiated for four days. The state of myotube differentiation was validated by the 
expression level of the differentiation marker MF-20 (myosin heavy chain) in all three 
cell lines (Supplementary Fig. 1a). We first analyzed the presence and the 
ultrastructure of caveolae at the plasma membrane of myotubes by electron 
microscopy. In WT myotubes, we observed numerous invaginated structures 
corresponding to bona fide caveolae i.e. characteristic 60-100 nm cup-shaped 
invaginations that were connected to the plasma membrane, or to larger vacuoles of 
variable size deeper inside the cell known as rosettes, and that could still be 
connected to the plasma membrane. In contrast, a lot less caveolae could be 
detected at the plasma membrane of mutant myotubes and very few, if any, large 
vacuolar structures were observed (Fig. 1a and 1b). While we could still visualize a 
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few caveolae in mutant myotubes, they were often grouped in the same area and 
large areas of plasma membrane were completely devoid of caveolae (not shown). 
Interestingly, we could observe, mainly in mutant myotubes, the presence of 
aberrant oversized caveolae (Fig. 1a). 
This drastic decrease in caveolae number led us to investigate the localization 
of Cav3, which is required for caveolae assembly at the plasma membrane11. 
Immunoblot analysis showed a reduced expression of mutant Cav3 (P28L: - 50%; 
R26Q: - 51%) as compared to WT (Fig. 1c and 1d), with a shifted band for the R26Q 
mutant corresponding to the Cav3 mutant form, as reported previously25. Cav3 
immunostaining revealed that WT Cav3 was mainly associated with the plasma 
membrane of myotubes and partially localized in the Golgi complex, defined by 
GM130 staining (Fig. 1e). In contrast, Cav3 strongly accumulated in the Golgi 
complex as shown by the colocalization with GM130 in the Cav3 P28L and R26Q 
myotubes, in agreement with earlier studies25,26. This indicates that the strong 
reduction in the number of caveolae present at the plasma membrane of the Cav3 
mutant myotubes is a consequence of the abnormal retention of mutant Cav3 in the 
Golgi complex. 
It was still possible that differentiated myotubes express Cav1, which could 
potentially participate to the formation of caveolae independently from Cav3. We 
therefore analyzed Cav1 expression in myotubes after four days of differentiation 
and found that Cav1 was indeed expressed to the same level in all three cell lines 
(Supplementary Fig. 1b). Cav1 colocalized perfectly with Cav3 at the plasma 
membrane and to a lesser extent at the Golgi complex in WT myotubes, whereas it 
was mainly present in the Golgi complex in Cav3 P28L and R26Q myotubes 
(Supplementary Fig. 1c). It indicates that Cav1 is likely to form hetero-oligomers with 
Cav3, and that the Cav3 P28L and R26Q mutants have a dominant effect on Cav1 
localization.  
 
Cav3 P28L and R26Q myotubes present major defects in membrane tension 
buffering and mechanoprotection. 
To know whether the almost total absence of caveolae at the plasma membrane of 
mutant myotubes could induce defects in cell mechanoprotection, we first 
determined if the Cav3 P28L and R26Q myotubes could buffer the increase of 
membrane tension induced by mechanical stress. We thus applied a 45 mOsm 
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hypo-osmotic shock to myotubes aligned by micropatterning and we measured the 
apparent membrane tension before and after 5 min of hypo-osmotic shock using 
membrane nanotube pulling with optical tweezers as described14. As expected, 
hypo-osmotic shock led to myotube swelling in WT and Cav3 mutant cells. While the 
mutant myotubes showed no significant changes in membrane tension in resting 
condition (Fig. 2a), they showed a significant increase of membrane tension (P28L: 
63% ± 7%; R26Q: 94% ± 11%) under 45 mOsm hypo-osmotic shock compared to 
WT myotubes (38% ± 9%) (Fig. 2b). These results clearly show that the Cav3 P28L 
and R26Q mutant myotubes have lost the ability to buffer membrane tension 
variations induced by mechanical stress. 
We next tested whether the lack of membrane tension buffering could result in 
insufficient mechanoprotection and increased membrane fragility in mechanically 
challenged mutant myotubes. We designed an assay to quantify the percentage of 
cells that rupture their membrane under mechanical stress. To monitor membrane 
bursting, micropatterned myotubes were incubated with calcein-AM, a permeant 
green fluorescent dye that only becomes fluorescent inside the cell, and with the 
nucleus specific blue dye DAPI to specifically visualize differentiated myotubes by 
nuclei staining (Supplementary Fig. 2b). Live imaging was performed on myotubes 
subjected to a 30 mOsm hypo-osmotic shock for 10 min in the presence of propidium 
iodide (PI), a non-permeant red fluorescent dye that cannot enter cells with intact 
plasma membrane. The concomitant decrease of calcein-AM fluorescence and the 
appearance of PI fluorescence in the nucleus indicate a loss of membrane integrity 
(Fig. 2c). In comparison to WT myotubes, Cav3 mutant myotubes not only showed a 
higher percentage of burst cells after a 10 min hypo-osmotic shock (WT: 53% ± 3%; 
P28L: 78% ± 2%; R26Q: 89% ± 2%) but also a shorter time of resistance to 
membrane bursting (WT: 4.5 min ± 0.2, P28L: 2.1 min ± 0.1, R26Q: 2.7 min ± 0.2) 
(Fig. 2d). When we apply a milder hypo-osmotic shock (150 mOsm), for which no 
increase in membrane tension could be measured, the plasma membrane of all 
three cell lines remained intact after 10 min of shock (Supplementary Fig. 2b and 
2c). We repeated these experiments in WT myotubes depleted for Cav3 and 
measured a percentage of burst cells that was similar to mutant myotubes (siCtl: 
23% ± 1%, siCav3: 89% ± 1%) (Fig. 2e and 2f; Supplementary Fig. 2d). Likewise, 
Cav3 depleted myotubes showed a significantly faster time of bursting as compared 
to control myotubes (siCtl: 3.1 min ± 0.2, siCav3: 2.4 min ± 0.1) (Fig. 2e and 2f). 
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Together, our results demonstrate that the Cav3 P28L and R26Q mutant myotubes 
are unable to provide the mechanoprotection that is required to maintain the integrity 
of the myotube plasma membrane under mechanical stress and behave similarly to 
myotubes depleted for Cav3. 
 
The IL6/STAT3 signaling pathway is constitutively hyperactivated in Cav3 P28L 
and R26Q mutant myotubes. 
Considering the key role of caveolae and caveolin in intracellular signaling12,13, we 
next investigated whether the loss of functional caveolae could impact some of the 
key signaling pathways in the muscle. We focused our analysis on the IL6/STAT3 
signaling pathway that has been associated with satellite cell exhaustion and muscle 
wasting29,30,31. Furthermore, the IL6 signal transducer glycoprotein gp130, which, 
together with the IL6 receptor subunit, assemble the IL6 receptor, has been localized 
in caveolae in a myeloma cell line32, suggesting a potential regulation of the IL6 
signaling pathway by caveolae. IL6 binding to the IL6 receptor is classically followed 
by the activation of receptor-bound JAK1 and JAK2 kinases, which in turn 
phosphorylate the signal transducer and activator of transcription 3 (STAT3) that is 
then translocated as a dimer to the nucleus where it activates the transcription of IL6 
sensitive genes33. 
We therefore monitored the level of STAT3 activation i.e. tyrosine (Tyr705) 
phosphorylation (pSTAT3) in myotubes stimulated for 5 and 15 min with 
physiological concentrations of IL6 (Figure 3). At steady state, in the absence of IL6 
stimulation, little tyrosine phosphorylation of STAT3, if any, could be detected in WT 
myotubes. In contrast, we found a substantially higher level of pSTAT3 in Cav3 P28L 
and R26Q mutant myotubes, even in the absence of IL6 stimulation. While IL6 
stimulation led to increased levels of pSTAT3 in WT myotubes, we still observed 
higher levels of pSTAT3 in Cav3 P28L and R26Q mutant myotubes for similar times 
of IL6 stimulation (Fig. 3a and 3b). To rule out the possible contribution of 
undifferentiated myotubes in IL6 signaling, we investigated the nuclear translocation 
of pSTAT3 by immunofluorescence since differentiated myotubes are characterized 
by the presence of multiple nuclei (Fig. 3c and 3d). Again, we detected a significantly 
higher level of pSTAT3 in the nuclei of mutant myotubes as compared to WT at 
steady state. After 15 min of IL6 stimulation, mutant myotubes exhibited higher 
pSTAT3 nuclear translocation, although it was less pronounced in P28L mutants. 
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Altogether, these data reveal that the IL6/STAT3 signaling pathway is constitutively 
hyperactivated in the Cav3 P28L and R26Q mutant myotubes.  
We next investigated whether the regulation of IL6/STAT3 signaling would 
require the presence of functional caveolae at the plasma membrane and thus the 
expression of Cav3. We therefore monitored the kinetics of STAT3 activation by IL6 
in WT myotubes depleted for Cav3. Immunoblot analysis showed a hyperactivation 
of the IL6 pathway in Cav3 depleted myotubes with an overall activation of STAT3 
(Fig. 3e and 3f). These results indicate that Cav3 is a negative regulator of the 
IL6/STAT3 pathway in healthy myotubes and that the depletion of Cav3 in WT 
myotubes reproduces the phenotype observed in the Cav3 mutants. It demonstrates 
that the absence of Cav3 and/or caveolae at the plasma membrane of mutant 
myotubes is responsible for the constitutive hyperactivation of the IL6/STAT3 
signaling pathway. 
STAT3 is a key transcription factor controlling the transcription of many 
downstream genes whose products mediate the pleiotropic effects of STAT3 in 
physiological and pathological contexts34. We therefore examined the consequences 
of the constitutive hyperactivation of the IL6/STAT3 pathway on gene expression. In 
the context of muscle disease, we investigated the transcription of muscle-related 
genes since STAT3 has been suggested to be involved in their regulation. We 
focused our analysis on the SOCS3, MYH8, ACTC1 and ACTN2 genes that are 
associated with muscle development and regeneration31. SOCS3 serves also as a 
positive control, as it is transcribed upon STAT3 activation and its gene product 
SOCS3 is a major actor in the negative regulation of this pathway33. Using 
quantitative PCR, we found an increased transcription of SOCS3, MYH8, ACTC1 
and ACTN2 genes (Fig. 3g). These data strongly suggest that the constitutive 
hyperactivation of STAT3 found in the Cav3 P28L and R26Q mutant myotubes is 
responsible for the deregulation of several genes involved in muscle 
pathophysiology. 
 
IL6/STAT3 mechanosignaling is impaired in Cav3 P28L and R26Q mutant 
myotubes. 
Although caveolae and caveolins have long been associated with signaling12,13, the 
integration of this function with their role in mechanosensing has not yet been 
reported. We have proposed the hypothesis that the mechano-dependent cycle of 
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caveolae disassembly and reassembly could impact some of the caveolae-
dependent signaling pathways13,35. We thus analyzed whether the regulation of the 
IL6/STAT3 pathway by caveolae could depend on mechanical stress. When 
myotubes were subjected to hypo-osmotic shock prior to IL6 stimulation, we 
observed a dramatic decrease of STAT3 activation (approx. 80%) in WT myotubes 
whereas no significant change was observed in Cav3 P28L and R26Q mutant 
myotubes (Fig. 4a and 4b). We also tested the effect of mechanical stretching on 
IL6/STAT3 signaling as this is more relevant to the nature of mechanical stress 
experienced by skeletal muscles during exercise. When we applied a 10% cyclic 
stretch at 0.5 Hz for 30 min to WT myotubes followed by IL6 stimulation, we also 
observed a drastic reduction of STAT3 activation, confirming that the IL6/STAT3 
pathway is tightly regulated by mechanical stress in muscle cells (Supplementary 
Fig. 3).  
We next determined whether the mechanical regulation of IL6 signaling 
required the presence of functional caveolae. We applied a hypo-osmotic shock to 
WT myotubes depleted of Cav3 and whereas no effect was observed at steady 
state, we found that STAT3 activation by IL6 was slightly decreased by mechanical 
stress (approx. 20%) in WT myotubes. More importantly no changes were observed 
in Cav3 depleted myotubes (Fig. 4c and 4d). The poor adhesion of Cav3 P28L and 
R26Q mutant myotubes on the stretching membrane did not allow us to confirm 
these data under cyclic stretching. Nevertheless, these results confirm that the 
IL6/STAT3 signaling pathway is negatively regulated by mechanical stress in 
myotubes and that this regulation is lost in the absence of functional caveolae as 
shown in Cav3 P28L and R26Q mutant myotubes and in WT myotubes depleted for 
Cav3.  
 
Expression of WT Cav3 is sufficient to rescue a normal phenotype in Cav3 
P28L myotubes. 
Our experiments showing that the depletion of Cav3 in WT myotubes faithfully 
reproduces the mechanoprotection and signaling defects observed in P28L and 
R26Q myotubes, implies that the absence of Cav3 at the plasma membrane, as a 
result of its abnormal retention in the Golgi complex, is responsible for the observed 
phenotype. To validate this hypothesis, we generated stable WT and P28L 
myoblasts transduced either by GFP alone or by WT Cav3 tagged with GFP (Cav3-
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GFP). Immunofluorescent microscopy confirmed that expressed Cav3-GFP was 
mainly localized at the plasma membrane and not retained at the Golgi complex in 
Cav3-GFP P28L myotubes (Fig. 5a and Supplementary Fig. 4a). We performed 
electron microscopy to see whether Cav3 WT expression would allow us to 
reconstitute a pool of structurally defined caveolae at the plasma membrane of Cav3 
P28L myotubes expressing GFP or Cav3-GFP. While the plasma membrane of 
control GFP myotubes presented few, often isolated, caveolae structures, Cav3-GFP 
rescued myotubes presented a significantly higher number of bona fide caveolae, 
including larger vacuolar structures with connected caveolae i.e. rosettes (Fig. 5b 
and 5c), as classically observed in WT myotubes (Fig. 1c). These observations 
confirm that the decrease in the number of caveolae in Cav3 P28L myotubes is a 
direct consequence of the retention of Cav3 P28L in the Golgi complex.  
Next, we examined whether the reconstitution of the caveolae reservoir at the 
plasma membrane of Cav3 P28L myotubes was sufficient to rescue the regulatory 
role of caveolae in mechanoprotection and IL6/STAT3 signaling. We therefore 
monitored the resistance to membrane bursting of GFP- and WT Cav3-GFP 
expressing P28L myotubes as described above. Notably, Cav3-GFP P28L myotubes 
showed a strong increase in the resistance to membrane bursting under hypo-
osmotic shock as compared to GFP P28L myotubes (GFP: 49% ± 3%; Cav3-GFP: 
18% ± 2%). It also took a significantly longer time for Cav3-GFP P28L myotubes to 
burst as compared to GFP P28L myotubes (GFP: 1.6 min ± 0.1; Cav3-GFP: 2.3 min 
± 0.2) (Fig. 5d and 5e). Finally, we analyzed the regulation of the IL6/STAT3 
pathway by monitoring STAT3 phosphorylation and nuclear translocation in GFP and 
Cav3-GFP expressing P28L myotubes. At steady state, we observed a significant 
decrease of pSTAT3 activation and nuclear translocation in Cav3-GFP P28L 
myotubes as compared to GFP P28L myotubes, indicating that the expression of 
Cav3 was sufficient to reduce the hyperactivation of STAT3 observed at steady state 
in Cav3 P28L myotubes (Fig. 5f and 5g). Upon IL6 stimulation, we measured a 
slightly decreased but not significant pSTAT3 nuclear translocation in Cav3-GFP 
P28L myotubes, similarly to what we observed when comparing WT to non-
transduced Cav3 P28L myotubes (Fig. 3d and 5g). Interestingly, we also found that 
the expression of Cav3-GFP in WT myotubes led to a decrease of pSTAT3 
activation and nuclear translocation at steady state as compared to non transduced 
WT myotubes (Supplementary Fig. 4c). Altogether, these results show that the 
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expression and localization of Cav3 at the plasma membrane of P28L myotubes is 
sufficient to restore membrane mechanoprotection and the regulation of IL6/STAT3 
signaling by caveolae.  
 
Discussion 
In the present work, we investigated two aspects of caveolae that have been so far 
poorly characterized in human muscle cells. We first addressed the role of caveolae 
in mechanosensing and mechanoprotection, a new function of caveolae that has 
been recently established by several investigators in various cell types. When cells 
experience acute mechanical stress such as cell swelling or cell stretching, caveolae 
flatten out into the plasma membrane to provide extra membrane area and prevents 
membrane tension increase and membrane rupture14,15,16,17,36. In agreement with 
these studies, we found that the presence of functional caveolae was absolutely 
required to protect human myotubes against severe mechanical stress. Thus, the 
Cav3 P28L and R26Q mutant myotubes presented a major defect in 
mechanoprotection with a lack of membrane tension buffering and increased 
sensibility to membrane rupture. Whereas the mutant myotubes showed a dramatic 
decrease in the number of caveolae present at the plasma membrane, the 
expression of wild type Cav3 allowed to restore a number of caveolae sufficient to 
reinstall mechanoprotection. The depletion of Cav3 in healthy myotubes faithfully 
reproduced the phenotypes observed in Cav3 P28L and R26Q myotubes indicating 
that the retention of Cav3 in the Golgi complex is responsible for the absence of a 
functional reservoir of caveolae at the plasma membrane and thereby the lack of 
mechanoprotection in these mutants. Our finding that Cav3 P28L and R26Q 
myotubes still express caveolae at the plasma membrane, albeit to a much lesser 
extent, most likely indicates that this number is too low to assure an efficient 
mechanoprotection and/or that these caveolae are not fully functional as suggested 
by their aberrant size. It is tempting to speculate that the increased fragility of the 
mutant myotubes membrane could be related to the pathological phenotype reported 
in Cav3-related muscle dystrophies. We were however surprised that these defects 
were mainly observed when mutant myotubes were subjected to a severe hypo-
osmotic shock. Mild hypo-osmotic shocks did not allow to reveal mechanoprotection 
defects in mutant myotubes. This is indeed in agreement with early electron 
microscopy studies showing that Aplysia californica smooth muscle and frog skeletal 
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muscle fibers must be stretched up to nonphysiological levels such as three times 
the in situ length in order to visualize the presence of flattened caveolae37,38. This is 
also consistent with the mild-to-moderate clinical symptoms described in these 
patients39. 
This incited us to explore other functions of caveolae that could also be 
deregulated by caveolae dysfunction in Cav3 mutant myotubes. We investigated the 
regulation of muscle cells signaling as several signaling defects have been described 
in muscle dystrophies and caveolae have long been associated with the regulation of 
intracellular signaling. Indeed, Cav3 has been involved in the regulation of distinct 
signaling pathways important for muscle function such as calcium homeostasis40, the 
insulin/GLUT4/Akt pathway41 or TrkA and EGFR signaling26. We focused our 
analysis on the interleukin-6 (IL6)/STAT3 signaling pathway which has been shown 
to play an essential role in muscle tissue homeostasis42. In addition, the IL6 pathway 
is tightly associated to mechanical stress in muscle cells as IL6 is secreted mostly 
during physical exercise43. Our data show for the first time a major deregulation of 
the IL6/STAT3 signaling pathway in the Cav3 mutant myotubes with a constitutive 
hyperactivation of STAT3 at steady state. This defect translated into increased 
STAT3 nuclear translocation and expression of MYH8, SOCS3, ACTC1 and ACTN2, 
genes that are known to be regulated by STAT3 and that have been associated with 
muscle development and regeneration. As for the defects in mechanoprotection, the 
deregulation of the IL6/STAT3 signaling pathway could be reproduced by depleting 
healthy myotubes from Cav3, indicating that the absence of Cav-3 and/or caveolae 
was responsible for the hyperactivation of STAT3. More importantly, we observed 
that IL6/STAT3 signaling was regulated by mechanical stress in a Cav3-dependent 
manner in human myotubes. The regulation of IL6/STAT3 mechanosignaling by 
caveolae was lost in Cav3-mutant myotubes or when healthy myotubes were 
depleted of Cav3. Again, as observed for mechanoprotection, the regulation of IL6 
signaling could be rescued in P28L Cav3 myotubes transduced by the WT form of 
Cav3, supporting the role of bona fide caveolae in the regulation of these two 
processes.  
The first CAV3 mutation associated with muscle disorders was described 20 
years ago and today it has been extended to five distinct genetic disorders: rippling 
muscle disease (RMD), distal myopathies (DM), hyperCKemia (HCK), limb-girdle 
muscular dystrophy 1C (LGMD-1C), and familial hypertrophic cardiomyopathy 
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(HCM)20,39. Although many studies have addressed the role of these mutations in 
muscle damages, the underlying mechanisms remain poorly characterized. Cav3 
has been involved in several aspects of muscle physiology including myoblast 
fusion44 and T-tubules organization45. Moreover, Cav3 interacts with the dystrophin 
complex46 and regulates the trafficking of dysferlin47, two important muscle proteins 
whose expression and localization are deregulated in severe myopathies. It is 
therefore likely that the mechanisms by which Cav3 mutations are responsible for 
muscle dystrophies are multiple.  
In conclusion, we describe a new mechanism by which the Cav3 mutations 
can be deleterious in human myotubes. We uncovered a new regulation of 
IL6/STAT3 signaling by caveolae under mechanical stress. Our findings revealed a 
striking similarity between the regulation of mechanoprotection and the control of 
IL6/STAT3 signaling by caveolae under mechanical stress. Our data confirm that the 
retention of Cav3 P28L and R26Q in the Golgi complex is responsible for the 
absence of functional and morphologically defined caveolae at the plasma 
membrane, which in turn results in deficient mechanoprotection and IL6/STAT3 
mechanosignaling. The IL6/STAT3 pathway is tightly associated with the regulation 
of muscle mass and size31,42. It is likely that the alteration of mechanoprotection and 
muscle size, two critical parameters for general muscle homeostasis, are deleterious 
for muscle tissue integrity. It is therefore tempting to propose that the caveolae-
dependent mechano-regulation of the IL6/STAT3 pathway that we have unraveled 
here is critical to couple the activation of the IL6/STAT3 pathway with the intensity of 
mechanical stress that myotubes constantly experience during their lifetime thereby 
preventing a chronic hyperactivation of IL6/STAT3, through a negative feedback 
loop, that would be otherwise pathological to muscle cells. 
 
 
Methods 
 
Cell lines. P28L and R26Q human myoblasts were immortalized by the platform for 
immortalization of human cells of the Institute of Myology as described in 48. Briefly, 
myoblasts were transduced with lentiviral vectors encoding hTERT and cdk4 and 
containing puromycin (P28L) or puromycin and neomycin (R26Q) selection markers. 
Transduced cells were selected with puromycin (1 µg/ml) for 6 days (P28L) or with 
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puromycin (1 µg/ml) for 6 days and neomycin (1 mg/ml) for 10 days (R26Q). Cells 
were seeded at clonal density, and individual myogenic clones were isolated.  
For caveolin-3 expression, immortalized WT and P28L myoblasts were transduced 
with lentiviral vectors expressing WT caveolin-3 and a GFP reporter gene (MOI 5). A 
GFP lentiviral vector was used as control (MOI 5).  
  
Cell culture. All cells were grown at 37°C under 5% of CO2. All myoblasts cell lines 
were cultured in Skeletal Muscle Cell Growth Medium (Promocell) supplemented 
with 20% FCS (Gibco, Life technologies), 50 µg/mL of fetuine, 10 ng/mL of epidermal 
growth factor, 1 ng/mL basic fibroblast growth factor, 10 µg/mL of insulin and 0.4 
µ/mL of dexamethasone (Promocell). Prior to any cell seeding, surfaces (well, 
coverslip, patterned coverslips) are coated with 0.01% of matrigel (v/v) (Sigma) for 
15 min at 37°C. For myoblast differentiation, confluent cells (80-100% confluency) 
are put in DMEM high-glucose Glutamax (Gibco, Life Technologies), supplemented 
with 0.1% of insulin (v/v) (Sigma) for 4 days.  
 
Antibodies and reagents. Mouse anti-αTubulin (Sigma-Aldrich, clone B512, T5168, 
1/1000 for WB); mouse anti-caveolin-3 (Santa Cruz, clone A3, sc-5310, 1/1000 for 
WB, 1/250 for IF); rabbit anti-caveolin-1 (Cell Signaling, 3238, 1/1000 for WB, 1/500 
for IF); goat anti-GM130 (Santa Cruz, clone P-20, sc-16268, 1/50 for IF); mouse anti-
MF20 (kind gift of Vincent Mouly, 1/100 for WB, 1/20 for IF); mouse anti-STAT3 (Cell 
Signaling, clone 124H6, 9139, 1/1000 for WB); rabbit anti-pSTAT3 (Cell Signaling, 
clone D3A7, 9145, 1/1000 for WB, 1/75 for IF); Secondary antibodies conjugated to 
Alexa FITC, Cy3, Cy5 or horseradish peroxidase (Beckman Coulter or Invitrogen). 
DAPI (Sigma-Aldrich).  
 
RNA interference-mediated silencing. Myoblasts were transfected with small 
interfering RNAs (siRNAs) using HiPerFect (Qiagen) according to the manufacturer’s 
instructions at days 0 and 2 of differentiation and were cultured in differentiation 
medium for a total of 4 days. Experiments were performed on validation of silencing 
efficiency by immunoblot analysis using specific antibodies and normalizing to the 
total level of tubulin used as loading controls. 20 nM of a pool of four siRNA targeting 
Cav3 were used (SI03068730, SI02625665, SI02625658 and SI00146188, 
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QIAGEN), Control siRNA (1022076, QIAGEN) was used at the same concentration 
and served as reference point. 
 
Immunoblotting. Cells were lysed in sample buffer (62.5 mM Tris/HCl pH 6.0, 2% 
v/v SDS, 10% glycerol v/v, 40 mM dithiothreitol and 0.03% w/v phenol red). Lysates 
were analyzed by SDS–PAGE and Western blot analysis and immunoblotted with 
the indicated primary antibodies and horseradish peroxidase- conjugated secondary 
antibodies. Chemiluminescence signal was revealed using Pierce™ ECL Western 
Blotting Substrate, SuperSignal West Dura Extended Duration Substrate or 
SuperSignal West Femto Substrate (Thermo Scientific Life Technologies). 
Acquisition and quantification were performed with the ChemiDoc MP Imaging 
System (Bio-rad).  
 
Immunofluorescence. Myoblasts were grown and differentiated on coverslips for 4 
days. For Cav3, Cav1, MF-20, GM130 staining, cells are fixed with 4% PFA (v/v) 
(Sigma-Aldrich) for 10 min at RT, quenched in 50 mM NH4Cl and then permeabilized 
with 0.2% BSA (v/v) and 0.05% saponin (v/v) (Sigma-Aldrich) in PBS for 20 min. 
Cells are incubated sequentially with indicated primary and fluorescence-conjugated 
secondary antibody in permeabilization buffer for 1h at RT.  For pSTAT3 staining, 
cells are fixed and permeabilized with cold methanol for 15 min at -20°C. After 
washes with PBS 0.2% BSA (v/v), cells are incubated sequentially with indicated 
primary and fluorescence-conjugated secondary antibody in PBS 0.2% (v/v) for 1 h 
at RT. In both protocols, coverslips are mounted in Fluoromount-G mounting medium 
(eBioscience) supplemented with 2 µg/mL of DAPI (Sigma-Aldrich). Acquisition of 
images are done using a spinning disk microscope (inverted Spinning Disk Confocal 
Roper/Nikon; Camera: CCD 1392x1040 CoolSnap HQ2 ; objective : 60x CFI Plan 
Apo VC).  
 
Electron microscopy. Epon embedding was used to preserve the integrity of cell 
structures. Myotubes were fixed sequentially for 1 h at room temperature with 1.25% 
glutaraldehyde in 0.1 M Na-Cacodylate and then overnight at 4°C. 
Cells were washed extensively with 0.1 M Na-Cacodylate pH 7.2. Membrane fixation 
was performed for 1 h at room temperature with 1% OsO4 in 0.1 M Na-Cacodylate 
pH 7.2. Cells were dehydrated by incubation with aqueous solutions of ethanol at 
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increasing concentrations (50, 70, 90, then 100%, each for 10 min at RT). 
Embedding was finally performed in LX112 resin. Cells were infiltrated with a 1:1 
LX112:ethanol solution, washed with LX112, and embedded overnight at 60°C in 
LX112 resin. Ultrathin 65 nm sections were sliced using a Leica UCT ultramicrotome 
and mounted on nickel formvar/ carbon-coated grids for observations. Contrast was 
obtained by incubation of the sections for 10 min in 4% uranyl acetate followed by 1 
min in lead citrate.  
Electron micrographs were acquired on a Tecnai Spirit electron microscope (FEI, 
Eindhoven, The Netherlands) equipped with a 4k CCD camera (EMSIS GmbH, 
Münster, Germany) 
 
Micropatterning. 18 mm coverslips were micropatterned as described in (Carpi et 
al., 2011) using a photo-mask with lines of 10 µm of width, separated by 60 µm. In 
both force measurements and membrane bursting assay, myoblasts are plated at 
confluency on line micropatterns coverslips coated with 0.01% of matrigel (v/v) 
(Sigma) for 15 min at 37°C. Differentiation of myoblasts is achieved as described 
above in section Cell culture.  
 
Force Measurements. Plasma membrane tethers were extracted from cells by a 
concanavalin A (Sigma-Aldrich) coated bead (3 µm in diameter, Polysciences) 
trapped in optical tweezers. The optical tweezers are made of a 1064 nm laser beam 
(ytterbium fiber laser, λ = 1064 nm, TEM 00, 5 W, IPG Photonics, Oxford, MA) 
expanded and steered (optics by Elliot Scientific, Harpenden, UK) in the back focal 
plane of the microscope objective (Apo-TIRF 100× NA 1.45, Nikon). The whole setup 
was mounted on a Nikon Eclipse-Ti inverted microscope. The sample was 
illuminated by transmitted light, and movies were acquired at 10 Hz with an EM-
charge-coupled device camera (Andor iXon 897) driven by Micro-Manager. The fine 
movements and particularly the translational movement necessary to pull the 
membrane tether were performed using a custom-made stage mounted on a 
piezoelectric element (P753, Physik Instrumente, Karlsruhe, Germany) driven by a 
servo controller (E665, Physik Instrumente) and a function generator (Sony Tektronix 
AFG320). 
Calibration was performed using an oscillatory modulation driven by a function 
generator and measuring the response of the bead to an oscillatory motion of the 
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stage. We measured k = 159 pN/µm. This relationship is linear in the laser power 
range used for the experiments (0.4–1.2 W). 
The membrane tether was held at constant length to measure the static force. For 
measuring membrane tension changes due to hypo-osmotic shock, a first tether was 
first pulled at 300 mOsm (iso condition). A second tube was pulled on the same cell 
5 min after diluting the medium with milliQ water to obtain 45 mOsm. The position of 
the bead used to compute tether forces was detected from the images using a 
custom ImageJ macro.  
 
Membrane bursting assay. Line micropatterned myotubes are incubated in 5 
µg/mL of calcein-AM (Life techonologies) and 50 µg/mL of DAPI (Sigma-Aldrich) for 
15 min at 37°C in the dark. Medium was then switched back with differentiation 
medium to wash out the excess of calcein-AM. The medium is then switched again 
with a 30 mOsm hypo-osmotic shock medium obtained after a dilution of 10% 
medium and 90% H2O, supplemented with 2 mg/mL of PI (Sigma). Immediately after 
medium switching, pictures are taken every minute for 10 min using a 
videomicroscope (Inverted microscope Nikon Ti-E, Camera: CCD 1392x1040 
CoolSnap HQ2, objective: 10x CFI Fluor). 
 
IL6 stimulation. Myotubes were starved 4 h by switching the differentiation medium 
to DMEM medium. In resting conditions, cells are then stimulated by switching the 
medium with DMEM with 0.2% BSA (w/v), supplemented with 10 ng/mL of human 
recombinant IL6 (R&D) for 0, 5 or 15 min at 37°C. For hypo-osmotic conditions, 
medium was first switched to 75% hypo-osmotic shock (25% DMEM, 75% H2O) for 5 
min and then switched to the same medium supplemented with 10 ng/mL of IL6 for 5 
more minutes at 37°C. For stretching conditions, myoblasts were differentiated on 
fibronectin (Sigma-Aldrich) coated stretchable plates (Uniflex® culture plate, Flexcell 
International) and were then subjected or not to 30 min of cyclic stretch (10% 
elongation, 0.5 Hz), using the FX-4000T TM Tension Plus device (Flexcell 
International), followed or not by 5 min of 10 ng/mL IL6 stimulation. Cells are lysed 
and samples are analyzed by immunoblotting. For the analysis, pSTAT3 levels were 
quantified by calculating the ratio between pSTAT3 and STAT3, both normalized to 
Tubulin signal. For the analysis of pSTAT3 nuclear translocation, myotubes were 
differentiated on coverslips, stimulated with IL6 as described above for 0 min or 15 
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min and were then fixed for further immunofluorescence analysis. Quantification 
corresponds to the ratio between the mean pSTAT3 intensity in the nuclei on the one 
in the cytoplasm. 
 
Quantitative PCR. Cells were lysed and RNA extraction was performed using an 
extraction kit (RNeasy Plus, Qiagen). Reverse-transcription reaction was performed 
with 1 µg of RNA per reaction, using high capacity cDNA reverse-transcritpion kit 
(Applied biosystem).  qPCR was performed on 50 ng of cDNA for a reaction in a total 
volume of 20 µL, using Taqman Gene Expression Assays (GAPDH: 
Hs02786624_g1 ; ACTC1: Hs01109515_m1 ; MYH8: Hs00267293_m1 ; SOCS3: 
Hs02330328_s1, ACTN2: Hs00153809_m1, Applied biosystem) and a Lightcycler 
480 Probes Master kit (Roche). Relative expression levels were calculated using 
∆∆CT method with fold changes calculated as 2–∆∆CT. 
 
Statistical analyses 
All analyses were performed using GraphPad Prism version 6.0 and 7.0, GraphPad 
Software, La Jolla California USA, www.graphpad.com. Two-tailed (paired or 
unpaired) t-test was used if comparing only two conditions. For comparing more than 
two conditions, Kurskal-Wallis test was used with Dunn’s multiple comparison test (if 
comparing all conditions to the control condition). Significance of mean comparison 
is marked on the graphs by asterisks. Error bars denote SEM or SD. 
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Figure legends 
 
Figure 1 | Characterization of caveolae and Cav3 expression in WT, Cav3 P28L 
and Cav3 R26Q myotubes. (a) Electron micrographs of WT, Cav3 P28L and Cav3 
R26Q myotubes. Caveolae, interconnected caveolae and aberrant sized caveolae 
are indicated with black arrowheads, asterisks and white arrowheads, respectively. 
(b) Quantification of the number of caveolae / µm2 in (a). (c) Immunoblot analysis of 
total levels of Cav3 in WT, Cav3 P28L and Cav3 R26Q differentiated myotubes. 
Tubulin serves as a loading control. (d) Quantification of the expression of Cav3 in 
(c) by calculating the ratio between Cav3 and tubulin expression. (e) 
Immunofluorescent labeling of Cav3 and GM130 in WT, Cav3 P28L or Cav3 R26Q 
myotubes analyzed by confocal microscopy. Arrows in inset indicate the plasma 
membrane and arrowheads indicate the Golgi complex. (a) Scale bar = 200 nm. 
Representative cells quantified in (b) (number of regions analyzed: WT = 115, P28L 
= 154, R26Q = 146; Total area screened: WT = 1140 µm2, P28L = 1187 µm2, R26Q 
= 1216 µm2) (d) Quantification was done on 3 independent experiments (e) Scale 
bar = 10 µm. Reproducibility of experiments: (a) Representative cells. (b), (c) and (d) 
Representative data for 3 experiments. Mean value ± SEM. (b, d) Statistical analysis 
with a two-tailed unpaired t test, * P<0,05; *** P<0,0001. 
 
 
Figure 2 | Cav3 P28L and Cav3 R26Q myotubes present major defects in 
membrane tension buffering and membrane integrity. (a, b) Membrane tension 
measurement analysis using optical tweezers and nanotube pulling on 
micropatterned WT, Cav3 P28L or Cav3 R26Q myotubes. Membrane tethers were 
pulled in the perpendicular axis of aligned myotubes after micropatterning in resting 
conditions and 5 min after a 45 mOsm hypo-osmotic shock (a, b, left panels).  
Membrane tension was analyzed in resting condition (a, right panel) and the 
difference of membrane tension before and after hypo-osmotic shock was 
calculated, reflecting the percentage of increase of membrane tension upon 
mechanical stress (b, right panel). 
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(c, e) Micropatterned WT, Cav3 P28L or Cav3 R26Q myotubes (c) or WT ctl (siCtl) 
and Cav3-depleted (siCav3) myotubes (e) were loaded with calcein-AM (green). The 
medium was switched with a 30 mOsm medium supplemented with propidium iodide 
(PI, red). Representative pictures were taken at the indicated times during hypo-
osmotic shock. Arrows correspond to myotubes and asterisks correspond to burst 
myotubes. (d, f) Quantification of the percentage of burst myotubes (upper panel) 
and mean time of bursting in minutes (lower panel) in (c) and (e), respectively. (a, b) 
Scale bar = 5 µm. (c, e) Scale bar = 120 µm. Reproducibility of experiments: (a) 
Representative pictures and quantifications from 7 independent experiments (WT 
n=20, P28L n=23 and R26Q n=22) (b) Representative pictures and quantifications 
from 7 independent experiments (WT n=20, P28L n=27 and R26Q n=18). (c) 
Representative data of 3 independent experiments quantified in (d) (% burst cells: 
WT n=310, P28L n=299 and R26Q n=271; mean time of bursting: WT n=165, P28L 
n=233 and R26Q n=240). (e) Representative data of 3 independent experiments 
quantified in (f) (% burst cells: siCtl n=749 and siCav3 n=569; mean time of bursting: 
siCtl n=171 and siCav3 n=506). Mean value ± SD. (a, b) Statistical analyses were 
done using Kurskal-Wallis test. (d, f) Statistical analysis with two-tailed unpaired t 
test; * P<0,05; *** P<0,001. 
 
Figure 3 | Constitutive hyperactivation of IL6/STAT3 signaling in Cav3 P28L 
and Cav3 R26Q myotubes. (a) Immunoblot analysis of pSTAT3 and STAT3 levels 
in WT, Cav3 P28L and Cav3 R26Q myotubes stimulated for the indicated times with 
10 ng/mL IL6. Tubulin serves as a loading control. (b) Quantification of STAT3 
activation of (a), corresponding to the ratio pSTAT3 on STAT3 total levels after 
normalization to tubulin levels. (c) Confocal microscopy of immunofluorescent 
pSTAT3 in WT, Cav3 P28L and Cav3 R26Q myotubes stimulated or not for 15 min 
with 10 ng/mL IL6. White dashed lines outline nucleus boundaries (d) Quantification 
of pSTAT3 nuclear translocation in (c) corresponding to nuclei/cytoplasm mean 
intensity ratio of pSTAT3. (e) Immunoblot analysis of pSTAT3 levels in WT ctl (siCtl) 
and Cav3-depleted (siCav3) myotubes stimulated for the indicated times with 10 
ng/mL IL6. (f) Quantification of STAT3 activation in (e), corresponding to the ratio 
pSTAT3 on STAT3 total level after normalization with tubulin level. (g) Expression of 
STAT3 related genes: from left to right SOCS3, MYH8, ACTC1 and ACTN2 in WT, 
Cav3 P28L or Cav3 R26Q myotubes. (c) Scale bar = 10 µm. Reproducibility of 
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experiments: (a, c and e) Representative data. (b) Quantification was done on 4 
independent experiments. (d) Quantification was done on 3 independent 
experiments (0 min: WT n=41, P28L n=25, R26Q n=21; 15 min: WT n=22, P28L 
n=30, R26Q n=30). (f) Quantification was done on 4 experiments. (g) Quantification 
was done on 5 (SOCS3), 8 (MYH8), 3 (ACTC1) and 7 (ACTN2) independent 
experiments. Mean value ± SEM. (b, f) Statistical analysis with two-tailed paired t 
test. (d, g) Statistical analysis with two-tailed unpaired t test * P<0,05; ** P<0,01; *** 
P<0,001; ns, non significant. 
 
Figure 4 | IL6/STAT3 mechanosignaling is impaired in Cav3 P28L and R26Q 
myotubes. (a, c) Immunoblot analysis of pSTAT3 and STAT3 levels in WT, Cav3 
P28L and Cav3 R26Q myotubes. (a) WT ctl (siCtl) or Cav3-depleted (siCav3) 
myotubes (c) subjected or not to a 75 mOsm hypo-osmotic shock (Hypo-Osm) for 10 
min, followed by stimulation or not with 10 ng/mL IL6 for 5 min. Tubulin serves as 
loading control. (b, d) Quantification of STAT3 activation in (a) and (c) respectively, 
corresponding to the ratio pSTAT3 on STAT3 total level after normalization to tubulin 
level.  
Reproducibility of experiments: (a, c) Representative data. (b) Quantification was 
done on 5 and 3 independent experiments for WT and mutants respectively. (d) 
Quantification was done on 4 independent experiments. Mean value ± SEM. (b, d) 
Statistical analysis with two-tailed paired t test; * P<0,05; ** P<0,01; ns, non 
significant. 
 
Figure 5 | Expression of WT Cav3 rescues a normal phenotype in Cav3 P28L 
and R26Q myotubes. 
(a) Immunofluorescent labeling of Cav3 and Golgi marker GM130 in Cav3 P28L GFP 
and P28L Cav3-GFP transduced myotubes analyzed by confocal microscopy. 
Arrows in inset indicate the plasma membrane and arrowheads indicate the Golgi 
complex. (b) Electron micrographs of Cav3 P28L GFP and P28L Cav3-GFP 
transduced myotubes. Caveolae and interconnected caveolae are indicated with 
arrowheads and asterisks, respectively. (c) Quantification of the number of caveolae/ 
µm2 (left panel) and the total number of caveolae in (b) (right panel). (d) 
Micropatterned Cav3 P28L GFP and P28L Cav3-GFP transduced myotubes were 
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loaded with calcein-AM (green). The medium was switched with a 30 mOsm medium 
supplemented with propidium iodide (PI, red). Representative pictures were taken at 
the indicated times during hypo-osmotic shock. Arrows correspond to myotubes and 
asterisks correspond to burst myotubes. (e) Quantification of the percentage of burst 
myotubes (upper panel) and mean time of bursting in minutes (lower panel) in (d). (f) 
Confocal microscopy of immunofluorescent pSTAT3 in Cav3 P28L GFP or P28L 
Cav3-GFP transduced myotubes stimulated or not for 15 min with 10 ng/mL IL6. 
White dashed lines outline nucleus boundaries (g) Quantification of pSTAT3 nuclear 
translocation in (f) corresponding to nuclei/cytoplasm mean intensity ratio of 
pSTAT3. (a) Scale bar = 10 µm. (b) Scale bar = 200 nm. (d) Scale bar = 120 µm. (f) 
Scale bar = 10 µm. Reproducibility of experiments: (a) Representative pictures of 3 
experiments. (b) Representative pictures quantified in (c) (number of analyzed 
regions: P28L GFP = 169, P28L Cav3-GFP = 182; Total screened area: P28L GFP = 
1405 µm2, P28L Cav3-GFP = 1349 µm2) (d) Show representative data of 3 
experiments quantified in (e) (% burst cells: GFP n=353 and Cav3-GFP n=358; time 
of burst: GFP n=175 and Cav3-GFP n=65). (f) Show representative data of 3 
experiments quantified in (g) (control: GFP n=33 and Cav3-GFP n=42; 15 min: GFP 
n=14 and Cav3-GFP n=13). Mean value ± SEM. (c), (e) and (g) Statistical analysis 
with a two-tailed unpaired t test; ** P<0,01; *** P<0,0001; ns, non significant. 
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Supplementary figure legends 
 
Supplementary figure 1 | MF20 and Cav1 expression in WT, Cav3 P28L and 
R26Q myotubes. (a, b) Immunoblot analysis of total levels of MF20 (a) and Cav1 
(b) in WT, Cav3 P28L and Cav3 R26Q myotubes. Tubulin serves as a loading 
control. (c) Cav3, Cav1 and Golgi marker GM130 immunofluorescence were 
analyzed by confocal microscopy in WT, Cav3 P28L and Cav3 R26Q myotubes. (a), 
(b) and (c) Representative data for 3 experiments. (c) Scale bar = 10 µm. 
 
Supplementary figure 2 | Efficient membrane tension buffering and 
mechanoprotection in Cav3 P28L and Cav3 R26Q myotubes under mild hypo-
osmotic shock. (a) Calcein-AM and DAPI fluorescence of WT, Cav3 P28L and 
Cav3 R26Q myotubes prior to hypo-osmotic shock in the membrane bursting assay 
described in Figure 2c. Insets show DAPI in myotubes indicated with arrows in 
Figure 2c.  (b) Micropatterned WT, Cav3 P28L and Cav3 R26Q myotubes were 
loaded with calcein-AM (green). The medium was switched to a 150 mOsm medium 
supplemented with propidium iodide (PI, red). Representative pictures were taken at 
the indicated times during hypo-osmotic shock. Arrows correspond to myotubes and 
asterisks correspond to burst myotubes. (c) Membrane tension measurement 
analysis using optical tweezers and nanotube pulling on micropatterned WT, Cav3 
P28L and Cav3 R26Q myotubes. Membrane tethers were pulled in the perpendicular 
axis of myotubes after micropatterning in resting conditions and 5 min after a 150 
mOsm hypo-osmotic shock (upper panel).  Membrane tension was analyzed in 
resting condition (lower panel, left) and the difference of membrane tension before 
and after hypo-osmotic shock was calculated, reflecting the percentage of increase 
of membrane tension upon mechanical stress (lower panel, right) (d) Immunoblot 
analysis of Cav3 depletion in Figure 2e. (a, b) Scale bar = 120 µm. (c) Scale bar = 
5µm Reproducibility of experiments: (c) Quantifications were done on 5 independent 
experiments (WT n=17, P28L n=16, R26Q n=14). Mean value ± SD. Statistical 
analyses were done using Kruskal-Wallis test; ns, non significant. 
 
Supplementary figure 3 | IL6/STAT3 signaling in WT myotubes under cyclic 
stretch. (a) Immunoblot analysis of pSTAT3 and STAT3 levels in WT myotubes 
subjected or not to 30 min cyclic stretch. Myotubes were then stimulated or not with 
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10 ng/mL IL6 for 5 min. Tubulin serves as a loading control. (b) Quantification of 
STAT3 activation in (a) corresponding to the ratio pSTAT3 on STAT3 total levels 
after normalization to tubulin levels. Reproducibility of experiments: (b) Quantification 
was done on 3 experiments. Mean value ± SEM. Statistical analyses were done 
using two-tailed paired t test; * P<0,05. 
 
Supplementary figure 4 | Effect of Cav3 expression in mechanoprotection and 
IL6 signaling in WT myotubes. (a) Immunofluorescent labeling of Cav3 and Golgi 
marker GM130 in WT GFP and WT Cav3-GFP transduced myotubes analyzed by 
confocal microscopy. Arrows and arrowheads in inset indicate the plasma membrane 
and the Golgi complex respectively. (b) Quantification of the percentage of burst 
myotubes after a 30 mOsm hypo-osmotic shock (left panel) and mean time of 
bursting in minutes (right panel) in (a). (c) Quantification of pSTAT3 nuclear 
translocation in WT GFP or WT Cav3-GFP transduced myotubes stimulated or not 
for 15 min with 10 ng/mL IL6, corresponding to nuclei/cytoplasm mean intensity ratio 
of pSTAT3. (a) Scale bar = 10 µm. Reproducibility of experiments: (a) 
Representative data from 3 independent experiments. (b) Quantification was done 
on 3 independent experiments (% burst: GFP n=714, Cav3-GFP n=610; time of 
burst: GFP n=80, Cav3-GFP n=171). (c) Quantification was done on 3 independent 
experiments (control: GFP n=16, Cav3-GFP n=21; 15 min: GFP n=16, Cav3-GFP 
n=21). (b, c) Statistical analyses were done using two-tailed unpaired t test; 
***P<0,0001; *P<0,05; ns, non significant. 
 	
 
WT P28L R26Q
MF20
Tubulin
220 kDa
55 kDa
a
WT P28L R26Q
Cav1
Tubulin
21 kDa
55 kDa
b
GM130Cav1 Merge Zoom
W
T
P
28
L
R
26
Q
Cav3
c
Supplementary figure 1. Dewulf et al.
0 min 2 min 5 min 10 min
W
T
C
alcein A
M
P
I
P
28
L
R
26
Q
C
al
ce
in
-A
M
D
A
P
I
b
c
0
20
40
60
80
-50
0
50
100
150
Te
th
er
 fo
rc
e 
(p
N
)
WT P28L R26Q WT P28L R26Q
∆f
/f 
(%
) 
150 mOsm
ns ns
ns ns
WT P28L R26Q
is
o
 h
yp
o
(1
50
 m
O
sm
)
WT P28LZoom DAPI Zoom DAPI R26Q Zoom DAPI
a
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
siCtl
Cav3 21 kDa
siCav3
CHC 180 kDa
d
Supplementary figure 2. Dewulf et al.
apSTAT3
Tubulin
79 kDa
55 kDa
STAT3 79 kDa
0 5 0 5
- - + +
IL6 (min)
30 min stretch
b
1.5
0.0
0.5
1.0
(p
ST
AT
3/
tu
b)
 / 
(S
TA
T3
/tu
b)
- +- +30 min stretch
IL6 (min) 0 5 0 5
*
Supplementary figure 3. Dewulf et al.
aGM130Cav3GFP merge
GFP
GM130
Cav3
WT + GFP
zo
om
merge
GM130Cav3GFP merge
GFP
GM130
Cav3
WT + Cav3-GFP
merge
0.0
0.1
0.2
0.3
0.4
%
 b
ur
st
 c
el
ls
+ GFP + Cav3-GFP
tim
e 
of
 b
ur
st
in
g 
(m
in
) ns
***
0
1
2
3
4
5
+ GFP + Cav3-GFP
b
0
1
2
3
4
0
5
10
15
pS
TA
T3
 n
uc
le
us
 / 
cy
to
pl
as
m ns
*
pS
TA
T3
 n
uc
le
us
 / 
cy
to
pl
as
m
+ GFP + Cav3-GFP + GFP + Cav3-GFP
WT: WT:
WT: WT:
c
Supplementary figure 4. Dewulf et al.
Université Paris-Saclay           
Espace Technologique / Immeuble Discovery  
Route de l’Orme aux Merisiers RD 128 / 91190 Saint-Aubin, France  
 
Titre : Mécanosignalisation par les cavéoles : un rôle nouveau dans le contrôle de la signalisation 
JAK-STAT 
Mots clés : mécanosignalisation ; mécanotransduction ;  cavéoles ; JAK-STAT 
Résumé : Les cavéoles sont des invaginations en 
forme de coupelle à la membrane plasmique. Ces 
organelles multifonctionnelles jouent entre autres, un 
rôle clé dans la mécano-protection et la signalisation 
cellulaire. En effet, les cavéoles ont la faculté de 
s’aplanir en réponse à l’augmentation de la tension 
membranaire, afin de protéger la cellule des 
contraintes mécaniques. Les cavéoles jouant un rôle 
clé dans la signalisation cellulaire, nous avions émis 
l’hypothèse que le cycle mécano-dépendent de 
désassemblage/réassemblage des cavéoles constitue 
un interrupteur mécanique de certaines voies de 
signalisation. Ce projet consiste à élucider le 
mécanisme moléculaire responsable du contrôle de 
la voie de signalisation JAK-STAT par la mécanique 
des cavéoles. Dans ces travaux, nous avons pu 
démontré que la cavéoline-1 (Cav1), un constitutant 
essentiel des cavéoles est libérée et devient 
hautement mobile au niveau de la membrane 
plasmique. Considérant les propriétés de 
signalisation de Cav1, Nous avons testé l’effet du 
désassemblage des cavéoles sur la signalisation 
cellulaire. Un  criblage à haut débit, nous a permis 
identifié la voie de signalisation JAK- STAT  
stimulée par  l’IFN-α comme voie modèle pour cette 
étude. En effet, la transduction du signal JAK-STAT 
induit par l’IFN-α est modulée par la mécanique des 
cavéoles. Afin de disséquer le mécanisme 
moléculaire responsable du contrôle de la 
signalisation JAK-STAT par la mécanique des 
cavéoles, nous avons déterminé le rôle de Cav1 dans 
ce contrôle. Nous avons observé que Cav1 est un 
régulateur négatif de la phosphorylation de STAT3 
dépendante de la kinase JAK1. De plus, nous avons 
démontré que Cav1 interagit avec JAK1 en fonction 
de la tension membranaire. Nous avons également 
démontré que cette interaction Cav1-JAK1 fait 
intervenir le « scaffolding domain » de Cav1 (CSD), 
et que celui-ci est responsable de l’abolition de 
l’activité kinase de JAK1. Par conséquent, 
l’interaction de Cav1 avec JAK1 empêche 
l’activation de STAT3 par la kinase JAK1. Ces 
résultats démontrent que les cavéoles sont des 
organelles de mécano-signalisation, qui, lors d’un 
stress mécanique,  libèrent de la Cav1 non cavéolaire 
capable d’inactiver la kinase JAK1, empêchant ainsi, 
la transduction du signal JAK-STAT.  
 
 
 
Title : Mechanosignaling through cavolae : A new role for the control of JAK-STAT signaling 
Keywords : Mechaosignaling ; Mechanotransduction ;  Caveolae ; JAK-STAT 
Abstract : Caveolae are small cup-shaped plasma 
membrane invaginations. These multifunctional 
organelles play a key role in cell mechanoprotection 
and cell signaling. Indeed our laboratory reported 
that caveolae have the ability to flatten out upon 
membrane tension increase, protecting cells from 
mechanical strains. Since caveolae play a key role in 
cell signaling we hypothesized that the mechano-
dependent cycle of caveolae 
disassembly/reassembly may constitute a 
mechanical switch for signaling pathways. In this 
project, we elucidated the molecular mechanism 
underlying the control of JAK-STAT signaling by 
caveolae mechanics. We showed that caveolin-1 
(Cav1), an essential caveolar component is released 
and become highly mobile at the plasma membrane 
under mechanical stress. Considering that caveolae 
are important signaling hubs at the plasma 
membrane, we addressed the effects of the 
mechanical release of Cav1 on cell signaling. Using 
high throughput screening, we identified the JAK-
STAT signaling pathway as a candidate. To further 
dissect the molecular mechanism underlying the 
control of JAK-STAT signaling by caveolae 
mechanics, we addressed the role of Cav1 in the 
control of JAK-STAT signaling stimulated by IFN-
α. We found that Cav1 was a specific negative 
regulator of the JAK1 dependent STAT3 
phosphorylation. Furthermore, the level of Cav1 
interaction with JAK1 depended on mechanical 
stress. We could show that Cav1-JAK1 interaction 
was mediated by the caveolin scaffolding domain 
(CSD), abolishing JAK1 kinase activity, hence, 
interfering with STAT3 activation upon IFN-α 
stimulation. Altogether our results show that 
caveolae are mechanosignaling organelles that 
disassemble under mechanical stress, releasing non-
caveolar Cav1, which binds to the JAK1 kinase and 
inhibits its catalytic activity, preventing thereby 
JAK-STAT signal transduction. 
 
